Multipartite signaling proteins and uses thereof

ABSTRACT

The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.14/608,098, filed Jan. 28, 2015, which is a continuation-in-part ofPCT/US2014/047852, filed Jul. 23, 2014, which in turn claims the benefitof U.S. Provisional Application No. 61/934,092, filed Jan. 31, 2014, andU.S. Provisional Application No. 61/859,697, filed Jul. 29, 2013, eachof which is incorporated by reference in its entirety.

STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided intext format in lieu of a paper copy, and is hereby incorporated byreference into the specification. The name of the text file containingthe Sequence Listing is BLBD 036 05US ST25.txt. The text file is about634 KB, was created on Aug. 13, 2019, and is being submittedelectronically via EFS-Web.

BACKGROUND Technical Field

The present disclosure relates to compositions and methods for usingmulti-component proteins in immunotherapy and, more particularly, usingchemically induced multimerization to generate chimeric antigen receptorproteins for modulating spatial and temporal control of cellular signalinitiation and downstream responses during adoptive immunotherapy.

Description of the Related Art

Cellular therapy is emerging as a powerful paradigm for deliveringcomplex signals for biological action. In contrast to small molecule andbiologic drug compositions, cells have the potential to execute uniquetherapeutic tasks owing to their myriad sensory and response programsand increasingly defined mechanisms of genetic control. To achieve suchtherapeutic value, cells need to be outfitted with machinery for sensingand integrating chemical and/or biological information associated withlocal physiological environments.

The most clinically advanced example of engineered sensory-responsemachinery is chimeric antigen receptors (CARs) in genetically engineeredT cells for use in adoptive cellular immunotherapy (see June et al.,Nat. Biotechnol. 30:611, 2012; Restifo et al., Nat. Rev. Immunol.12:269, 2012). Antigen binding stimulates the signaling domains on theintracellular segment of the CAR, thereby transducing signals thatunleash inflammatory and cytotoxicity mechanisms. CAR-based adoptivecellular immunotherapy has been used to treat cancer patients withtumors refractory to conventional standard-of-care treatments (see Gruppet al., N. Engl. J. Med. 368:1509, 2013; Kalos et al., Sci. Transl. Med.3:95ra73, 2011).

In addition to targeting and initiating T cell activation, an effectiveadoptive cellular immunotherapy would preferably also modulate T cellexpansion and persistence, as well as the strength and quality of T cellsignaling. But, current CAR-mediated T cell responses do not realize thefull potential of T cell activation and proliferation. Improvement ofCAR function has been achieved by including costimulatory signalingdomains into the CAR structure (see, e.g., Kowolik et al., Cancer Res.66:10995, 2006; Milone et al., Mol. Ther. 17:1453, 2009; Pule et al.,Mol. Ther. 12:933, 2005; Carpenito et al., Proc. Nat'l Acad. Sci. U.S.A.106:3360, 2009), but the clinical results have been mixed (see, e.g.,Brentjens et al., Blood 118:4817, 2011; Till et al., Blood 119:3940,2012; Kochenderfer and Rosenberg, Nat. Rev. Clin. Oncol. 10:267, 2013).Others have included, in addition to a CAR, co-expression ofcostimulatory ligands (see, e.g., Stephan et al., Nat. Med. 13:1440,2007), costimulatory receptors (see, e.g., Duong et al., Immunother.3:33, 2011; Wilkie et al., J. Clin. Immunol. 32:1059, 2012), andcytokines (see, e.g., Hsu et al., J. Immunol. 175:7226, 2005;Quintarelli et al., Blood 110:2793, 2007).

A concern with the use of CARs is toxicity, which arises in two forms:one is the targeted destruction of normal tissue and the second iscytokine-release associated adverse events (e.g., cytokine storm). Forexample, collateral damage observed with CD19-targeted CARs is B-cellaplasia (Kalos et al., 2011; Kochenderfer et al., Blood 119:2709, 2012).Such off-target effects could be very dangerous, particularly if thetarget antigen is found on other tissues, such as the heart or lung. Thecytokine storms associated with large numbers of activated T cells canbe life threatening (Kalos et al., 2011; Kochenderfer et al., 2012).Unlike conventional drug treatments where reducing drug dosage cancontrol toxicity, the proliferation of T cells cannot be controlled withcurrent CAR technologies and, therefore, immunopathology will resultonce a threshold level of T cells is reached.

In view of the limitations associated with CAR-mediated T cellresponses, there is a need in the art for alternative compositions andmethods useful for immunotherapy in which modulation of immune cellsignal initiation and expansion is controllable. The present disclosuremeets such needs, and further provides other related advantages.

SUMMARY OF THE INVENTION

The present disclosure describes improved chimeric antigen receptorsignaling complexes and non-natural cell compositions having signaltransduction systems that are controlled—both in their activation anddeactivation—by pharmacological agents. Numerous pharmacologicallycontrolled, multipartite signal transduction systems are contemplatedherein.

In various embodiments, the present invention contemplates, in part, anon-natural cell, comprising: a first nucleic acid molecule encoding afirst fusion protein comprising a first multimerization domain, a firsthydrophobic domain, and an actuator domain, wherein the firstmultimerization domain localizes extracellularly when the first fusionprotein is expressed; and a second nucleic acid molecule encoding asecond fusion protein comprising a binding domain and a secondmultimerization domain, and a second hydrophobic domain; wherein a firstbridging factor promotes the formation of a polypeptide complex on thenon-natural cell surface with the bridging factor associated with anddisposed between the multimerization domains of the first and secondfusion proteins.

In particular embodiments, the first and second multimerization domainsare the same or different.

In additional embodiments, the multimerization domains of the first andsecond fusion proteins associate with a bridging factor selected fromrapamycin or a rapalog thereof, coumermycin or a derivative thereof,gibberellin or a derivative thereof, abscisic acid (ABA) or a derivativethereof, methotrexate or a derivative thereof, cyclosporin A or aderivative thereof, FKCsA or a derivative thereof, trimethoprim(Tmp)-synthetic ligand for FKBP (SLF) or a derivative thereof, or anycombination thereof.

In certain embodiments, the first and second multimerization domains area pair selected from FKBP and FRB, FKBP and calcineurin, FKBP andcyclophilin, FKBP and bacterial DHFR, calcineurin and cyclophilin, PYL1and ABI1, or GIB1 and GAI, or variants thereof.

In certain embodiments, the first multimerization domain comprises afirst FKBP polypeptide or variant thereof, and the secondmultimerization domain comprises a first FRB polypeptide or variantthereof.

In further embodiments, the first multimerization domain comprises afirst FRB polypeptide or variant thereof, and the second multimerizationdomain comprises a first FKBP polypeptide or variant thereof.

In some embodiments, the bridging factor is sirolimus, everolimus,novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus,umirolimus, or zotarolimus.

In additional embodiments, the first fusion protein has at least onemultimerization domain of FKBP, DHFR or GyrB.

In particular embodiments, the binding domain of the polypeptide complexspecifically binds to a target located on a target cell surface.

In particular embodiments, the first hydrophobic domain is atransmembrane domain selected from the group of a CD4, CD8, AMN, or CD28transmembrane domain.

In some embodiments, the second hydrophobic domain comprises a CD154transmembrane domain.

In certain embodiments, the second hydrophobic domain comprises a CD71transmembrane domain.

In particular embodiments, a particular transmembrane domain may beincluded in the first or second fusion proteins as a type I or type IItransmembrane domain.

In further embodiments, the first hydrophobic domain and the secondhydrophobic domain do not increase cytotoxic activity of the non-naturalcell in the absence of the bridging factor.

In additional embodiments, the first hydrophobic domain and the secondhydrophobic domain increase cytotoxic activity of the non-natural cellin the absence of the bridging factor, wherein the increase in cytotoxicactivity is less than the cytotoxic activity in the presence of thebridging factor.

In certain embodiments, the actuator domain comprises a lymphocytereceptor signaling domain.

In additional embodiments, the actuator domain comprises one or aplurality of immunoreceptor tyrosine-based activation motifs (ITAMs).

In some embodiments, the actuator domain comprises CD3ε, CD3δ, CD3ζ,pTα, TCRα, TCRβ, FcRα, FcRβ, FcRγ, NKG2D, CD22, CD79A, or CD79B, or anycombination thereof.

In particular embodiments, the first nucleic acid molecule encodes thefirst fusion protein further comprising a different actuator domain, acostimulatory domain, an adhesion factor, or any combination thereof.

In further embodiments, the costimulatory domain is selected from CD27,CD28, CD30, CD40, LAT, Zap70, ICOS, DAP10, 4-1BB, CARD11, HVEM, LAG3,SLAMF1, Lck, Fyn, Slp76, TRIM, OX40, or any combination thereof.

In additional embodiments, the actuator domain comprises a cytoplasmicportion that associates with a cytoplasmic signaling protein.

In some embodiments, the cytoplasmic signaling protein is a lymphocytereceptor or signaling domain thereof, a protein comprising a pluralityof immunoreceptor tyrosine-based activation motifs (ITAMs), acostimulatory domain, an adhesion factor, or any combination thereof.

In particular embodiments, the lymphocyte receptor or signaling domainthereof is CD3ε, CD3δ, CD3ζ, pTα, TCRα, TCRβ, FcRα, FcRβ, FcRγ, NKG2D,CD22, CD79A, or CD79B, or any combination thereof.

In particular embodiments, the costimulatory domain is selected fromCD27, CD28, CD30, CD40, LAT, Zap70, ICOS, DAP10, 4-1BB, CARD11, HVEM,LAG3, SLAMF1, Lck, Fyn, Slp76, TRIM, OX40, or any combination thereof.

In further embodiments, the non-natural cell further overexpresses acostimulatory factor, an immunomodulatory factor, an agonist for acostimulatory factor, an agonist for an immunomodulatory factor, or anycombination thereof.

In certain embodiments, the second nucleic acid molecule further encodesa secretion signal such that the second fusion protein is secreted fromthe non-natural cell when expressed, and optionally further encodes ananchor domain.

In additional embodiments, the binding domain of the second fusionprotein is a single chain antibody variable region, a receptorectodomain, or a ligand.

In particular embodiments, the single chain antibody variable region isa domain antibody, sFv, scFv, F(ab′)₂, or Fab.

In some embodiments, the binding domain of the second fusion protein isamino terminal to the multimerization domain.

In additional embodiments, the binding domain of the second fusionprotein is carboxy terminal to the multimerization domain.

In further embodiments, the second nucleic acid molecule encoding thesecond fusion protein further comprises a sequence encoding a linkerdisposed between the binding domain and the second multimerizationdomain.

In particular embodiments, the fusion proteins comprising a bindingdomain have one, two, three, or four binding domains.

In certain embodiments, the one, two, three, or four binding domains arespecific for one target or up to four different targets.

In certain embodiments, the binding domain is specific for a target thatis an antigen associated with a cancer, an inflammatory disease, anautoimmune disease, or a graft versus host disease.

In additional embodiments, the cancer is a solid malignancy or ahematologic malignancy.

In particular embodiments, the hematologic malignancy associated antigentarget is CD19, CD20, CD22, CD33, or CD37.

In some embodiments, the binding domain specifically binds to a targetselected from α-folate receptor, α_(v)β₆ integrin, BCMA, B7-H3, B7-H6,CAIX, CD19, CD20, CD22, CD30, CD33, CD37, CD44, CD44v6, CD44v7/8, CD70,CD123, CD138, CD171, CEA, DLL4, EGP-2, EGP-40, CSPG4, EGFR, EGFR familyincluding ErbB2 (HER2), EGFRvIII, EPCAM, EphA2, EpCAM, FAP, FBP, fetalacetylcholine receptor, Fzd7, GD2, GD3, Glypican-3 (GPC3), h5T4,IL-11Rα, IL13R-α2, KDR, κ light chain, λ light chain, LeY, L1CAM,MAGE-A1 mesothelin, MHC presented peptides, MUC1, MUC16, NCAM, NKG2Dligands, Notch 1, Notch2/3, NY-ESO-1, PRAME, PSCA, PSMA, Survivin,TAG-72, TEMs, TERT, VEGFR2, and ROR1.

In further embodiments, the encoded first fusion protein comprises afirst multimerization domain of FRB T2098L, a transmembrane domain, acostimulatory domain of 4-1BB, and actuator domain of CD3ζ;wherein thesecond encoded fusion protein comprises a binding domain of an scFvspecific for CD19 and a second multimerization domain of FKBP12 and aCD154 or a CD71 transmembrane domain; and wherein the first bridgingfactor that promotes the formation of a polypeptide complex on thenon-natural cell surface is rapalog AP21967.

In particular embodiments, the encoded first fusion protein comprises afirst multimerization domain of FRB, a transmembrane domain, acostimulatory domain of 4-1BB, and actuator domain of CD3ζ; wherein thesecond encoded fusion protein comprises a binding domain of an scFvspecific for CD19 and a second multimerization domain of FKBP12 and aCD154 or a CD71 transmembrane domain; and wherein the first bridgingfactor that promotes the formation of a polypeptide complex on thenon-natural cell surface is Rapamycin, temsirolimus or everolimus.

In various embodiments, the present invention contemplates, in part, amethod for treating a hyperproliferative, inflammatory, autoimmune, orgraft-versus-host disease, comprising: administering a non-natural cellaccording to any one of embodiments contemplated herein; andadministering a bridging factor, wherein the bridging factor promotesthe formation of a polypeptide complex on the recombinant cell surfacewith the bridging factor associated with and disposed between themultimerization domains of the first and second fusion proteins; whereinthe binding domain of the polypeptide complex specifically binds a cellsurface target on a hyperproliferative, inflammatory, autoimmune, orgraft-versus-host disease cell to promote an immunomodulatory responseand thereby treats the hyperproliferative, inflammatory, autoimmune, orgraft-versus-host disease.

In certain embodiments, the method further comprises administering anagent that antagonizes or blocks an inhibitor of T-cell activation.

In additional embodiments, the agent antagonizes or blocks a T-cellligand.

In particular embodiments, the agent antagonizes or blocks a T-cellreceptor.

In particular embodiments, the agent that antagonizes or blocks aninhibitor of T-cell activation is an anti-PD1 antibody or antigenbinding fragment thereof, anti-PD-L1 antibody or antigen bindingfragment thereof, or an anti-CTLA4 antibody or antigen binding fragmentthereof or an engineered homing endonuclease that targets PD-1.

In some embodiments, the method further comprises administering acytokine agonist.

In various embodiments, the present invention contemplates, in part, afusion polypeptide heterocomplex, comprising: a first fusion proteincomprising a first multimerization domain, a first hydrophobic domain,and an actuator domain; a second fusion protein comprising anextracellular binding domain, a second multimerization domain, and asecond hydrophobic domain; and a bridging factor; wherein the firstfusion protein, second fusion protein, and bridging factor associate toform a polypeptide heterocomplex with the bridging factor associatedwith and disposed between the multimerization domains of the first andsecond fusion proteins.

In further embodiments, the binding domain is a single chain antibodyvariable region, a receptor ectodomain, or a ligand.

In certain embodiments, the single chain antibody variable region is adomain antibody, sFv, scFv, F(ab′)₂, or Fab.

In certain embodiments, the binding domain is amino terminal to themultimerization domain.

In some embodiments, the binding domain is carboxy terminal to themultimerization domain.

In particular embodiments, the first multimerization domain comprises afirst FKBP polypeptide or variant thereof, and the secondmultimerization domain comprises a first FRB polypeptide or variantthereof.

In additional embodiments, the first multimerization domain comprises afirst FRB polypeptide or variant thereof, and the second multimerizationdomain comprises a first FKBP polypeptide or variant thereof.

In particular embodiments, the first hydrophobic domain is atransmembrane domain.

In some embodiments, the second hydrophobic domain comprises a CD154transmembrane domain.

In certain embodiments, the second hydrophobic domain comprises a CD71transmembrane domain.

In particular embodiments, the first hydrophobic domain and the secondhydrophobic domain do not increase cytotoxic activity of the non-naturalcell in the absence of the bridging factor.

In further embodiments, the first hydrophobic domain and the secondhydrophobic domain increase cytotoxic activity of the non-natural cellin the absence of the bridging factor, wherein the increase in cytotoxicactivity is less than the cytotoxic activity in the presence of thebridging factor.

In certain embodiments, the actuator domain comprises a lymphocytereceptor chain.

In particular embodiments, the bridging factor is rapamycin or a rapalogthereof, coumermycin or a derivative thereof, gibberellin or aderivative thereof, ABA or a derivative thereof, methotrexate or aderivative thereof, cyclosporin A or a derivative thereof, FKCsA or aderivative thereof, or Tmp-SLF or a derivative thereof.

In additional embodiments, the second fusion protein further comprises asub-threshold signaling domain.

In some embodiments, the binding domain is specific for a target that isan antigen associated with a cancer, an inflammatory disease, anautoimmune disease, or a graft versus host disease.

In particular embodiments, the cancer is a hematologic malignancy havingan antigen target of CD19, CD20, CD22, CD33, or CD37.

In various embodiments, the present invention contemplates, in part, anucleic acid molecule encoding any one or more of the fusion proteinscontemplated herein.

In certain embodiments, the nucleic acid molecule is disposed between 5′and 3′ polynucleotide sequences homologous to a genomic locus.

In various embodiments, the present invention contemplates, in part, anexpression vector containing a nucleic acid encoding any one or more ofthe fusion proteins contemplated herein.

In further embodiments, the first and second fusion proteins are encodedas a polycistronic message or as a single protein separated by a 2Apeptide.

In additional embodiments, the polycistronic message comprises aninternal ribosome entry site (IRES) between the nucleotide sequencesthat encode the fusion proteins.

In particular embodiments, the first protein is expressed from a firstpromoter and the second fusion protein is expressed from a secondpromoter.

In some embodiments, the first promoter is selected from the groupconsisting of: a CMV promoter, an EF1α promoter, and an MND promoter.

In particular embodiments, the second promoter is selected from thegroup consisting of: a CMV promoter, an EF1α promoter, and an MNDpromoter.

In further embodiments, the first promoter and the second promoter arenot the same promoter.

BRIEF DESCRIPTION THE DRAWINGS

FIGS. 1A-1M show schematics of various types of multipartite signalingcomplexes of this disclosure.

FIG. 2 shows a schematic of an assay to detect specific cell killing andcytokine secretion with a particular multipartite signaling complex ofthis disclosure.

FIGS. 3A and 3B show the cytotoxic properties of human T cellsexpressing a multipartite signaling complex of this disclosure.

FIG. 4 shows the cytokine secretion profile of human T cells expressinga multipartite signaling complex of this disclosure.

FIG. 5 shows that use of independent multimerization domains havingdifferent specificities for bridging components allows for directedcytotoxic activity of human T cells expressing a multipartite signalingcomplex of this disclosure. In addition, this figure shows that human Tcells expressing a multipartite signaling complex of this disclosure canbe cytotoxic even when the DARIC binding and signaling components areindividually expressed in separate cells.

FIG. 6 shows that bridging factors can function in the DARIC system atclinically relevant concentrations.

FIG. 7 shows that a DARIC binding component can be released from a cellor tethered to the cell surface and still functionally associate with aDARIC signaling component to form a multipartite signaling complex ofthis disclosure.

FIG. 8 shows that a DARIC binding component may be tethered to the cellsurface via GPI-anchor and still functionally associate with a DARICsignaling component in the presence of a bridging factor to form amultipartite signaling complex of this disclosure.

FIG. 9 shows a DARIC system targeting an additional model antigen,CD123, that may be used either to eradicate a myeloid cancer, or in aconditioning regimen to ablate myeloid cells prior to a bone marrowtransplant.

FIG. 10 shows that the FRB and FKBP12 multimerization domains may beappended to the DARIC binding component or signaling component and stillform a functional multipartite signaling complex in the presence of abridging factor.

FIG. 11 shows that the coupling of the DARIC binding and signalingcomponents can be deactivated by the addition of an anti-bridgingfactor, a monovalent drug that binds only to one of the multimerizationdomains and thereby blocks the activation of the cell.

FIG. 12 shows that T cells harboring a dual vector promoter thatexpresses both the DARIC binding component and the DARIC signalingcomponent mediates a target cell specific cytotoxic response.

FIGS. 13A-C show that T cells expressing a DARIC signaling component canmediate antigen specific cytotoxicity when a soluble DARIC bindingcomponent that recognizes the target cell is provided in trans, e.g.,secreted into the culture medium or extracellular milieu as a model fordelivery of the DARIC binding component as a separate biologic drug.

FIGS. 14A-B shows that a prototypical transmembrane DARIC bindingcomponent harboring a CD4 transmembrane domain has residual signalingactivity in the absence of a bridging factor against autologous B cells.The residual signaling activity is reduced or eliminated when the CD4transmembrane domain is replaced with another transmembrane domain,e.g., a CD71 or CD154 transmembrane domain.

FIG. 15A shows that T cells expressing DARIC complexes comprisingalternative transmembrane domains (CD154 TM) have increased antigenspecific cytotoxicity in the presence a bridging factor and also showlittle or no basal cytotoxicity in the absence of the bridging factor.FIG. 15B shows that T cells expressing DARIC complexes comprisingalternative transmembrane domains (CD71 TM) or transmembrane topologymaintain antigen specific cytotoxicity in the presence a bridging factorand also show reduced basal cytotoxicity in the absence of the bridgingfactor.

DETAILED DESCRIPTION

In one embodiment, multi-component fusion proteins for use in modulatinga biological response to immunotherapy, such as adoptive immunotherapy,are provided. By way of background, signal transduction by cell surfacereceptors converts extracellular information into intracellularresponses and requires machinery for both ligand recognition andtransmembrane signal transduction. Cell surface receptors recognizeligands through the use of an extracellular binding domain and, uponligand binding, transduce signals across the plasma membrane viamembrane spanning domains connected with intracellular signalingdomains. These occur either as single-chain units, where binding andsignaling are linked directly, or through multi-chain contacts wherebycell surface binding of ligand allows intracellular interactions ofsignaling domains with other proteins to mediate cell signaltransduction.

An advantage of the compositions and methods contemplated herein is toprovide both spatial and temporal control over such signal transductionbinding and signaling activities. Since the binding componentisexpressed on the surface, or delivered in a recombinant form, it isthen present in the extracellular environment without being basallycoupled to any cell signal transduction machinery. The transmembranesignaling fusion protein to be expressed by the cell of interestcomprises one or more intracellular signaling (actuator) domains fusedvia a transmembrane domain to an extracellular multimerization domain,such as a FRB or FKBP12 protein (whichever is not present on the bindingcomponent).

In one embodiment, this disclosure provides a binding component and asignaling component that are each expressed as separate fusion proteins,but contain an extracellular multimerization mechanism (bridging factor)for recoupling of the two functional components on a cellsurface—referred to herein as DARIC binding and signalingcomponents—which provides temporal control. In particular embodiments,DARIC components have surprisingly low or negligible recoupling in theabsence of the bridging factor but still maintain potent cell signalingproperties in the presence of bridging factor.

But, the temporal control achieved through the multimerization mechanismdescribed herein only primes the machinery for signaling. The chemicallyinduced multimerization reconstitutes a signaling-potentiated receptor,but it does not activate downstream signaling because there is noaggregation of intracellular signaling components. Spatial control is,therefore, achieved on the basis of the presence or absence of a targetrecognized by the binding domain on the binding component. Since thebinding component fusion protein is displayed on the outside of thecell, it only localizes to cells expressing the target antigen, suchthat cells will only become activated when both target antigen (e.g.,cell surface antigen) and the bridging factor are present.

In certain embodiments, a recombinant or non-natural cell comprises afirst nucleic acid molecule encoding a first fusion protein comprising afirst multimerization domain, a first hydrophobic domain, and anactuator domain, wherein the first multimerization domain localizesextracellularly when the first fusion protein is expressed isadministered to a subject having a hyperproliferative disease (e.g.,cancer), an inflammatory disease, an autoimmune disease, or agraft-versus-host disease. Such a fusion protein can be referred to as aDARIC signaling component, which may be expressed as one or moretransmembrane protein(s). A DARIC signaling component may contain morethan one multimerization domain, including a multimerization domain thatpromotes homodimerization in the presence of homo-bivalent bridgingfactor. In such an embodiment (see FIG. 1c ), the administration of abridging factor will promote some level of basal signaling in theabsence of binding to an extracellular target—for example, as a way todrive cell proliferation in vitro or in vivo prior to activation with aDARIC binding component (which in this context functions like a drug).For T cells, it is known that lower level activation promotesproliferation, whereas the higher order multimerization (as would occurby high density of antigen on a target cell and heterodimerization ofthe DARIC components with a bridging component) would lead to activationof a cytotoxicity response.

In further embodiments, a subject receiving a recombinant (non-natural)cell (e.g., T cell) expressing a DARIC signaling component and a fusionprotein comprising a binding domain, a multimerization domain, and ahydrophobic domain (e.g., CD154 or CD71 transmembrane domain)—a DARICbinding component—and a bridging factor (e.g., rapamycin or rapalogthereof) to promote the formation of a polypeptide complex on thenon-natural cell surface with the bridging factor associated with anddisposed between the multimerization domains of the first and secondfusion proteins (DARIC signaling and binding components, respectively).In certain embodiments, a nucleic acid molecule further encodes a fusionprotein comprising a secretion signal, a binding domain, amultimerization domain, and a hydrophobic domain wherein the fusionprotein (DARIC binding component) is secreted from the non-natural cellwhen expressed. In some embodiments, a nucleic acid molecule furtherencodes a fusion protein comprising a secretion signal, a bindingdomain, a multimerization domain, and a hydrophobic domain wherein theexpressed fusion protein (DARIC binding component) is expressed on thecell surface of the non-natural cell (see FIG. 11-K). The DARIC bindingcomponent will specifically bind to a target cell (e.g., cancer,autoimmune) either before or after associating with the DARIC signalingcomponent through the bridging factor, wherein in the absence of thebridging factor the complex will not elicit an appreciable cellularresponse, and wherein the tripartite association of the two DARICcomponents and bridging factor will trigger a cellular response thattreats the hyperproliferative, inflammatory, autoimmune, orgraft-versus-host disease. For example, the presence at least one DARICbinding component and a cell surface target would lead to increasingsignals proportional to the density of target due to multimerization.

In a further embodiment, the DARIC signaling component may be created byleveraging existing activating receptors on the cell (e.g., T cell)surface using a drug regulated bi-specific engager (BiTE). In thisinstance, both DARIC components are secreted: a binding component thatbinds to a target cell, and a signaling component that binds to areceptor (e.g., the TCR/CD3 complex) on a T cell. In one embodiment, anon-natural cell secretes both components. In another embodiment, one ormore non-natural cells secretes one or more of the components.

In a particular embodiment, a non-natural cell further comprises adeconstructed drug regulated bispecific T cell engager (BiTE) expressedas separate fusion proteins is provided. The BiTE comprises a DARICsignaling component comprising a binding agent that binds a T cellreceptor and a first multimerization domain; and a DARIC bindingcomponent comprising a binding agent that binds an antigen on a targetcell and a second multimerization domain, such as a FRB or FKBP12protein (whichever is not present on the binding component). Only uponthe application of the FRB/FKBP12 coupling drug (e.g., rapamycin or arapalog thereof) do the BiTE components form a complex that is capableof initiating signal transduction.

In particular preferred embodiments, DARIC signaling and bindingcomponents are provided that exhibit potent antigen specific cytotoxicresponses in the presence of a bridging factor and minimal ornon-detectable cytotoxic activity in the absence of the bridging factor,e.g., FIG. 15.

Prior to setting forth this disclosure in more detail, it may be helpfulto an understanding thereof to provide definitions of certain terms tobe used herein. Additional definitions are set forth throughout thisdisclosure.

Reference throughout this specification to “one embodiment,” “anembodiment,” “a particular embodiment,” “a related embodiment,” “acertain embodiment,” “an additional embodiment,” or “a furtherembodiment” or combinations thereof means that a particular feature,structure or characteristic described in connection with the embodimentis included in at least one embodiment of the present invention. Thus,the appearances of the foregoing phrases in various places throughoutthis specification are not necessarily all referring to the sameembodiment. Furthermore, the particular features, structures, orcharacteristics may be combined in any suitable manner in one or moreembodiments. It is also understood that the positive recitation of afeature in one embodiment, serves as a basis for excluding the featurein a particular embodiment.

In the present description, any concentration range, percentage range,ratio range, or integer range is to be understood to include the valueof any integer within the recited range and, when appropriate, fractionsthereof (such as one tenth and one hundredth of an integer), unlessotherwise indicated. Also, any number range recited herein relating toany physical feature, such as polymer subunits, size or thickness, areto be understood to include any integer within the recited range, unlessotherwise indicated. As used herein, the terms “about” means (1)±1%,±2%, ±3%, ±4%, ±5%, ±10%, ±15%, or ±20% of the indicated range, value orstructure; (2) a value includes the inherent variation of error for themethod being employed to determine the value; or (3) a value includesthe variation that exists among replicate experiments, unless otherwiseindicated. It should be understood that the terms “a” and “an” as usedherein refer to “one or more” of the enumerated components. The use ofthe alternative (e.g., “or”) should be understood to mean either one,both, or any combination thereof of the alternatives or enumeratedcomponents. As used herein, the terms “include,” “have” and “comprise”are used synonymously, which terms and variants thereof are intended tobe construed as non-limiting.

As used herein, a protein or polypeptide “consists essentially of”several domains (e.g., a binding domain, a linker or spacer, ahydrophobic domain, a multimerization domain, an actuator domain) whenthe portions outside of the several domains (e.g., amino acids at theamino- or carboxy-terminus or between two domains), in combination,contribute to at most 20% (e.g., at most 15%, 10%, 8%, 6%, 5%, 4%, 3%,2% or 1%) of the length of the protein or polypeptide and do notsubstantially affect (i.e., do not alter the activity by more than 50%,such as no more than 40%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%)the activities of one or more of the various domains (e.g., the targetbinding affinity of the binding domain, the capability of themultimerization domain to facilitate complex formation, and thecapability of the actuator domain to transmit functional signals to acell). In certain embodiments, a protein (e.g., a single chainpolypeptide) consists essentially of a binding domain that specificallybinds a target, a linker, and a multimerization domain, wherein theprotein may comprise junction amino acids at the amino- and/orcarboxy-terminus of the protein or between two different domains (e.g.,between the binding domain and the multimerization domain, between themultimerization domain and the linker).

A “fusion protein” or “chimeric protein,” as used herein, refers to aprotein that includes polypeptide components derived from one or moreparental proteins or polypeptides and does not naturally occur in a hostcell. A fusion protein will contain two or more naturally-occurringamino acid sequences that are linked together in a way that does notoccur naturally. For example, a fusion protein may have two or moreportions from the same protein linked in a way not normally found in acell, or a fusion protein may have portions from two, three, four, fiveor more different proteins linked in a way not normally found in a cell.A fusion protein can be encoded by a nucleic acid molecule wherein anucleotide sequence encoding one protein or portion thereof is appendedin frame with, and optionally separated by nucleotides that encode alinker, spacer or junction amino acids, a nucleic acid molecule thatencodes one or more different proteins or a portion thereof. In certainembodiments, a nucleic acid molecule encoding a fusion protein isintroduced into a host cell and expressed.

As used herein, the term “host” refers to a cell (e.g., T cell) ormicroorganism that may be genetically modified with an exogenous nucleicacid molecule to produce a polypeptide of interest (e.g., DARIC bindingor signaling components). In certain embodiments, a host cell mayoptionally already possess or be modified to include other geneticmodifications that confer desired properties related or unrelated tofusion protein biosynthesis (e.g., deleted, altered or truncated TCR;increased costimulatory factor expression). In certain embodiments, ahost cell is a human T cell or a human T cell with TCRα, TCRβ, or bothknocked out with a site-specific nuclease (e.g., a LAGLIDADG homingendonuclease, LHE).

As used herein, “recombinant” or “non-natural” refers to an organism,microorganism, cell, nucleic acid molecule, or vector that has at leastone engineered genetic alteration or has been modified by theintroduction of a heterologous nucleic acid molecule, or refers to acell that has been altered such that the expression of an endogenousnucleic acid molecule or gene can be controlled. Recombinant also refersto a cell that is derived from a non-natural cell or is progeny of anon-natural cell having one or more such modifications. Geneticalterations include, for example, modifications introducing expressiblenucleic acid molecules encoding proteins, or other nucleic acid moleculeadditions, deletions, substitutions or other functional alteration of acell's genetic material. For example, recombinant cells may expressgenes or other nucleic acid molecules that are not found in identical orhomologous form within a native (wild-type) cell (e.g., a fusion orchimeric protein), or may provide an altered expression pattern ofendogenous genes, such as being over-expressed, under-expressed,minimally expressed, or not expressed at all.

Recombinant methods for expression of exogenous or heterologous nucleicacids in cells are well known in the art. Such methods can be founddescribed in, for example, Sambrook et al., Molecular Cloning: ALaboratory Manual, Third Ed., Cold Spring Harbor Laboratory, N.Y.(2001); and Ausubel et al., Current Protocols in Molecular Biology, JohnWiley and Sons, Baltimore, Md. (1999). Exemplary exogenous proteins orenzymes to be expressed include scFv, CD3ζ,FKBP, FRB, cytokines, or anycombination thereof. Genetic modifications to nucleic acid moleculesencoding fusion proteins can confer a biochemical or metaboliccapability to a recombinant or non-natural cell that is altered from itsnaturally occurring state.

As used herein, the term “endogenous” or “native” refers to a gene,protein, compound or activity that is normally present in a host cell.The term “homologous” or “homolog” refers to a molecule or activity froman exogenous (non-native) source that is the same or similar molecule oractivity as that found in or derived from a host cell, species orstrain.

As used herein, “heterologous” nucleic acid molecule, construct orsequence refers to a nucleic acid molecule or portion of a nucleic acidmolecule sequence that is not native to a cell in which it is expressed,a nucleic acid molecule or portion of a nucleic acid molecule native toa host cell that has been altered or mutated, or a nucleic acid moleculewith an altered expression as compared to the native expression levelsunder similar conditions. For example, a heterologous control sequence(e.g., promoter, enhancer) may be used to regulate expression of a geneor a nucleic acid molecule in a way that is different than the gene or anucleic acid molecule that is normally expressed in nature or culture.In certain embodiments, a heterologous nucleic acid molecule may behomologous to a native host cell gene, but may have an alteredexpression level or have a different sequence or both. In otherembodiments, heterologous or exogenous nucleic acid molecules may not beendogenous to a host cell or host genome (e.g., fusion protein), butinstead may have been introduced into a host cell by transformation(e.g., transfection, electroporation), wherein the added molecule mayintegrate into the host genome or can exist as extra-chromosomal geneticmaterial either transiently (e.g., mRNA) or stably for more than onegeneration (e.g., episomal viral vector, plasmid or otherself-replicating vector).

In certain embodiments, more than one heterologous or exogenous nucleicacid molecule can be introduced into a host cell as separate nucleicacid molecules, as a polycistronic nucleic acid molecule, as a singlenucleic acid molecule encoding a fusion protein, or any combinationthereof, and still be considered as more than one heterologous orexogenous nucleic acid. When two or more exogenous nucleic acidmolecules are introduced into a host cell, it is understood that the twomore exogenous nucleic acid molecules can be introduced as a singlenucleic acid molecule (e.g., on a single vector), on separate vectors,as single or multiple mRNA molecules, integrated into the hostchromosome at a single site or multiple sites, and each of theseembodiments is still to be considered two or more exogenous nucleic acidmolecules. Thus, the number of referenced heterologous nucleic acidmolecules or protein activities refers to the number of encoding nucleicacid molecules or the number of protein activities, not the number ofseparate nucleic acid molecules introduced into a host cell.

For example, a cell can be modified to express two or more heterologousor exogenous nucleic acid molecules, which may be the same or different,that encode one or more fusion proteins, as disclosed herein. In certainembodiments, a host cell will contain a first nucleic acid moleculeencoding a first fusion protein and a separate second nucleic acidmolecule encoding a second fusion protein, or a host cell will contain asingle polycistronic nucleic acid molecule that encodes a first fusionprotein and second fusion protein, or single nucleic acid molecule thatencodes a first fusion protein, a self-cleaving amino acid sequence anda second fusion protein.

Suitable protease cleavages sites and self-cleaving peptides are knownto the skilled person (see, e.g., in Ryan et al., 1997. J. Gener. Virol.78, 699-722; Scymczak et al. (2004) Nature Biotech. 5, 589-594).Exemplary protease cleavage sites include, but are not limited to thecleavage sites of potyvirus NIa proteases (e.g., tobacco etch virusprotease), potyvirus HC proteases, potyvirus P1 (P35) proteases,byovirus NIa proteases, byovirus RNA-2-encoded proteases, aphthovirus Lproteases, enterovirus 2A proteases, rhinovirus 2A proteases, picorna 3Cproteases, comovirus 24K proteases, nepovirus 24K proteases, RTSV (ricetungro spherical virus) 3C-like protease, PYVF (parsnip yellow fleckvirus) 3C-like protease, heparin, thrombin, factor Xa and enterokinase.Due to its high cleavage stringency, TEV (tobacco etch virus) proteasecleavage sites are preferred in one embodiment, e.g., EXXYXQ(G/S), forexample, ENLYFQG and ENLYFQS, wherein X represents any amino acid(cleavage by TEV occurs between Q and G or Q and S).

In certain embodiments, the self-cleaving polypeptide site comprises a2A or 2A-like site, sequence or domain (Donnelly et al., 2001. J. Gen.Virol. 82:1027-1041). In a particular embodiment, the viral 2A peptideis an aphthovirus 2A peptide, a potyvirus 2A peptide, or a cardiovirus2A peptide.

In one embodiment, the viral 2A peptide is selected from the groupconsisting of: a foot-and-mouth disease virus (FMDV) 2A peptide, anequine rhinitis A virus (ERAV) 2A peptide, a Thosea asigna virus (TaV)2A peptide, a porcine teschovirus-1 (PTV-1) 2A peptide, a Theilovirus 2Apeptide, and an encephalomyocarditis virus 2A peptide.

A “polypeptide complex” or “protein complex,” as used herein, refers toa dimer, trimer, or higher order multimer formed by at least twodifferent single chain polypeptides, comprising at least one chainhaving a binding domain specific for a target and one chain having anactuator domain. This term does not include an antibody formed from foursingle chain polypeptides (i.e., two light chains and two heavy chains).A “dimer” refers to a biological entity that contains two subunitsassociated with each other, and a “polypeptide complex” refers to abiological entity that includes at least two proteins subunits and abridging factor associated with each other, via one or more forms ofintramolecular forces, including covalent bonds (e.g., disulfide bonds)and other interactions (e.g., electrostatic interactions, salt bridges,hydrogen bonding, and hydrophobic interactions), and is stable underappropriate conditions (e.g., under physiological conditions, in anaqueous solution suitable for expressing, purifying, and/or storingrecombinant proteins, or under conditions for non-denaturing and/ornon-reducing electrophoresis).

A “single chain polypeptide” is a single, linear and contiguousarrangement of covalently linked amino acids. It does not include twopolypeptide chains that link together in a non-linear fashion, such asvia an interchain disulfide bond (e.g., a half immunoglobulin moleculein which a light chain links with a heavy chain via a disulfide bond).In certain embodiments, a single chain polypeptide may have or form oneor more intrachain disulfide bonds. In certain other embodiments, two ormore single chain polypeptides (e.g., fusion proteins) may associate viaan interchain disulfide bond to provide a potentially active complexprovided the complex is made up of at least one non-natural protein,such as fusion or chimeric proteins and is not a natural antibody.

A “multimerization domain,” as used herein, refers to a polypeptidemolecule that preferentially interacts or associates with anotherdifferent polypeptide molecule directly or via a bridging molecule,wherein the interaction of the different multimerization domainssubstantially contribute to or efficiently promote multimerization(i.e., the formation of a dimer, trimer, or multipartite complex, whichmay be a homodimer, heterodimer, homotrimer, heterotrimer, homomultimer,heteromultimer). Representative multimerization domains of the presentdisclosure include an FKBP, FRB, calcineurin, cyclophilin, bacterialDHFR, PYL1, ABI1, GIB1, GAI, or variants thereof, as provided herein.

In certain embodiments, a polypeptide complex comprises (i) a firstfusion protein having a first multimerization domain and (ii) secondfusion protein having a second multimerization domain that is not thesame as the first multimerization domain, wherein the first and secondmultimerization domains substantially contribute to or efficientlypromote formation of the polypeptide complex in the presence of abridging factor. The interaction(s) between the first and secondmultimerization domains substantially contributes to or efficientlypromotes the multimerization of the first and second fusion proteins ifthere is a statistically significant reduction in the associationbetween the first and second fusion proteins in the absence of the firstmultimerization domain, the second multimerization domain, or thebridging factor. In certain embodiments, when the first and secondfusion proteins are co-expressed, at least about 60%, for instance, atleast about 60% to about 70%, at least about 70% to about 80%, at leastabout 80% to about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or100%, and at least about 90% to about 92%, 93%, 94%, 95%, 96%, 97%, 98%,or 99% of the first and second single chain polypeptides form multimerswith each other in the presence of a bridging factor.

As used herein, “hydrophobic domain” refers to an amino acid sequencehaving a three-dimensional structure that is thermodynamically stable ina cell membrane. The structure of a hydrophobic domain may comprise analpha helix, a beta barrel, a beta sheet, a beta helix, or anycombination thereof. In certain embodiments, a hydrophobic domain is atransmembrane domain, such as one derived from an integral membraneprotein (e.g., receptor, cluster of differentiation (CD) molecule,enzyme, transporter, cell adhesion molecule, or the like).

As used herein, “anchor domain” refers to an amino acid sequence orother molecule that promotes tethering, anchoring or association of afusion protein of this disclosure with a cell surface. Exemplary anchordomains include an amino acid sequence with a structure that is stablein a cell membrane or an amino acid sequence that promotes the additionof a glycolipid (also known as glycosyl phosphatidylinositols or GPIs),or the like. By way of background, a GPI molecule ispost-translationally attached to a protein target by a transamidationreaction, which results in the cleavage of a carboxy-terminal GPI signalsequence (see, e.g., White et al., J. Cell Sci. 113:721, 2000) and thesimultaneous transfer of the already synthesized GPI anchor molecule tothe newly formed carboxy-terminal amino acid (seewww.ncbi.nlm.nih.gov/books/NBK20711 for exemplary GPI anchors, which GPIanchors are incorporated by reference in their entirety. In certainembodiments, an anchor domain is a hydrophobic domain (e.g.,transmembrane domain) or a GPI signal sequence. In some embodiments, anucleic acid molecule encoding a fusion protein of this disclosure withan anchor domain results in a fusion protein further comprising a GPImolecule.

An “actuator domain,” as used herein, directly or indirectly, promotes abiological or physiological response in a cell when receiving theappropriate signal. In certain embodiments, the actuator domain is partof a protein or protein complex that receives a signal when bound or itbinds to a target molecule and the binding triggers a signal from theactuator domain. The actuator domain may directly promote a cellularresponse when it contains signaling domains or motifs, such as animmunoreceptor tyrosine-based activation motif (ITAM). In otherembodiments, an actuator domain will indirectly promote a cellularresponse by associating with one or more other proteins that directlypromote a cellular response. Exemplary actuator domains include CD2,CD3ε, CD3δ, CD3ζ, pTα, TCRα, TCRβ, FcRα, FcRβ, FcRγ, NKG2D, CD79A,CD79B, CD22, CD27, CD28, CD30, CD40, LAT, Zap70, ICOS, DAP10, 4-1BB,CARD11, HVEM, LAG3, SLAMF1, Lck, Fyn, Slp76, TRIM, OX40, or anycombination thereof.

In particular embodiments, a “transmembrane domain” refers to a portionof the signaling component that fuses an extracellular multimerizationdomain and one or more intracellular signaling domains and anchors thesignaling component to the plasma membrane of the T cell. In oneembodiment, the transmembrane domain may be heterologous to otherdomains of the fusion polypeptides contemplated herein. In certainembodiments, a “transmembrane domain” refers to a portion of the bindingcomponent that is fused to an extracellular multimerization domain andanchors the binding component to the plasma membrane of the T cell. Thetransmembrane domain may be derived either from a natural, synthetic,semi-synthetic, or recombinant source. Illustrative transmembranedomains may be derived from (i.e., comprise at least the transmembraneregion(s) of) the alpha, beta or zeta chain of the T-cell receptor,CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37,CD45, CD64, CD71, CD80, CD86, CD 134, CD137, CD152, CD 154, AMN, andPD1. In various embodiments, a transmembrane domain of a bindingcomponent and/or signaling component is fused to a short oligo- orpolypeptide linker, preferably between 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10amino acids in length and that optionally links the transmembrane domainand the intracellular signaling domain of the signaling component. Inparticular embodiments, a fusion protein contemplated herein comprises atype I transmembrane domain. In other embodiments, a fusion proteincontemplated herein comprises a type II transmembrane domain. In certainembodiments, a fusion protein contemplated herein comprises a type Itransmembrane domain that has been converted to a type I transmembranedomain from a type II transmembrane domain. In other embodiments, afusion protein contemplated herein comprises a type II transmembranedomain that has been converted to a type II transmembrane domain from atype I transmembrane domain.

A “binding domain” (also referred to as a “binding region,” “bindingagent,” or “binding moiety”), as used herein, refers to one or moreproteins, polypeptides, oligopeptides, or peptides that possesses theability to specifically recognize and bind to a target (e.g., CD19,CD20). A binding domain includes any naturally occurring, synthetic,semi-synthetic, or recombinantly produced binding partner for abiological molecule or another target of interest. Exemplary bindingdomains include single chain antibody variable regions (e.g., domainantibodies, sFv, scFv, Fab), receptor ectodomains (e.g., c-Met), orligands (e.g., cytokines, chemokines, or cell surface associatedligands). In particular embodiments, a binding domain comprises anantibody or antigen binding fragment thereof, including but not limitedto a Camel Ig (a camelid antibody (VHH)), Ig NAR, Fab fragments, Fab′fragments, F(ab)′2 fragments, F(ab)′3 fragments, Fv, single chain Fvantibody (“scFv”), bis-scFv, (scFv)2, minibody, diabody, triabody,tetrabody, disulfide stabilized Fv protein (“dsFv”), and single-domainantibody (sdAb, Nanobody). A variety of assays are known for identifyingbinding domains of the present disclosure that specifically bind aparticular target, including Western blot, ELISA, and Biacore analysis.

A binding domain and a fusion protein thereof “specifically binds” atarget if it binds the target with an affinity or K_(a) (i.e., anequilibrium association constant of a particular binding interactionwith units of 1/M) equal to or greater than 10⁵ M⁻¹, while notsignificantly binding other components present in a test sample. Bindingdomains (or fusion proteins thereof) may be classified as “highaffinity” binding domains (or fusion proteins thereof) and “lowaffinity” binding domains (or fusion proteins thereof). “High affinity”binding domains refer to those binding domains with a K_(a) of at least10⁷ M⁻¹, at least 10⁸M⁻¹, at least 10⁹M⁻¹, at least 10¹⁰ M⁻¹, at least10¹¹M⁻¹, at least 10¹² M⁻¹, or at least 10¹³ M⁻¹. “Low affinity” bindingdomains refer to those binding domains with a K_(a) of up to 10⁷ M⁻¹, upto 10⁶ M⁻¹, up to 10⁵ M⁻¹. Alternatively, affinity may be defined as anequilibrium dissociation constant (Ka) of a particular bindinginteraction with units of M (e.g., 10⁻⁵ M to 10⁻¹³ M). Affinities ofbinding domain polypeptides and fusion proteins according to the presentdisclosure can be readily determined using conventional techniques (see,e.g., Scatchard et al. (1949) Ann. N.Y. Acad. Sci. 51:660; and U.S. Pat.Nos. 5,283,173, 5,468,614, or the equivalent).

“T cell receptor” (TCR) is a molecule found on the surface of T cellsthat, along with CD3, is generally responsible for recognizing antigensbound to major histocompatibility complex (MHC) molecules. It consistsof a disulfide-linked heterodimer of the highly variable a and β chainsin most T cells. In other T cells, an alternative receptor made up ofvariable y and 6 chains is expressed. Each chain of the TCR is a memberof the immunoglobulin superfamily and possesses one N-terminalimmunoglobulin variable domain, one immunoglobulin constant domain, atransmembrane region, and a short cytoplasmic tail at the C-terminal end(see, Abbas and Lichtman, Cellular and Molecular Immunology (5th Ed.),Editor: Saunders, Philadelphia, 2003; Janeway et al., Immunobiology: TheImmune System in Health and Disease, 4^(th) Ed., Current BiologyPublications, p148, 149, and 172, 1999). TCR as used in the presentdisclosure may be from one or various animal species, including human,mouse, rat, or other mammals.

“CD3” is known in the art as a multi-protein complex of six chains (see,Abbas and Lichtman, 2003; Janeway et al., p172 and 178, 1999). Inmammals, the complex comprises a CD3γ chain, a CD3δ chain, two CD3εchains, and a homodimer of CD3ζ chains. The CD3γ, CD3δ and CD3ε chainsare highly related cell surface proteins of the immunoglobulinsuperfamily containing a single immunoglobulin domain. The transmembraneregions of the CD3γ, CD3δ,and CD3ε chains are negatively charged, whichis a characteristic that allows these chains to associate with thepositively charged T cell receptor chains. The intracellular tails ofthe CD3γ, CD3δ, and CD3ε chains each contain a single conserved motifknown as an immunoreceptor tyrosine-based activation motif or ITAM,whereas each CD3ζ chain has three. It is believed the ITAMs areimportant for the signaling capacity of a TCR complex. CD3 as used inthe present disclosure may be from one or various animal species,including human, mouse, rat, or other mammals.

“TCR complex,” as used herein, refers to a complex formed by theassociation of CD3 with TCR. For example, a TCR complex can be composedof a CD3γ chain, a CD3δ chain, two CD3ε chains, a homodimer of CD3ζchains, a TCRα chain, and a TCRβ chain. Alternatively, a TCR complex canbe composed of a CD3γ chain, a CD3δ chain, two CD3ε chains, a homodimerof CD3ζ chains, a TCRγ chain, and a TCRδ chain.

“A component of a TCR complex,” as used herein, refers to a TCR chain(i.e., TCRα, TCRβ, TCRγ or TCRδ), a CD3 chain (i.e., CD3γ, CD3δ, CD3ε orCD3ζ), or a complex formed by two or more TCR chains or CD3 chains(e.g., a complex of TCRα and TCRβ, a complex of TCRγ and TCRδ, a complexof CD3ε and CD3δ,a complex of CD3γ and CD3ε, or a sub-TCR complex ofTCRα, TCRβ, CD3γ, CD3δ, and two CD3ε chains).

Terms understood by those in the art of antibody technology are eachgiven the meaning acquired in the art, unless expressly defineddifferently herein. Antibodies are known to have variable regions, ahinge region, and constant domains. Immunoglobulin structure andfunction are reviewed, for example, in Harlow et al., Eds., Antibodies:A Laboratory Manual, Chapter 14 (Cold Spring Harbor Laboratory, ColdSpring Harbor, 1988).

For example, the terms “VL” and “VH” refer to the variable bindingregion from an antibody light and heavy chain, respectively. Thevariable binding regions are made up of discrete, well-definedsub-regions known as “complementarity determining regions” (CDRs) and“framework regions” (FRs). The term “CL” refers to an “immunoglobulinlight chain constant region” or a “light chain constant region,” i.e., aconstant region from an antibody light heavy chain. The term “CH” refersto an “immunoglobulin heavy chain constant region” or a “heavy chainconstant region,” which is further divisible, depending on the antibodyisotype into CH1, CH2, and CH3 (IgA, IgD, IgG), or CH1, CH2, CH3, andCH4 domains (IgE, IgM). A “Fab” (fragment antigen binding) is the partof an antibody that binds to antigens and includes the variable regionand CH1 of the heavy chain linked to the light chain via an inter-chaindisulfide bond.

As used herein, “an Fc region constant domain portion” or “Fc regionportion” refers to the heavy chain constant region segment of the Fcfragment (the “fragment crystallizable” region or Fc region) from anantibody, which can include one or more constant domains, such as CH2,CH3, CH4, or any combination thereof. In certain embodiments, an Fcregion portion includes the CH2 and CH3 domains of an IgG, IgA, or IgDantibody and any combination thereof, or the CH3 and CH4 domains of anIgM or IgE antibody and any combination thereof. In one embodiment, theCH2CH3 or the CH3CH4 structures are from the same antibody isotype, suchas IgG, IgA, IgD, IgE, or IgM. By way of background, the Fc region isresponsible for the effector functions of an immunoglobulin, such asADCC (antibody-dependent cell-mediated cytotoxicity), ADCP(antibody-dependent cellular phagocytosis), CDC (complement-dependentcytotoxicity) and complement fixation, binding to Fc receptors (e.g.,CD16, CD32, FcRn), greater half-life in vivo relative to a polypeptidelacking an Fc region, protein A binding, and perhaps even placentaltransfer (see Capon et al., Nature, 337:525 (1989)).

A “linker” or “spacer” refers to an amino acid sequence that connectstwo proteins, polypeptides, peptides, domains, regions, or motifs andmay provide a spacer function compatible with interaction of the twosub-binding (e.g., multimerization) domains so that the resultingpolypeptide retains a specific binding affinity to a target molecule orretains signaling activity (e.g., actuator domain activity). In certainembodiments, a linker is comprised of about two to about 35 amino acids,for instance, or about four to about 20 amino acids or about eight toabout 15 amino acids or about 15 to about 25 amino acids. In otherembodiments, a spacer may have a particular structure, such as anantibody CH2CH3 domain, hinge domain or the like. In one embodiment, aspacer comprises the CH2 and CH3 domains of IgG1 or IgG4.

The DARIC components may further comprise one or more “hinge domains,”which plays a role in positioning the domains to enable proper cell/cellcontact, antigen binding and activation. A DARIC may comprises one ormore hinge domains between the binding domain and the multimerizationdomain and/or the transmembrane domain (TM) or between themultimerization domain and the transmembrane domain. The hinge domainmay be derived either from a natural, synthetic, semi-synthetic, orrecombinant source. The hinge domain can include the amino acid sequenceof a naturally occurring immunoglobulin hinge region or an alteredimmunoglobulin hinge region.

An “altered hinge region” refers to (a) a naturally occurring hingeregion with up to 30% amino acid changes (e.g., up to 25%, 20%, 15%,10%, or 5% amino acid substitutions or deletions), (b) a portion of anaturally occurring hinge region that is at least 10 amino acids (e.g.,at least 12, 13, 14 or 15 amino acids) in length with up to 30% aminoacid changes (e.g., up to 25%, 20%, 15%, 10%, or 5% amino acidsubstitutions or deletions), or (c) a portion of a naturally occurringhinge region that comprises the core hinge region (which may be 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, or 15, or at least 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, or 15 amino acids in length). In certain embodiments,one or more cysteine residues in a naturally occurring immunoglobulinhinge region may be substituted by one or more other amino acid residues(e.g., one or more serine residues). An altered immunoglobulin hingeregion may alternatively or additionally have a proline residue of awild type immunoglobulin hinge region substituted by another amino acidresidue (e.g., a serine residue).

Other illustrative hinge domains suitable for use in the DARICsdescribed herein include the hinge region derived from the extracellularregions of type 1 membrane proteins such as CD8α, CD4, CD28 and CD7,which may be wild-type hinge regions from these molecules or may bealtered. In another embodiment, the hinge domain comprises a CD8α hingeregion.

“Junction amino acids” or “junction amino acid residues” refer to one ormore (e.g., about 2-10) amino acid residues between two adjacent motifs,regions or domains of a polypeptide, such as between a binding domainand an adjacent multimerization domain or between a hydrophobic regionand an adjacent multimerization domain or between a peptide linker orspacer that links two motifs, regions or domains and an adjacentactuator domain. Junction amino acids may result from the constructdesign of a fusion protein (e.g., amino acid residues resulting from theuse of a restriction enzyme site during the construction of a nucleicacid molecule encoding a fusion protein).

An “altered domain” or “altered protein” refers to a motif, region,domain, peptide, polypeptide, or protein with a sequence identity to awild type motif, region, domain, peptide, polypeptide, or protein (e.g.,a wild type human FKBP12, FRP, ITAM, CD3ζ, TCR) of at least 75% (e.g.,80%, 82%, 84%, 86%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99%, or 99.5%). For example, an “altered FKBP” refers to a FKBP with asequence identity to a wild type FKBP (e.g., a human FKBP) of at least75% (e.g., 80%, 82%, 84%, 86%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99%, or 99.5%). Similarly, an “altered CD3ζ” refers to a CD3ζwith a sequence identity to a wild type CD3ζ (e.g., a human CD3ζ) of atleast 75% (e.g., 80%, 82%, 84%, 86%, 88%, 90%, 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99%, or 99.5%).

As used herein, “nucleic acid” or “nucleic acid molecule” refers to anyof deoxyribonucleic acid (DNA), ribonucleic acid (RNA),oligonucleotides, fragments generated, for example, by the polymerasechain reaction (PCR) or by in vitro translation, and fragments generatedby any of ligation, scission, endonuclease action, or exonucleaseaction. In certain embodiments, the nucleic acids of the presentdisclosure are produced by PCR. Nucleic acids may be composed ofmonomers that are naturally occurring nucleotides (such asdeoxyribonucleotides and ribonucleotides), analogs of naturallyoccurring nucleotides (e.g., α-enantiomeric enantiomeric forms ofnaturally-occurring nucleotides), or a combination of both. Modifiednucleotides can have modifications in or replacement of sugar moieties,or pyrimidine or purine base moieties. Nucleic acid monomers can belinked by phosphodiester bonds or analogs of such linkages. Analogs ofphosphodiester linkages include phosphorothioate, phosphorodithioate,phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate,phosphoranilidate, phosphoramidate, morpholino, or the like. The term“nucleic acid molecule” also includes “peptide nucleic acids” (PNAs),which comprise naturally occurring or modified nucleic acid basesattached to a polyamide backbone. Nucleic acid molecules can be eithersingle stranded or double stranded.

As used herein, “mutation” refers to a change in the sequence of anucleic acid molecule or polypeptide molecule as compared to a referenceor wild-type nucleic acid molecule or polypeptide molecule,respectively. A mutation can result in several different types of changein sequence, including substitution, insertion or deletion ofnucleotide(s) or amino acid(s). In other embodiments, a mutation is asubstitution of one or more nucleotides or residues.

The term “construct” refers to any polynucleotide that contains arecombinant nucleic acid. A construct may be present in a vector (e.g.,a bacterial vector, a viral vector) or may be integrated into a genome.A “vector” is a nucleic acid molecule that is capable of transportinganother nucleic acid. Vectors may be, for example, plasmids, cosmids,viruses, a RNA vector or a linear or circular DNA or RNA molecule thatmay include chromosomal, non-chromosomal, semi-synthetic or syntheticnucleic acids. Exemplary vectors are those capable of autonomousreplication (episomal vector) and/or expression of nucleic acids towhich they are linked (expression vectors).

Viral vectors include retrovirus, adenovirus, parvovirus (e.g.,adeno-associated viruses), coronavirus, negative strand RNA viruses suchas ortho-myxovirus (e.g., influenza virus), rhabdovirus (e.g., rabiesand vesicular stomatitis virus), paramyxovirus (e.g., measles andSendai), positive strand RNA viruses such as picornavirus andalphavirus, and double-stranded DNA viruses including adenovirus,herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barrvirus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox andcanarypox). Other viruses include Norwalk virus, togavirus, flavivirus,reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example.Examples of retroviruses include avian leukosis-sarcoma, mammalianC-type, B-type viruses, D-type viruses, HTLV-BLV group, lentivirus,spumavirus (Coffin, J. M., Retroviridae: The viruses and theirreplication, In Fundamental Virology, Third Edition, B. N. Fields, etal., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).

“Lentiviral vector,” as used herein, means HIV-based lentiviral vectorsthat are very promising for gene delivery because of their relativelylarge packaging capacity, reduced immunogenicity and their ability tostably transduce with high efficiency a large range of different celltypes. Lentiviral vectors are usually generated following transienttransfection of three (packaging, envelope and transfer) or moreplasmids into producer cells. Like HIV, lentiviral vectors enter thetarget cell through the interaction of viral surface glycoproteins withreceptors on the cell surface. On entry, the viral RNA undergoes reversetranscription, which is mediated by the viral reverse transcriptasecomplex. The product of reverse transcription is a double-strandedlinear viral DNA, which is the substrate for viral integration in theDNA of infected cells.

“Integrative lentiviral vectors (or LV),” as used herein, means suchvectors as examples of those that are able to integrate into the genomeof a target cell.

By “non-integrative lentiviral vectors” (or NILV) is meant efficientgene delivery vectors that do not integrate into the genome of a targetcell through the action of the viral integrase. In one embodiment, aNILV refers to a lentivirus having an integrase protein mutated tospecifically decrease its integrase activity. Illustrative mutations inthe HIV-1 pol gene suitable to reduce integrase activity include, butare not limited to: H12N, H12C, H16C, H16V, S81 R, D41A, K42A, H51A,Q53C, D55V, D64E, D64V, E69A, K71A, E85A, E87A, D116N, D1161, D116A,N120G, N1201, N120E, E152G, E152A, D35E, K156E, K156A, E157A, K159E,K159A, K160A, R166A, D167A, E170A, H171A, K173A, K186Q, K186T, K188T,E198A, R199c, R199T, R199A, D202A, K211A, Q214L, Q216L, Q221 L, W235F,W235E, K236S, K236A, K246A, G247W, D253A, R262A, R263A and K264H.

The term “operably-linked” refers to the association of nucleic acidsequences on a single nucleic acid fragment so that the function of oneis affected by the other. For example, a promoter is operably-linkedwith a coding sequence when it is capable of affecting the expression ofthat coding sequence (i.e., the coding sequence is under thetranscriptional control of the promoter). “Unlinked” means that theassociated genetic elements are not closely associated with one anotherand the function of one does not affect the other.

As used herein, “expression vector” refers to a DNA construct containinga nucleic acid molecule that is operably-linked to a suitable controlsequence capable of effecting the expression of the nucleic acidmolecule in a suitable host. Such control sequences include a promoterto effect transcription, an optional operator sequence to control suchtranscription, a sequence encoding suitable mRNA ribosome binding sites,and sequences which control termination of transcription andtranslation. The vector may be a plasmid, a phage particle, a virus, orsimply a potential genomic insert. Once transformed into a suitablehost, the vector may replicate and function independently of the hostgenome, or may, in some instances, integrate into the genome itself. Inthe present specification, “plasmid,” “expression plasmid,” “virus” and“vector” are often used interchangeably.

The polynucleotides of the present invention, regardless of the lengthof the coding sequence itself, may be combined with other DNA sequences,such as promoters and/or enhancers, untranslated regions (UTRs), signalsequences, Kozak sequences, polyadenylation signals, additionalrestriction enzyme sites, multiple cloning sites, internal ribosomalentry sites (IRES), recombinase recognition sites (e.g., LoxP, FRT, andAtt sites), termination codons, transcriptional termination signals, andpolynucleotides encoding self-cleaving polypeptides, epitope tags, asdisclosed elsewhere herein or as known in the art, such that theiroverall length may vary considerably. It is therefore contemplated thata polynucleotide fragment of almost any length may be employed, with thetotal length preferably being limited by the ease of preparation and usein the intended recombinant DNA protocol.

In particular embodiments, a vector for use in practicing the inventionincluding, but not limited to expression vectors and viral vectors, willinclude exogenous, endogenous, or heterologous control sequences such aspromoters and/or enhancers. An “endogenous” control sequence is onewhich is naturally linked with a given gene in the genome. An“exogenous” control sequence is one which is placed in juxtaposition toa gene by means of genetic manipulation (i.e., molecular biologicaltechniques) such that transcription of that gene is directed by thelinked enhancer/promoter. A “heterologous” control sequence is anexogenous sequence that is from a different species than the cell beinggenetically manipulated.

The term “promoter” as used herein refers to a recognition site of apolynucleotide (DNA or RNA) to which an RNA polymerase binds. An RNApolymerase initiates and transcribes polynucleotides operably linked tothe promoter. In particular embodiments, promoters operative inmammalian cells comprise an AT-rich region located approximately 25 to30 bases upstream from the site where transcription is initiated and/oranother sequence found 70 to 80 bases upstream from the start oftranscription, a CNCAAT region where N may be any nucleotide.

The term “enhancer” refers to a segment of DNA which contains sequencescapable of providing enhanced transcription and in some instances canfunction independent of their orientation relative to another controlsequence. An enhancer can function cooperatively or additively withpromoters and/or other enhancer elements. The term “promoter/enhancer”refers to a segment of DNA which contains sequences capable of providingboth promoter and enhancer functions.

Illustrative expression control sequences suitable for use in particularembodiments of the invention include, but are not limited to, acytomegalovirus (CMV) immediate early promoter, a viral simian virus 40(SV40) (e.g., early or late), a Moloney murine leukemia virus (MoMLV)LTR promoter, a Rous sarcoma virus (RSV) LTR, a herpes simplex virus(HSV) (thymidine kinase) promoter, H5, P7.5, and P11 promoters fromvaccinia virus, an elongation factor 1-alpha (EF1a) promoter, earlygrowth response 1 (EGR1), ferritin H (FerH), ferritin L (FerL),Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), eukaryotic translationinitiation factor 4A1 (EIF4A1), heat shock 70kDa protein 5 (HSPAS), heatshock protein 90kDa beta, member 1 (HSP90B1), heat shock protein 70kDa(HSP70), β-kinesin (β-KIN), the human ROSA 26 locus (Irions et al.,Nature Biotechnology 25, 1477-1482 (2007)), a Ubiquitin C promoter(UBC), a phosphoglycerate kinase-1 (PGK) promoter, a cytomegalovirusenhancer/chicken (3-actin (CAG) promoter, a (3-actin promoter and amyeloproliferative sarcoma virus enhancer, negative control regiondeleted, d1587rev primer-binding site substituted (MND) promoter(Challita et al., J Virol. 69(2):748-55 (1995)).

In one embodiment, a vector of the invention comprises a MND promoter.

In one embodiment, a vector of the invention comprises an EF1a promotercomprising the first intron of the human EF1a gene.

In one embodiment, a vector of the invention comprises an EF1a promoterthat lacks the first intron of the human EF1a gene.

In one embodiment, a vector is a bicistronic vector comprising at leasttwo promoters. In a particular embodiment, a bicistronic vectorcomprises two or more promoters selected from the group consisting of: aCMV promoter, an SV40 promoter, an MoMLV LTR promoter, an RSV LTR, anHSV-TK promoter, H5, P7.5, and P11 promoters from vaccinia virus, anEF1a promoter, a UBC promoter, a PGK promoter, a CAG promoter, a β-actinpromoter and an MND promoter.

The term “expression”, as used herein, refers to the process by which apolypeptide is produced based on the nucleic acid sequence of a gene.The process includes both transcription and translation.

The term “introduced” in the context of inserting a nucleic acidsequence into a cell, means “transfection”, or “transformation” or“transduction” and includes reference to the incorporation of a nucleicacid sequence into a eukaryotic or prokaryotic cell wherein the nucleicacid sequence may be incorporated into the genome of the cell (e.g.,chromosome, plasmid, plastid, or mitochondrial DNA), converted into anautonomous replicon, or transiently expressed (e.g., transfected mRNA).

“Sequence identity,” as used herein, refers to the percentage of aminoacid residues in one sequence that are identical with the amino acidresidues in another reference polypeptide sequence after aligning thesequences and introducing gaps, if necessary, to achieve the maximumpercent sequence identity, and not considering any conservativesubstitutions as part of the sequence identity. The percentage sequenceidentity values are generated by the NCBI BLAST2.0 software as definedby Altschul et al. (1997) “Gapped BLAST and PSI-BLAST: a new generationof protein database search programs,” Nucleic Acids Res. 25:3389-3402,with the parameters set to default values.

In certain embodiments, an altered immunoglobulin domain only containsconservative amino acid substitutions of a wild type immunoglobulindomain. In certain other embodiments, an altered immunoglobulin domainonly contains non-conservative amino acid substitutions of a wild typeimmunoglobulin domain. In yet other embodiments, an alteredimmunoglobulin domain contains both conservative and non-conservativeamino acid substitutions.

A “conservative substitution” is recognized in the art as a substitutionof one amino acid for another amino acid that has similar properties.Exemplary conservative substitutions are well known in the art (see,e.g., WO 97/09433, page 10, published Mar. 13, 1997; Lehninger,Biochemistry, Second Edition; Worth Publishers, Inc. NY:NY (1975),pp.71-77; Lewin, Genes IV, Oxford University Press, NY and Cell Press,Cambridge, Mass. (1990), p. 8). In certain embodiments, a conservativesubstitution includes a leucine to serine substitution.

As used herein, the term “derivative” refers to a modification of one ormore amino acid residues of a peptide by chemical or biological means,either with or without an enzyme, e.g., by glycosylation, alkylation,acylation, ester formation, or amide formation. Generally, a“derivative” differs from an “analogue” in that a parent polypeptide maybe the starting material to generate a “derivative,” whereas the parentpolypeptide may not necessarily be used as the starting material togenerate an “analogue.” A derivative may have different chemical,biological or physical properties of the parent polypeptide. Forexample, a derivative may be more hydrophilic or it may have alteredreactivity (e.g., a CDR having an amino acid change that alters itsaffinity for a target, or FKBP having an amino acid change that altersits affinity for rapamycin or a rapalog thereof) as compared to theparent polypeptide.

A “receptor” is a protein present in the plasma membrane or in thecytoplasm of a cell to which a signal molecule (i.e., a ligand, such asa hormone, neurotransmitter, toxin, cytokine) may bind or attach. Thebinding of the single molecule to the receptor may result in aconformational change of the receptor, which can initiate a cellularresponse. However, some ligands merely block receptors without inducingany response (e.g., antagonists). Some receptor proteins are peripheralmembrane proteins, many hormone and neurotransmitter receptors aretransmembrane proteins that are embedded in the phospholipid bilayer ofcell membranes, and another major class of receptors are intracellularproteins such as those for steroid and intracrine peptide hormonereceptors.

As used herein, the term “isolated” refers to a substance that has beenremoved from the source in which it naturally occurs. A substance neednot be purified in order to be isolated. For example, a protein producedin a host cell is considered isolated when it is removed or releasedfrom the cell. A protein contained within a crude cell lysate fractionis considered “isolated” for purposes of the present disclosure.Further, an “isolated nucleic acid molecule” refers to a polynucleotidemolecule in the form of a separate fragment or as a component of alarger nucleic acid construct, which has been separated from its sourcecell, including the chromosome it normally resides in, at least once.For example, a DNA molecule that encodes a recombinant polypeptide,peptide, or variant thereof, which has been separated from the genomicDNA of a cell, is an isolated nucleic acid molecule. Another example ofan isolated nucleic acid molecule is a bacteriophage promoter (e.g., T5or T7), or nucleic acid expression control sequence, which can be clonedinto a vector capable of replication in a suitable host cell. Stillanother example of an isolated nucleic acid molecule is a chemicallysynthesized or PCR synthesized nucleic acid molecule.

As used herein, the term “purified” refers to a substance that has beenrendered at least partially free of contaminants and other materialsthat typically accompany it. Substances can be purified to varyingdegrees. A substance is “substantially pure” when a preparation orcomposition of the substance contains less than about 1% contaminants. Asubstance is “essentially pure” when a preparation or composition of thesubstance contains less than about 5% contaminants. A substance is“pure” when a preparation or composition of the substance contains lessthan about 2% contaminants. For substances that are “purified tohomogeneity,” contaminants cannot be detected with conventionalanalytical methods.

“Treatment,” “treating” or “ameliorating” refers to either a therapeutictreatment or prophylactic/preventative treatment. A treatment istherapeutic if at least one symptom of disease in an individualreceiving treatment improves or a treatment may delay worsening of aprogressive disease in an individual, or prevent onset of additionalassociated diseases.

A “therapeutically effective amount (or dose)” or “effective amount (ordose)” of a specific binding molecule or compound refers to that amountof the compound sufficient to result in amelioration of one or moresymptoms of the disease being treated in a statistically significantmanner. When referring to an individual active ingredient, administeredalone, a therapeutically effective dose refers to that ingredient alone.When referring to a combination, a therapeutically effective dose refersto combined amounts of the active ingredients that result in thetherapeutic effect, whether administered serially or simultaneously.

The term “pharmaceutically acceptable” refers to molecular entities andcompositions that do not produce allergic or other serious adversereactions when administered using routes well known in the art.

A “subject in need” refers to a subject at risk of, or suffering from, adisease, disorder or condition that is amenable to treatment oramelioration with a non-natural cell, polypeptide complex or acomposition thereof provided herein. In certain embodiments, a subjectis a human.

Additional definitions are provided throughout the present disclosure.In certain aspects, the instant disclosure is directed to a non-naturalcell, comprising (a) a first nucleic acid molecule encoding a firstfusion protein comprising a first multimerization domain, a hydrophobicdomain, and an actuator domain, wherein the first multimerization domainlocalizes extracellularly when the first fusion protein is expressed;and (b) a second nucleic acid molecule encoding a second fusion proteincomprising a binding domain and a second multimerization domain, whereinthe second fusion protein localizes extracellularly, either secretedfrom the cell or anchored to the cell surface, when expressed; wherein afirst bridging factor promotes the formation of a polypeptide complex onthe non-natural cell surface with the bridging factor associated withand disposed between the multimerization domains of the first and secondfusion proteins. In certain embodiments, the second fusion protein(e.g., DARIC binding component) further comprises an anchor domain(e.g., transmembrane domain, GPI signal sequence), wherein theextracellularly localized second fusion protein is tethered or anchoredto the surface of the non-natural cell. In certain embodiments, a fusionprotein is anchored to the surface of a non-natural cell by atransmembrane domain, such as a transmembrane domain from CD4, CD8,CD28, CD71, CD154, AlVIN, or the like. In some embodiments, a fusionprotein is anchored to the surface of a non-natural cell by a GPImolecule.

In particular embodiments, a non-natural cell comprises a multipartitesignaling complex comprising a first fusion polypeptide that comprises afirst hydrophobic domain, e.g., a transmembrane domain, and a secondfusion polypeptide that comprises a second hydrophobic domain, e.g., atransmembrane domain, wherein the hydrophobic domains of the first andsecond fusion polypeptides do not associate or interact in such a way asto increase cytotoxic activity of the non-natural cell in the absence ofthe bridging factor.

In other particular embodiments, a non-natural cell comprises amultipartite signaling complex comprising a first fusion polypeptidethat comprises a first hydrophobic domain, e.g., a transmembrane domain,and a second fusion polypeptide that comprises a second hydrophobicdomain, e.g., a transmembrane domain, wherein the hydrophobic domains ofthe first and second fusion polypeptides associate or interact in such away as to increase cytotoxic activity of the non-natural cell in theabsence of the bridging factor , but wherein the increase is less thanthe increase in or level of cytotoxic activity of the non-natural cellin the presence of the bridging factor. In a further embodiment, a firstfusion protein, rather than comprising its own hydrophobic and actuatordomains, instead comprises a binding domain that binds to atransmembrane protein expressed on the surface of a T cell thatcomprises a hydrophobic and actuator domain (e.g., TCR/CD3 or the like).

In further aspects, the instant disclosure is directed to a firstnon-natural cell comprising a heterologous nucleic acid moleculeencoding a first fusion protein comprising a first multimerizationdomain, a hydrophobic domain, and an actuator domain, wherein the firstmultimerization domain localizes extracellularly when the first fusionprotein is expressed; and a second non-natural cell comprising aheterologous a second nucleic acid molecule encoding a second fusionprotein comprising a binding domain and a second multimerization domain,wherein the second fusion protein is released extracellularly whenexpressed; wherein a first bridging factor promotes the formation of apolypeptide complex on the first non-natural cell surface with thebridging factor associated with and disposed between the multimerizationdomains of the first and second fusion proteins.

In certain embodiments, the first and second multimerization domains arethe same or different. Exemplary bridging factors that associate withmultimerization domains and are useful with the fusion proteins of thisdisclosure include rapamycin (sirolimus) or a rapalog thereof,coumermycin or a derivative thereof, gibberellin or a derivativethereof, abscisic acid (ABA) or a derivative thereof, methotrexate or aderivative thereof, cyclosporin A or a derivative thereof, FKCsA or aderivative thereof, trimethoprim (Tmp)-synthetic ligand for FKBP (SLF)or a derivative thereof, or any combination thereof.

Exemplary rapamycin analogs (rapalogs) include those disclosed in U.S.Pat. No. 6,649,595, which rapalog structures are incorporated herein byreference. In certain embodiments, a bridging factor is a rapalog withsubstantially reduced immunosuppressive effect as compared to rapamycin.A “substantially reduced immunosuppressive effect” refers to a rapaloghaving at least less than 0.1 to 0.005 times the immunosuppressiveeffect observed or expected for an equimolar amount of rapamycin, asmeasured either clinically or in an appropriate in vitro (e.g.,inhibition of T cell proliferation) or in vivo surrogate of humanimmunosuppressive activity. Alternatively, “substantially reducedimmunosuppressive effect” refers to a rapalog having an EC₅₀ value insuch an in vitro assay that is at least 10 to 250 times larger than theEC₅₀ value observed for rapamycin in the same assay. Other exemplaryrapalogs include everolimus, novolimus, pimecrolimus, ridaforolimus,tacrolimus, temsirolimus, umirolimus, and zotarolimus.

In certain embodiments, multimerization domains will associate with abridging factor being a rapamycin or rapalog thereof. For example, thefirst and second multimerization domains are a pair selected from FKBPand FRB. FRB domains are polypeptide regions (protein “domains”) thatare capable of forming a tripartite complex with an FKBP protein andrapamycin or rapalog thereof. FRB domains are present in a number ofnaturally occurring proteins, including mTOR proteins (also referred toin the literature as FRAP, RAPT1, or RAFT) from human and other species;yeast proteins including Tor1 and Tor2; and a Candida FRAP homolog.Information concerning the nucleotide sequences, cloning, and otheraspects of these proteins is already known in the art. For example, aprotein sequence accession number for a human mTOR is GenBank AccessionNo. L34075.1 (Brown et al., Nature 369:756, 1994).

FRB domains for use in the fusion proteins of this disclosure generallycontain at least about 85 to about 100 amino acid residues. In certainembodiments, an FRB amino acid sequence for use in fusion proteins ofthis disclosure will comprise a 93 amino acid sequence Ile-2021 throughLys -2113 and a mutation of T2098L, based the amino acid sequence ofGenBank Accession No. L34075.1. A FRB domain for use in fusion proteinsof this disclosure will be capable of binding to a complex of an FKBPprotein bound to rapamycin or a rapalog thereof of this disclosure. Incertain embodiments, a peptide sequence of an FRB domain comprises (a) anaturally occurring peptide sequence spanning at least the indicated 93amino acid region of human mTOR or corresponding regions of homologousproteins; (b) a variant of a naturally occurring FRB in which up toabout ten amino acids, or about 1 to about 5 amino acids or about 1 toabout 3 amino acids, or in some embodiments just one amino acid, of thenaturally-occurring peptide have been deleted, inserted, or substituted;or (c) a peptide encoded by a nucleic acid molecule capable ofselectively hybridizing to a DNA molecule encoding a naturally occurringFRB domain or by a DNA sequence which would be capable, but for thedegeneracy of the genetic code, of selectively hybridizing to a DNAmolecule encoding a naturally occurring FRB domain.

FKBPs (FK506 binding proteins) are the cytosolic receptors formacrolides, such as FK506, FK520 and rapamycin, and are highly conservedacross species lines. For the purpose of this disclosure, FKBPs areproteins or protein domains that are capable of binding to rapamycin orto a rapalog thereof and further forming a tripartite complex with anFRB-containing protein or fusion protein. An FKBP domain may also bereferred to as a “rapamycin binding domain”. Information concerning thenucleotide sequences, cloning, and other aspects of various FKBP speciesis known in the art (see, e.g., Staendart et al., Nature 346:671, 1990(human FKBP12); Kay, Biochem. 1 3/4:361, 1996). Homologous FKBP proteinsin other mammalian species, in yeast, and in other organisms are alsoknown in the art and may be used in the fusion proteins disclosedherein. The size of FKBP domains for use in this invention varies,depending on which FKBP protein is employed. An FKBP domain of a fusionprotein of this disclosure will be capable of binding to rapamycin or arapalog thereof and participating in a tripartite complex with anFRB-containing protein (as may be determined by any means, direct orindirect, for detecting such binding).

The peptide sequence of an FKBP domain of an FKBP fusion protein of thisinvention comprises (a) a naturally occurring FKBP peptide sequence,preferably derived from the human FKBP12 protein (GenBank Accession No.AAA58476.1) or a peptide sequence derived therefrom, from another humanFKBP, from a murine or other mammalian FKBP, or from some other animal,yeast or fungal FKBP; (b) a variant of a naturally occurring FKBPsequence in which up to about ten amino acids, or about 1 to about 5amino acids or about 1 to about 3 amino acids, or in some embodimentsjust one amino acid, of the naturally-occurring peptide have beendeleted, inserted, or substituted; or (c) a peptide sequence encoded bya nucleic acid molecule capable of selectively hybridizing to a DNAmolecule encoding a naturally occurring FKBP or by a DNA sequence whichwould be capable, but for the degeneracy of the genetic code, ofselectively hybridizing to a DNA molecule encoding a naturally occurringFKBP.

Other multimerization domain pairs include FKBP and calcineurin, FKBPand cyclophilin, FKBP and bacterial DHFR, calcineurin and cyclophilin,PYL1 and ABI1, or GIB1 and GAI, or variants thereof.

In yet other embodiments, an anti-bridging factor blocks the associationof at least two first fusion proteins with the bridging factor. Forexample, cyclosporin or FK506 could be used as anti-bridging factors totitrate out rapamycin and, therefore, stop signaling since only onemultimerization domain is bound. In certain embodiments, ananti-bridging factor (e.g., cyclosporine, FK506) is an immunosuppressiveagent. For example, an immunosuppressive anti-bridging factor may beused to block or minimize the function of the fusion proteins of theinstant disclosure and at the same time inhibit or block an unwanted orpathological inflammatory response in a clinical setting.

In certain embodiments, a first fusion protein (e.g., DARIC signalingcomponent) has a first multimerization domain comprising a first FKBPpolypeptide or variant thereof, and a second fusion protein (e.g., DARICbinding component) has a second multimerization domain comprising afirst FRB polypeptide or variant thereof. In other embodiments, a firstfusion protein (e.g., DARIC signaling component) has a firstmultimerization domain comprising a first FRB polypeptide or variantthereof, and a second fusion protein (e.g., DARIC binding component) hasa second multimerization domain comprising a first FKBP polypeptide orvariant thereof. In any of these embodiments, the second fusion proteinfurther comprises an anchor domain (e.g., transmembrane domain, GPIsignal sequence) and optionally a sub-threshold signaling domain. Insome embodiments, a second fusion protein contains a GPI molecule,wherein the GPI signal sequence has been removed or altered to attachthe GPI molecule.

In certain embodiments, a first nucleic acid molecule encoding a firstfusion protein comprising a first multimerization domain, a thirdmultimerization domain, a hydrophobic domain, and an actuator domain,wherein the first and third multimerization domains localizeextracellularly when the first fusion protein is expressed in a cell. Incertain embodiments, the third multimerization domain of the firstfusion protein is a binding domain for a bridging factor selected fromrapamycin or a rapalog thereof, coumermycin or a derivative thereof,gibberellin or a derivative thereof, ABA or a derivative thereof,methotrexate or a derivative thereof, cyclosporin A or a derivativethereof, FKCsA or a derivative thereof, Tmp-SLF or a derivative thereof,or any combination thereof.

In still further embodiments, a second bridging factor promotes theassociation of at least two first fusion proteins with the bridgingfactor associated with and disposed between the third multimerizationdomains of the first fusion proteins. In certain embodiments, a proteincomplex that is formed is a homocomplex comprising at least two firstfusion proteins, wherein the multimerization domains may be DHFR (withthe bridging molecule being methotrexate) or GyrB (with the bridgingmolecule being coumermycin) or FKBP (with the bridging molecule beingAP1903 or AP20187). In certain other embodiments, a protein complex is aheterocomplex comprising one or more first fusion proteins and one ormore second fusion proteins.

In certain embodiments, a hydrophobic domain is a transmembrane domain,such as a transmembrane domain from CD4, CD8, CD28, CD71, CD154, AMN orthe like. In some embodiments, a fusion protein (e.g., DARIC bindingcomponent) comprises an anchor domain, such as a transmembrane domain orGPI signal sequence. In certain embodiments, the transmembrane domain isfrom CD4, CD8, CD28, CD71, CD154, AMN or the like. In furtherembodiments, a fusion protein (e.g., DARIC binding component) contains aGPI molecule, wherein the GPI signal sequence has been removed oraltered to attach the GPI molecule.

In further embodiments, the actuator domain comprises a lymphocytereceptor signaling domain or comprises an amino acid sequences havingone or a plurality of immunoreceptor tyrosine-based activation motifs(ITAMs). In still further embodiments, an actuator domain comprises acytoplasmic portion that associates with a cytoplasmic signalingprotein, wherein the cytoplasmic signaling protein is a lymphocytereceptor or signaling domain thereof, a protein comprising a pluralityof immunoreceptor tyrosine-based activation motifs (ITAMs), acostimulatory domain, an adhesion factor, or any combination thereof.Exemplary actuator domains include, but are not limited to, CD2, CD3ε,CD3δ, CD3ζ, pTα, TCRα, TCRβ, FcRα, FcRβ, FcRγ, NKG2D, CD22, CD79A, andCD79B, CD27, CD28, CD30, CD40, LAT, Zap70, ICOS, DAP10, 4-1BB, CARD11,HVEM, LAG3, SLAMF1, Lck, Fyn, Slp76, TRIM, OX40, or any combinationthereof. In yet further embodiments, a first nucleic acid moleculeencodes the first fusion protein further comprising one or moredifferent actuator domains, costimulatory domains, adhesion factors, orany combination thereof. As used herein, the term, “costimulatorysignaling domain,” or “costimulatory domain”, refers to an intracellularsignaling domain of a costimulatory factor. Exemplary costimulatorydomains include, but are not limited to intracellular signaling domainsfrom CD2, CD27, CD28, CD30, CD40, LAT, Zap70, ICOS, DAP10, 4-1BB,CARD11, HVEM, LAG3, SLAMF1, Lck, Fyn, Slp76, TRIM, and OX40.

In certain embodiments, a non-natural cell further overexpresses acostimulatory factor, an immunomodulatory factor, an agonist for acostimulatory factor, an agonist for an immunomodulatory factor, or anycombination thereof. In a related embodiment, cofactor IL-12 isoverexpressed or supplied to the cell.

Fusion protein binding domains useful in the instant invention includethose known in the art or as described herein, or those generated by avariety of methods known in the art (see, e.g., U.S. Pat. Nos. 6,291,161and 6,291,158). For example, fusion protein binding domains may beidentified by screening a Fab phage library for Fab fragments thatspecifically bind to a target of interest (see Hoet et al., Nat.Biotechnol. 23:344, 2005). Additionally, traditional strategies forhybridoma development, such as using a target antigen as an immunogen inconvenient systems (e.g., mice, HuMAb mouse®, TC mouse™, KM-mouse ®,llamas, sheep, chicken, rats, hamsters, rabbits, etc.), can be used todevelop anti-target antibodies having target-specific binding domains ofinterest.

Sources of further binding domains include target-specific antibodyvariable domains from various species (which can be formatted asantibodies, sFvs, scFvs, Fabs, or soluble VH domain or domainantibodies), including human, rodent, avian, and ovine. Additionalsources of binding domains include variable domains of antibodies fromother species, such as camelid (from camels, dromedaries, or llamas(Ghahroudi et al., FEBS Letters 414:521, 1997; Vincke et al., J. Biol.Chem. 284:3273, 2009; and Hamers-Casterman et al., Nature 363:446, 1993;and Nguyen et al., J. Mol. Biol. 275:413, 1998), nurse sharks (Roux etal., Proc. Nat'l. Acad. Sci. (USA) 95:11804, 1998), spotted ratfish(Nguyen et al., Immunogenetics 54:39, 2002), or lamprey (Herrin et al.,Proc. Nat'l. Acad. Sci. (USA) 105:2040, 2008 and Alder et al., NatureImmunol. 9:319, 2008). These antibodies can apparently formantigen-binding regions using only heavy chain variable region, i.e.,these functional antibodies are homodimers of heavy chains only(referred to as “heavy chain antibodies”) (Jespers et al., Nat.Biotechnol. 22:1161, 2004; Cortez-Retamozo et al., Cancer Res. 64:2853,2004; Baral et al., Nature Med. 12:580, 2006, and Barthelemy et al., J.Biol. Chem. 283:3639, 2008).

Other alternative sources of target-specific binding domains includessequences that encode random peptide libraries or sequences that encodean engineered diversity of amino acids in loop regions of alternativenon-antibody scaffolds, such as fibrinogen domains (see, e.g., Weisel etal. (1985) Science 230:1388), Kunitz domains (see, e.g., U.S. Pat. No.6,423,498), ankyrin repeat proteins (also known as DARPins; Binz et al.,J. Mol. Biol. 332:489, 2003 and Binz et al., Nat. Biotechnol. 22:575,2004), fibronectin binding domains (also known as adnectins ormonobodies; Richards et al., J. Mol. Biol. 326:1475, 2003; Parker etal., Protein Eng. Des. Sel. 18:435, 2005 and Hackel et al., J. Mol.Biol. 381:1238, 2008), cysteine-knot miniproteins (Vita et al., Proc.Nat'l. Acad. Sci. (USA) 92:6404, 1995; Martin et al., Nat. Biotechnol.21:71, 2002 and Huang et al., Structure 13:755, 2005), tetratricopeptiderepeat domains (Main et al., Structure 11:497, 2003 and Cortajarena etal., ACS Chem. Biol. 3:161, 2008), leucine-rich repeat domains (Stumppet al., J. Mol. Biol. 332:471, 2003), anticalins (Skerra, FEBS J.275:2677, 2008), lipocalin domains (see, e.g., PCT Publication No. WO2006/095164, Beste et al., Proc. Nat'l. Acad. Sci. (USA) 96:1898, 1999and Schönfeld et al., Proc. Nat'l. Acad. Sci. (USA) 106:8198, 2009),armadillo repeat proteins (ArmRPs; Varadamsetty et al., J. Mol. Biol.424:68, 2012), diabodies (Manzke et al., Int. J. Cancer 82:700, 1999),repebodies (Lee et al., Proc. Nat'l. Acad. Sci. U.S.A. 109: 3299, 2012),minibodies (Hu et al., Cancer Res. 56:3055, 1996), cyclotides (Craik etal., J. Mol. Biol. 294:1327, 1999), V-like domains (see, e.g., US PatentApplication Publication No. 2007/0065431), C-type lectin domains(Zelensky and Gready, FEBS J. 272:6179, 2005; Beavil et al.I, Proc.Nat'l. Acad. Sci. (USA) 89:753, 1992 and Sato et al., Proc. Nat'l. Acad.Sci. (USA) 100:7779, 2003), mAb² or Fcab™ (see, e.g., PCT PublicationNos. WO 2007/098934; WO 2006/072620), or the like (Nord et al., ProteinEng. 8:601, 1995; Nord et al., Nat. Biotechnol. 15:772, 1997; Nord etal., Eur. J. Biochem. 268:4269, 2001; and Binz et al. (2005) Nat.Biotechnol. 23:1257, 2005).

In certain embodiments, the binding domain of the second fusion proteinis a single chain antibody variable region, a receptor ectodomain, or aligand. In further embodiments, the single chain antibody variableregion is a domain antibody, sFv, scFv, F(ab′)₂, or Fab. In stillfurther embodiments, the binding domain of the second fusion protein isamino or carboxy terminal to the multimerization domain.

In certain further aspects, a non-natural cell comprises a nucleic acidmolecule that encodes a fusion comprising a binding domain andmultimerization domain, and optionally an anchor domain (e.g.,transmembrane domain, GPI signal sequence) or an anchor domain with asub-threshold signaling domain, wherein the binding domain specificallybinds to a target located on a target cell surface. In furtherembodiments, a binding domain is specific for a target that is anantigen associated with a cancer (e.g., solid malignancy, hematologicmalignancy), an inflammatory disease, an autoimmune disease, or a graftversus host disease. Exemplary target antigens include, but are notlimited to, α-folate receptor, α_(v)β₆ integrin, BCMA, B7-H3, B7-H6,CAIX, CD19, CD20, CD22, CD30, CD33, CD37, CD44, CD44v6, CD44v7/8, CD70,CD123, CD138, CD171, CEA, DLL4, EGP-2, EGP-40, CSPG4, EGFR, EGFR familyincluding ErbB2 (HER2), EGFRvIII, EPCAM, EphA2, EpCAM, FAP, FBP, fetalacetylcholine receptor, Fzd7, GD2, GD3, Glypican-3 (GPC3), h5T4,IL-11Rα, IL13R-α2, KDR, κ light chain, λ light chain, LeY, L1CAM,MAGE-A1, mesothelin, MHC presented peptides, MUC1, MUC16, NCAM, NKG2Dligands, Notchl, Notch2/3, NY-ESO-1, PRAME, PSCA, PSMA, Survivin,TAG-72, TEMs, TERT, VEGFR2, and ROR1.

In certain embodiments, such a binding fusion protein (DARIC bindingcomponent) forms a tripartite complex with DARIC signaling component anda bridging factor to form a polypeptide complex. Exemplary bridgingfactors for such a complex include rapamycin or a rapalog thereof,coumermycin or a derivative thereof, gibberellin or a derivativethereof, ABA or a derivative thereof, methotrexate or a derivativethereof, cyclosporin A or a derivative thereof, FKCsA or a derivativethereof, or Tmp-SLF or a derivative thereof.

In other embodiments, the instant disclosure is directed to anon-natural cell comprising (a) a heterologous first nucleic acidmolecule encoding a first fusion protein comprising a firstmultimerization domain, a hydrophobic domain, and an actuator domain,wherein the first multimerization domain localizes extracellularly whenthe first fusion protein is expressed; and (b) a second nucleic acidmolecule encoding a second fusion protein comprising a binding domain, asecond multimerization domain and an anchor domain (e.g., transmembranedomain, GPI molecule), wherein the second fusion protein localizes tothe cell surface when expressed; wherein a first bridging factorpromotes the formation of a polypeptide complex on the non-natural cellsurface with the bridging factor associated with and disposed betweenthe multimerization domains of the first and second fusion proteins. Incertain embodiments, the second fusion protein further comprises anintracellularly localized sub-threshold signaling domain.

As used herein, a “sub-threshold signaling domain” is not capable ofinducing or activating a sufficiently robust signal transduction cascadein the presence of one or more other sub-threshold signaling domains,but can induce or activate a signal transduction cascade or adjust asignal qualitatively in the presence of an actuator domain. For example,a second fusion protein tethered to a cell surface that associates withanother second fusion protein tethered to a cell surface will not induceor will minimally activate signal transduction. Exemplary sub-thresholdsignaling domains include costimulatory domains, such as CD28, CD2, CD4,CD5, CD8, CD9, CD27, CD44, CD46, CD81, CD137, LFA-1, ICAM-1, VLA-4,OX40, 4-1BB, LIGHT, SLAM, ICOS, CTLA-4, PD-1, or the like.

In particular embodiments, an encoded first fusion protein comprises afirst multimerization domain of FRB T2098L, a transmembrane domain, acostimulatory domain of 4-1BB, and actuator domain of CD3ζ wherein thesecond encoded fusion protein comprises a binding domain of an scFvspecific for CD19 and a second multimerization domain of FKBP12, andoptionally an anchor domain (e.g., transmembrane domain, GPI signalsequence) or an anchor domain with a sub-threshold signaling domain; andwherein the first bridging factor that promotes the formation of apolypeptide complex on the non-natural cell surface is rapalog AP21967.An exemplary first fusion protein has an amino acid sequence as setforth in SEQ ID NO.:15 and an exemplary second fusion protein has anamino acid sequence as set forth in SEQ ID NO.:1 or 56.

In certain embodiments, a DARIC binding component may have multiplebinding domains. For example, a non-natural cell further comprises athird nucleic acid molecule encoding a third fusion protein comprising abinding domain and a second multimerization domain, optionally an anchordomain (e.g., transmembrane domain, GPI signal sequence) or an anchordomain with a sub-threshold signaling domain, wherein the third fusionprotein localizes extracellularly when expressed. In relatedembodiments, the fusion proteins comprise a binding domain have one,two, three, or four binding domains, wherein the one, two, three, orfour binding domains are specific for one target or up to four differenttargets.

In any of the aforementioned embodiments, a second nucleic acid moleculeencoding a second (binding) fusion protein may further comprise asequence encoding a linker, spacer or junction amino acids disposedbetween the binding domain and the second multimerization domain. Incertain embodiments, a second nucleic acid molecule encoding a secondfusion protein (e.g., DARIC binding component) further comprises ananchor domain (e.g., transmembrane domain, GPI signal sequence) andoptionally a sub-threshold signaling domain. In further embodiments, asecond fusion protein (e.g., DARIC binding component) contains a GPImolecule, wherein the GPI signal sequence has been removed or altered toattach the GPI molecule.

Exemplary diseases or disorders associated with excess receptor-mediatedsignal transduction include cancer (e.g., solid malignancy andhematologic malignancy), autoimmune or inflammatory diseases orconditions, sepsis resulting from bacterial infection, and viralinfection.

In one aspect, the present disclosure provides a method for directing Tcell activation, comprising administering to a subject in need thereofan effective amount of a DARIC binding component or a pharmaceuticalcomposition thereof that specifically binds a target, such as a cellsurface target that is a tumor-specific antigen or other antigen ofchoice at a site or cell where T cell activation is desired.

Pharmaceutically acceptable carriers for therapeutic use are also wellknown in the pharmaceutical art, and are described, for example, in thePhysicians Desk Reference, 62nd edition. Oradell, N.J.: MedicalEconomics Co., 2008; Goodman & Gilman's The Pharmacological Basis ofTherapeutics, Eleventh Edition. McGraw-Hill, 2005; Remington: TheScience and Practice of Pharmacy, 20th Edition. Baltimore, Md.:Lippincott Williams & Wilkins, 2000; and The Merck Index, FourteenthEdition. Whitehouse Station, N.J.: Merck Research Laboratories, 2006;each of which is hereby incorporated by reference in relevant parts.Exemplary pharmaceutically acceptable carriers include sterile salineand phosphate buffered saline at physiological pH. Preservatives,stabilizers, dyes and the like may be provided in the pharmaceuticalcomposition. In addition, antioxidants and suspending agents may also beused.

Pharmaceutical compositions may also contain diluents such as buffers,antioxidants such as ascorbic acid, low molecular weight (less thanabout 10 residues) polypeptides, proteins, amino acids, carbohydrates(e.g., glucose, sucrose, dextrins), chelating agents (e.g., EDTA),glutathione and other stabilizers and excipients. Neutral bufferedsaline or saline mixed with nonspecific serum albumin are exemplarydiluents.

In another aspect, the present disclosure provides a method forinhibiting growth, metastasis or metastatic growth of a malignancy(e.g., a solid malignancy or a hematologic malignancy), comprisingadministering to a subject in need thereof an effective amount of a cellencoding a polypeptide complex provided herein or a composition thereof.

A wide variety of cancers, including solid malignancy and hematologicmalignancy, are amenable to the compositions and methods disclosedherein. Types of cancer that may be treated include adenocarcinoma ofthe breast, prostate, pancreas, colon and rectum; all forms ofbronchogenic carcinoma of the lung (including squamous cell carcinoma,adenocarcinoma, small cell lung cancer and non-small cell lung cancer);myeloid; melanoma; hepatoma; neuroblastoma; papilloma; apudoma;choristoma; branchioma; malignant carcinoid syndrome; carcinoid heartdisease; and carcinoma (e.g., Walker, basal cell, basosquamous,Brown-Pearce, ductal, Ehrlich tumor, Krebs 2, merkel cell, mucinous,non-small cell lung, oat cell, papillary, scirrhous, bronchiolar,bronchogenic, squamous cell, and transitional cell). Additional types ofcancers that may be treated include: histiocytic disorders; leukemia;histiocytosis malignant; Hodgkin's disease; non-Hodgkin's lymphoma;plasmacytoma; reticuloendotheliosis; melanoma; renal cell carcinoma;chondroblastoma; chondroma; chondrosarcoma; fibroma; fibrosarcoma; giantcell tumors; histiocytoma; lipoma; liposarcoma; mesothelioma; myxoma;myxosarcoma; osteoma; osteosarcoma; chordoma; craniopharyngioma;dysgerminoma; hamartoma; mesenchymoma; mesonephroma; myosarcoma;ameloblastoma; cementoma; odontoma; teratoma; thymoma; trophoblastictumor.

Further, the following types of cancers are also contemplated asamenable to treatment: adenoma; cholangioma; cholesteatoma; cyclindroma;cystadenocarcinoma; cystadenoma; granulosa cell tumor; gynandroblastoma;hepatoma; hidradenoma; islet cell tumor; Leydig cell tumor; papilloma;sertoli cell tumor; theca cell tumor; leimyoma; leiomyosarcoma;myoblastoma; myomma; myosarcoma; rhabdomyoma; rhabdomyosarcoma;ependymoma; ganglioneuroma; glioma; medulloblastoma; meningioma;neurilemmoma; neuroblastoma; neuroepithelioma; neurofibroma; neuroma;paraganglioma; paraganglioma nonchromaffin; and glioblastoma multiforme.The types of cancers that may be treated also include angiokeratoma;angiolymphoid hyperplasia with eosinophilia; angioma sclerosing;angiomatosis; glomangioma; hemangioendothelioma; hemangioma;hemangiopericytoma; hemangiosarcoma; lymphangioma; lymphangiomyoma;lymphangiosarcoma; pinealoma; carcinosarcoma; chondrosarcoma;cystosarcoma phyllodes; fibrosarcoma; hemangiosarcoma; leiomyosarcoma;leukosarcoma; liposarcoma; lymphangiosarcoma; myosarcoma; myxosarcoma;ovarian carcinoma; rhabdomyosarcoma; sarcoma; neoplasms;neurofibromatosis; and cervical dysplasia.

Additional exemplary cancers that are also amenable to the compositionsand methods disclosed herein are B-cell cancers, including B-celllymphomas (such as various forms of Hodgkin's disease, non-Hodgkinslymphoma (NHL) or central nervous system lymphomas), leukemias (such asacute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL),Hairy cell leukemia and chronic myoblastic leukemia) and myelomas (suchas multiple myeloma). Additional B cell cancers include smalllymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacyticlymphoma, splenic marginal zone lymphoma, plasma cell myeloma, solitaryplasmacytoma of bone, extraosseous plasmacytoma, extra-nodal marginalzone B-cell lymphoma of mucosa-associated (MALT) lymphoid tissue, nodalmarginal zone B-cell lymphoma, follicular lymphoma, mantle celllymphoma, diffuse large B-cell lymphoma, mediastinal (thymic) largeB-cell lymphoma, intravascular large B-cell lymphoma, primary effusionlymphoma, Burkitt lymphoma/leukemia, B-cell proliferations of uncertainmalignant potential, lymphomatoid granulomatosis, and post-transplantlymphoproliferative disorder.

In certain embodiments, cells encoding polypeptide complexes useful forinhibiting growth of a solid malignancy or metastasis or metastaticgrowth of a solid malignancy or a hematologic malignancy include thosethat specifically bind to a tumor or cancer antigen and a second targetantigen on the cancer cell.

In another aspect, the present disclosure provides a method for treatingan autoimmune or inflammatory disease, disorder or condition, comprisingadministering to a subject in need thereof an effective amount of a cellencoding a polypeptide complex provided herein or a composition thereof.

Exemplary autoimmune or inflammatory diseases, disorders or conditionsthat may be treated by the fusion proteins and compositions and unitdose forms thereof include inflammatory bowel disease (e.g., Crohn'sdisease or ulcerative colitis), diabetes mellitus (e.g., type Idiabetes), dermatomyositis, polymyositis, pernicious anaemia, primarybiliary cirrhosis, acute disseminated encephalomyelitis (ADEM),Addison's disease, ankylosing spondylitis, antiphospholipid antibodysyndrome (APS), autoimmune hepatitis, Goodpasture's syndrome, Graves'disease, Guillain-Barre syndrome (GB S), Hashimoto's disease, idiopathicthrombocytopenic purpura, systemic lupus erythematosus, lupus nephritis,neuropsychiatric lupus, multiple sclerosis (MS), myasthenia gravis,pemphigus vulgaris, asthma, psoriatic arthritis, rheumatoid arthritis,Sjogren's syndrome, temporal arteritis (also known as “giant cellarteritis”), autoimmune hemolytic anemia, Bullous pemphigoid,vasculitis, coeliac disease, chronic obstructive pulmonary disease,endometriosis, Hidradenitis suppurativa, interstitial cystitis, morphea,scleroderma, narcolepsy, neuromyotonia, vitiligo, and autoimmune innerear disease.

In certain embodiments, a method for treating a hyperproliferative,inflammatory, autoimmune, or graft-versus-host disease, comprises (a)administering a recombinant cell comprising a first and a second nucleicacid molecule, wherein the first nucleic acid molecule encodes a firstfusion protein comprising a first multimerization domain, a hydrophobicdomain, and an actuator domain, wherein the first multimerization domainlocalizes extracellularly when the first fusion protein is expressed,and the second nucleic acid molecule encodes a second fusion proteincomprising a binding domain and a second multimerization domain, whereinthe second fusion protein localizes extracellularly when expressed; and(c) administering a bridging factor, wherein the bridging factorpromotes the formation of a polypeptide complex on the recombinant cellsurface with the bridging factor associated with and disposed betweenthe multimerization domains of the first and second fusion proteins;wherein the binding domain of the polypeptide complex specifically bindsa cell surface target on a hyperproliferative disease cell to promote animmunomodulatory response and thereby treats the hyperproliferativedisease.

In particular embodiments, a method for treating a hyperproliferative,inflammatory, autoimmune, or graft-versus-host disease, comprises (a)administering one or more recombinant cells comprising a first nucleicacid molecule and a second nucleic acid molecule, wherein the firstnucleic acid molecule encodes a first fusion protein comprising abinding agent that binds a receptor expressed on a T cell and firstmultimerization domain, and the second nucleic acid molecule encodes asecond fusion protein comprising a binding agent that binds a cellsurface target on a hyperproliferative disease cell and a secondmultimerization domain, and (c) administering a bridging factor, whereinthe bridging factor promotes the formation of a polypeptide complex,e.g., a BiTE, with the bridging factor associated with and disposedbetween the multimerization domains of the first and second fusionproteins; wherein the binding agent of the first fusion protein binds areceptor on a T cell and the binding agent of the second fusion proteinbinds a cell surface target on a hyperproliferative disease cell topromote an immunomodulatory response and thereby treats thehyperproliferative disease.

In other embodiments, a method for treating a hyperproliferative,inflammatory, autoimmune, or graft-versus-host disease, comprises (a)administering a non-natural cell comprising a first nucleic acidmolecule encoding a first fusion protein comprising a firstmultimerization domain, a hydrophobic domain, and an actuator domain,wherein the first multimerization domain localizes extracellularly whenthe first fusion protein is expressed; (b) administering a second fusionprotein comprising a binding domain and a second multimerization domain,optionally comprising an anchor domain (e.g., transmembrane domain, GPIsignal sequence) or an anchor domain with a sub-threshold signalingdomain; and (c) administering a bridging factor, wherein the bridgingfactor promotes the formation of a polypeptide heterocomplex on therecombinant cell surface with the bridging factor associated with anddisposed between the multimerization domains of the first and secondfusion proteins; wherein the binding domain of the polypeptideheterocomplex specifically binds a cell surface target on ahyperproliferative disease cell to promote an immunomodulatory responseand thereby treats the hyperproliferative disease.

Any of the aforementioned non-natural cells, fusion proteins, bridgingfactors and other accessory molecules may be used in the methods oftreatment of this disclosure. In certain embodiments, a method furthercomprises administering an agent that antagonizes or blocks an inhibitorof T cell activation, such as an agent that antagonizes or blocks a Tcell ligand or a T cell receptor. In certain embodiments, an agent thatantagonizes or blocks an inhibitor of T cell activation is an anti-PD1antibody, anti-PD-L1 antibody, or an anti-CTLA4 antibody or antigenbinding fragment thereof, or an engineered homing endonuclease thattargets PD-1. In further embodiments, the method further comprisesadministering a cytokine agonist.

The cells, fusion proteins, bridging factors, other accessory moleculesor compositions thereof of the present disclosure may be administeredorally, topically, transdermally, parenterally, by inhalation spray,vaginally, rectally, or by intracranial injection, or any combinationthereof. In certain embodiments, fusion proteins, bridging factors, orcompositions thereof are administered parenterally. The term“parenteral,” as used herein, includes subcutaneous injections,intravenous, intramuscular, intracisternal injection, or infusiontechniques. Administration by intravascular, intravenous, intraarterial,intradermal, intramuscular, intramammary, intraperitoneal, intrathecal,retrobulbar, intrapulmonary injection and/or surgical implantation at aparticular site is contemplated as well. In certain embodiments, fusionproteins, bridging factors, or compositions thereof are administered byinjection, such as intravenously.

Also contemplated is the administration of recombinant cells with abridging factor, recombinant cells with a fusion protein and a bridgingfactor, or compositions thereof in combination with a second agent. Asecond agent may be one accepted in the art as a standard treatment fora particular disease state or disorder, such as in cancer, inflammation,autoimmunity, and infection. Exemplary second agents contemplatedinclude recombinant cells with a bridging factor, recombinant cells witha fusion protein and a bridging factor, or compositions thereof thatbind to targets different from those that the primary protein complexbinds, polyclonal antibodies, monoclonal antibodies,immunoglobulin-derived fusion proteins, chemotherapeutics, ionizingradiation, steroids, NSAIDs, anti-infective agents, or other active andancillary agents, or any combination thereof.

Second agents useful in combination with recombinant cells with abridging factor, recombinant cells with a fusion protein and a bridgingfactor, or compositions thereof provided herein may be steroids, NSAIDs,mTOR inhibitors (e.g., rapamycin (sirolimus), temsirolimus, deforolimus,everolimus, zotarolimus, curcumin, farnesylthiosalicylic acid),calcineurin inhibitors (e.g., cyclosporine, tacrolimus),anti-metabolites (e.g., mycophenolic acid, mycophenolate mofetil),polyclonal antibodies (e.g., anti-thymocyte globulin), monoclonalantibodies (e.g., daclizumab, basiliximab), and CTLA4-Ig fusion proteins(e.g., abatacept or belatacept).

Second agents useful for inhibiting growth of a solid malignancy,inhibiting metastasis or metastatic growth of a solid malignancy, ortreating or ameliorating a hematologic malignancy includechemotherapeutic agents, ionizing radiation, and other anti-cancerdrugs. Examples of chemotherapeutic agents contemplated as furthertherapeutic agents include alkylating agents, such as nitrogen mustards(e.g., mechlorethamine, cyclophosphamide, ifosfamide, melphalan, andchlorambucil); bifunctional chemotherapeutics (e.g., bendamustine);nitrosoureas (e.g., carmustine (BCNU), lomustine (CCNU), and semustine(methyl-CCNU)); ethyleneimines and methyl-melamines (e.g.,triethylenemelamine (TEM), tri ethylene thiophosphoramide (thiotepa),and hexamethylmelamine (HIVIM, altretamine)); alkyl sulfonates (e.g.,buslfan); and triazines (e.g., dacabazine (DTIC)); antimetabolites, suchas folic acid analogues (e.g., methotrexate, trimetrexate, andpemetrexed (multi-targeted antifolate)); pyrimidine analogues (such as5-fluorouracil (5-FU), fluorodeoxyuridine, gemcitabine, cytosinearabinoside (AraC, cytarabine), 5-azacytidine, and2,2′-difluorodeoxycytidine); and purine analogues (e.g,6-mercaptopurine, 6-thioguanine, azathioprine, 2′-deoxycoformycin(pentostatin), erythrohydroxynonyladenine (EHNA), fludarabine phosphate,2-chlorodeoxyadenosine (cladribine, 2-CdA)); Type I topoisomeraseinhibitors such as camptothecin (CPT), topotecan, and irinotecan;natural products, such as epipodophylotoxins (e.g., etoposide andteniposide); and vinca alkaloids (e.g., vinblastine, vincristine, andvinorelbine); anti-tumor antibiotics such as actinomycin D, doxorubicin,and bleomycin; radiosensitizers such as 5-bromodeozyuridine,5-iododeoxyuridine, and bromodeoxycytidine; platinum coordinationcomplexes such as cisplatin, carboplatin, and oxaliplatin; substitutedureas, such as hydroxyurea; and methylhydrazine derivatives such asN-methylhydrazine (MIH) and procarbazine.

Further therapeutic agents contemplated by this disclosure for treatmentof autoimmune diseases are referred to as immunosuppressive agents,which act to suppress or mask the immune system of the individual beingtreated. Immunosuppressive agents include, for example, non-steroidalanti-inflammatory drugs (NSAIDs), analgesics, glucocorticoids,disease-modifying antirheumatic drugs (DMARDs) for the treatment ofarthritis, or biologic response modifiers. Compositions in the DMARDdescription are also useful in the treatment of many other autoimmunediseases aside from rheumatoid arthritis.

Exemplary NSAIDs include ibuprofen, naproxen, naproxen sodium, Cox-2inhibitors (such as Vioxx or Celebrex), and sialylates. Exemplaryanalgesics include acetaminophen, oxycodone, tramadol of proporxyphenehydrochloride. Exemplary glucocorticoids include cortisone,dexamethasone, hydrocortisone, methylprednisolone, prednisolone, orprednisone. Exemplary biological response modifiers include moleculesdirected against cell surface markers (e.g., CD4, CD5, etc.), cytokineinhibitors, such as the TNF antagonists (e.g. etanercept (Enbrel),adalimumab (Humira) and infliximab (Remicade)), chemokine inhibitors andadhesion molecule inhibitors. The biological response modifiers includemonoclonal antibodies as well as recombinant forms of molecules.Exemplary DMARDs include azathioprine, cyclophosphamide, cyclosporine,methotrexate, penicillamine, leflunomide, sulfasalazine,hydroxychloroquine, Gold (oral (auranofin) and intramuscular) andminocycline.

In still further aspects, the instant disclosure provides a fusionpolypeptide heterocomplex, comprising (a) a first fusion proteincomprising a first multimerization domain, a hydrophobic domain, and anactuator domain; (b) a second fusion protein comprising an extracellularbinding domain and second multimerization domain; and (c) a bridgingfactor; wherein the first fusion protein, second fusion protein, andbridging factor associate to form a polypeptide heterocomplex with thebridging factor associated with and disposed between the multimerizationdomains of the first and second fusion proteins. Any of theaforementioned fusion protein components and bridging factors and may beused in these embodiments.

In other aspects, the instant disclosure provides a nucleic acidmolecule encoding any one or more of the aforementioned fusion proteins.Such nucleic acid molecules may be incorporated into an expressionvector (e.g., lentiviral vector), wherein the first and second fusionproteins are encoded as a polycistronic message or as a single proteinseparated by a 2A peptide. In certain embodiments, the polycistronicmessage comprises an internal ribosome entry site (IRES) between thenucleotide sequences that encode the fusion proteins.

Illustrative examples of DARIC binding and signaling components areprovided in SEQ ID NOs: 1-100 and below in Table 1.

TABLE 1 Exemplary DARIC Binding and Signaling Components SEQ ID NO.Construct Sequence   1 scFvCD19-FKBPMGSDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDG proteinTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSASGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELL KLEG   2 SS-scFvCD19-FKBPAUGCCCCUGGGCCUGCUGUGGCUGGGCCUGGCCCUGCUGGGC mRNAGCCCUGCACGCCCAGGCCGGAUCCGAUAUCCAGAUGACCCAGACCACCAGCAGCCUGAGCGCCAGCCUGGGCGAUAGAGUGACCAUCAGCUGCAGAGCCAGCCAGGACAUCAGCAAGUACCUGAACUGGUAUCAGCAGAAACCCGACGGCACCGUGAAGCUGCUGAUCUACCACACCAGCAGACUGCACAGCGGCGUGCCCAGCAGAUUUUCUGGCAGCGGCUCCGGCACCGACUACAGCCUGACCAUCUCCAACCUGGAACAGGAAGAUAUCGCUACCUACUUCUGUCAGCAAGGCAACACCCUGCCCUACACCUUCGGCGGAGGCACCAAGCUGGAAAUCACCGGCAGCACAAGCGGCAGCGGCAAGCCUGGAUCUGGCGAGGGAAGCACCAAGGGCGAAGUGAAACUGCAGGAAAGCGGCCCUGGACUGGUGGCCCCAAGCCAGUCUCUGAGCGUGACCUGUACCGUGUCCGGCGUGUCCCUGCCUGACUAUGGCGUGUCCUGGAUCAGACAGCCCCCCAGAAAGGGCCUGGAAUGGCUGGGAGUGAUCUGGGGCAGCGAGACAACCUACUACAACAGCGCCCUGAAGUCCCGGCUGACCAUCAUCAAGGACAACUCCAAGAGCCAGGUGUUCCUGAAGAUGAACAGCCUGCAGACCGACGACACCGCCAUCUACUACUGCGCCAAGCACUACUACUACGGCGGCAGCUACGCCAUGGACUACUGGGGCCAGGGCACAAGCGUGACCGUGUCCAGCGCUAGCGGCGGAGGUGGGAGCGGAGUGCAGGUGGAAACCAUCUCCCCAGGAGACGGGCGCACCUUCCCCAAGCGCGGCCAGACCUGCGUGGUGCACUACACCGGGAUGCUUGAAGAUGGAAAGAAAUUUGAUUCCUCCCGGGACAGAAACAAGCCCUUUAAGUUUAUGCUAGGCAAGCAGGAGGUGAUCCGAGGCUGGGAAGAAGGGGUUGCCCAGAUGAGUGUGGGUCAGAGAGCCAAACUGACUAUAUCUCCAGAUUAUGCCUAUGGUGCCACUGGGCACCCAGGCAUCAUCCCACCACAUGCCACUCUCGUCUUCGAUGUGGAGCUUCUAAAACUGGAAGGCUGA   3 SS-scFvCD19-FKBPATGCCCCTGGGCCTGCTGTGGCTGGGCCTGGCCCTGCTGGGCG DNACCCTGCACGCCCAGGCCGGATCCGATATCCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCCCCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCGGAGGTGGGAGCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCTGA   4 scFvCD19-FKBPMGSDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDG (F36V) proteinTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSASGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELL KLEG   5 SS-scFvCD19-FKBPAUGCCCCUGGGCCUGCUGUGGCUGGGCCUGGCCCUGCUGGGC (F36V) mRNAGCCCUGCACGCCCAGGCCGGAUCCGAUAUCCAGAUGACCCAGACCACCAGCAGCCUGAGCGCCAGCCUGGGCGAUAGAGUGACCAUCAGCUGCAGAGCCAGCCAGGACAUCAGCAAGUACCUGAACUGGUAUCAGCAGAAACCCGACGGCACCGUGAAGCUGCUGAUCUACCACACCAGCAGACUGCACAGCGGCGUGCCCAGCAGAUUUUCUGGCAGCGGCUCCGGCACCGACUACAGCCUGACCAUCUCCAACCUGGAACAGGAAGAUAUCGCUACCUACUUCUGUCAGCAAGGCAACACCCUGCCCUACACCUUCGGCGGAGGCACCAAGCUGGAAAUCACCGGCAGCACAAGCGGCAGCGGCAAGCCUGGAUCUGGCGAGGGAAGCACCAAGGGCGAAGUGAAACUGCAGGAAAGCGGCCCUGGACUGGUGGCCCCAAGCCAGUCUCUGAGCGUGACCUGUACCGUGUCCGGCGUGUCCCUGCCUGACUAUGGCGUGUCCUGGAUCAGACAGCCCCCCAGAAAGGGCCUGGAAUGGCUGGGAGUGAUCUGGGGCAGCGAGACAACCUACUACAACAGCGCCCUGAAGUCCCGGCUGACCAUCAUCAAGGACAACUCCAAGAGCCAGGUGUUCCUGAAGAUGAACAGCCUGCAGACCGACGACACCGCCAUCUACUACUGCGCCAAGCACUACUACUACGGCGGCAGCUACGCCAUGGACUACUGGGGCCAGGGCACAAGCGUGACCGUGUCCAGCGCUAGCGGCGGAGGUGGGAGCGGAGUGCAGGUGGAAACCAUCUCCCCAGGAGACGGGCGCACCUUCCCCAAGCGCGGCCAGACCUGCGUGGUGCACUACACCGGGAUGCUUGAAGAUGGAAAGAAAGUUGAUUCCUCCCGGGACAGAAACAAGCCCUUUAAGUUUAUGCUAGGCAAGCAGGAGGUGAUCCGAGGCUGGGAAGAAGGGGUUGCCCAGAUGAGUGUGGGUCAGAGAGCCAAACUGACUAUAUCUCCAGAUUAUGCCUAUGGUGCCACUGGGCACCCAGGCAUCAUCCCACCACAUGCCACUCUCGUCUUCGAUGUGGAGCUUCUAAAACUGGAAGGCUGA   6 SS-scFvCD19-FKBPATGCCCCTGGGCCTGCTGTGGCTGGGCCTGGCCCTGCTGGGCG (F36V) DNACCCTGCACGCCCAGGCCGGATCCGATATCCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCCCCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCGGAGGTGGGAGCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCTGA   7 scFvCD19-FRBMGSDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDG (T2098L) proteinTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSASGGGGSILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLLQAWDLYYHVFRRISKG   8 SS-scFvCD19-FRBAUGCCCCUGGGCCUGCUGUGGCUGGGCCUGGCCCUGCUGGGC (T2098L) mRNAGCCCUGCACGCCCAGGCCGGAUCCGAUAUCCAGAUGACCCAGACCACCAGCAGCCUGAGCGCCAGCCUGGGCGAUAGAGUGACCAUCAGCUGCAGAGCCAGCCAGGACAUCAGCAAGUACCUGAACUGGUAUCAGCAGAAACCCGACGGCACCGUGAAGCUGCUGAUCUACCACACCAGCAGACUGCACAGCGGCGUGCCCAGCAGAUUUUCUGGCAGCGGCUCCGGCACCGACUACAGCCUGACCAUCUCCAACCUGGAACAGGAAGAUAUCGCUACCUACUUCUGUCAGCAAGGCAACACCCUGCCCUACACCUUCGGCGGAGGCACCAAGCUGGAAAUCACCGGCAGCACAAGCGGCAGCGGCAAGCCUGGAUCUGGCGAGGGAAGCACCAAGGGCGAAGUGAAACUGCAGGAAAGCGGCCCUGGACUGGUGGCCCCAAGCCAGUCUCUGAGCGUGACCUGUACCGUGUCCGGCGUGUCCCUGCCUGACUAUGGCGUGUCCUGGAUCAGACAGCCCCCCAGAAAGGGCCUGGAAUGGCUGGGAGUGAUCUGGGGCAGCGAGACAACCUACUACAACAGCGCCCUGAAGUCCCGGCUGACCAUCAUCAAGGACAACUCCAAGAGCCAGGUGUUCCUGAAGAUGAACAGCCUGCAGACCGACGACACCGCCAUCUACUACUGCGCCAAGCACUACUACUACGGCGGCAGCUACGCCAUGGACUACUGGGGCCAGGGCACAAGCGUGACCGUGUCCAGCGCUAGCGGCGGAGGUGGGAGCAUCCUCUGGCAUGAGAUGUGGCAUGAAGGCCUGGAAGAGGCAUCUCGUUUGUACUUUGGGGAAAGGAACGUGAAAGGCAUGUUUGAGGUGCUGGAGCCCUUGCAUGCUAUGAUGGAACGGGGCCCCCAGACUCUGAAGGAAACAUCCUUUAAUCAGGCCUAUGGUCGAGAUUUAAUGGAGGCCCAAGAGUGGUGCAGGAAGUACAUGAAAUCAGGGAAUGUCAAGGACCUCCUCCAAGCCUGGGACCUCUAUUAUCAUGUGUUCCGACGAAUCUCAAAGGGCUGA   9 SS-scFvCD19-FRBATGCCCCTGGGCCTGCTGTGGCTGGGCCTGGCCCTGCTGGGCG (T2098L) DNACCCTGCACGCCCAGGCCGGATCCGATATCCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCCCCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCGGAGGTGGGAGCATCCTCTGGCATGAGATGTGGCATGAAGGCCTGGAAGAGGCATCTCGTTTGTACTTTGGGGAAAGGAACGTGAAAGGCATGTTTGAGGTGCTGGAGCCCTTGCATGCTATGATGGAACGGGGCCCCCAGACTCTGAAGGAAACATCCTTTAATCAGGCCTATGGTCGAGATTTAATGGAGGCCCAAGAGTGGTGCAGGAAGTACATGAAATCAGGGAATGTCAAGGACCTCCTCCAAGCCTGGGACCTCTATTATCATGTGTTCCGACGAATCTCAAAGGGCTGA  13 scFvCD19-TM-41BB-AUGGCUCUGCCUGUGACAGCUCUGCUGCUGCCUCUGGCCCUG CD3z-BFP mRNACUGCUCCAUGCCGCCAGACCCGGAUCCGAUAUCCAGAUGACCCAGACCACCAGCAGCCUGAGCGCCAGCCUGGGCGAUAGAGUGACCAUCAGCUGCAGAGCCAGCCAGGACAUCAGCAAGUACCUGAACUGGUAUCAGCAGAAACCCGACGGCACCGUGAAGCUGCUGAUCUACCACACCAGCAGACUGCACAGCGGCGUGCCCAGCAGAUUUUCUGGCAGCGGCUCCGGCACCGACUACAGCCUGACCAUCUCCAACCUGGAACAGGAAGAUAUCGCUACCUACUUCUGUCAGCAAGGCAACACCCUGCCCUACACCUUCGGCGGAGGCACCAAGCUGGAAAUCACCGGCAGCACAAGCGGCAGCGGCAAGCCUGGAUCUGGCGAGGGAAGCACCAAGGGCGAAGUGAAACUGCAGGAAAGCGGCCCUGGACUGGUGGCCCCAAGCCAGUCUCUGAGCGUGACCUGUACCGUGUCCGGCGUGUCCCUGCCUGACUAUGGCGUGUCCUGGAUCAGACAGCCACCCAGAAAGGGCCUGGAAUGGCUGGGAGUGAUCUGGGGCAGCGAGACAACCUACUACAACAGCGCCCUGAAGUCCCGGCUGACCAUCAUCAAGGACAACUCCAAGAGCCAGGUGUUCCUGAAGAUGAACAGCCUGCAGACCGACGACACCGCCAUCUACUACUGCGCCAAGCACUACUACUACGGCGGCAGCUACGCCAUGGACUACUGGGGCCAGGGCACAAGCGUGACCGUGUCCAGCGCUAGCGCCAAGCCUACCACCACCCCUGCCCCUAGACCUCCAACACCCGCCCCAACAAUCGCCAGCCAGCCUCUGUCUCUGAGGCCCGAGGCUUGUAGACCAGCUGCUGGCGGAGCCGUGCACACCAGAGGACUGGAUUUCGCCUGCGACAUCUACAUCUGGGCCCCUCUGGCCGGCACAUGUGGCGUGCUGCUGCUGAGCCUCGUGAUCACCAUGCAUAAACGGGGCAGAAAGAAACUCCUGUAUAUAUUCAAACAACCAUUUAUGAGACCAGUACAAACUACUCAAGAGGAAGAUGGCUGUAGCUGCCGAUUUCCAGAAGAAGAAGAAGGAGGAUGUGAACUGCGGGUGAAGUUCAGCAGAAGCGCCGACGCCCCUGCCUACCAGCAGGGCCAGAAUCAGCUGUACAACGAGCUGAACCUGGGCAGAAGGGAAGAGUACGACGUCCUGGAUAAGCGGAGAGGCCGGGACCCUGAGAUGGGCGGCAAGCCUCGGCGGAAGAACCCCCAGGAAGGCCUGUAUAACGAACUGCAGAAAGACAAGAUGGCCGAGGCCUACAGCGAGAUCGGCAUGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCUGUAUCAGGGCCUGUCCACCGCCACCAAGGAUACCUACGACGCCCUGCACAUGCAGGCCCUGCCCCCAAGGGGCGGCCGCUCCGGUGAGGGCAGAGGAAGUCUUCUAACAUGCGGUGACGUGGAGGAGAAUCCGGGCCCCUCUAGAAGCGAGCUGAUUAAGGAGAACAUGCACAUGAAGCUGUACAUGGAGGGCACCGUGGACAACCAUCACUUCAAGUGCACAUCCGAGGGCGAAGGCAAGCCCUACGAGGGCACCCAGACCAUGAGAAUCAAGGUGGUCGAGGGCGGCCCUCUCCCCUUCGCCUUCGACAUCCUGGCUACUAGCUUCCUCUACGGCAGCAAGACCUUCAUCAACCACACCCAGGGCAUCCCCGACUUCUUCAAGCAGUCCUUCCCUGAGGGCUUCACAUGGGAGAGAGUCACCACAUACGAAGACGGGGGCGUGCUGACCGCUACCCAGGACACCAGCCUCCAGGACGGCUGCCUCAUCUACAACGUCAAGAUCAGAGGGGUGAACUUCACAUCCAACGGCCCUGUGAUGCAGAAGAAAACACUCGGCUGGGAGGCCUUCACCGAGACGCUGUACCCCGCUGACGGCGGCCUGGAAGGCAGAAACGACAUGGCCCUGAAGCUCGUGGGCGGGAGCCAUCUGAUCGCAAACAUCAAGACCACAUAUAGAUCCAAGAAACCCGCUAAGAACCUCAAGAUGCCUGGCGUCUACUAUGUGGACUACAGACUGGAAAGAAUCAAGGAGGCCAACAACGAGACCUACGUCGAGCAGCACGAGGUGGCAGUGGCCAGAUACUGCGACCUCCCUAGCA AACUGGGGCACAAGCUUAAUUGA  15FRB(T2098L)-TM- MGSILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMER41BB-CD3z protein GPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLLQAWDLYYHVFRRISKASAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT KDTYDALHMQALPPRG  16SS-FRB(T2098L)-TM- AUGGCUCUGCCUGUGACAGCUCUGCUGCUGCCUCUGGCCCUG41BB-CD3z mRNA CUGCUCCAUGCCGCCAGACCCGGAUCCAUCCUCUGGCAUGAGAUGUGGCAUGAAGGCCUGGAAGAGGCAUCUCGUUUGUACUUUGGGGAAAGGAACGUGAAAGGCAUGUUUGAGGUGCUGGAGCCCUUGCAUGCUAUGAUGGAACGGGGCCCCCAGACUCUGAAGGAAACAUCCUUUAAUCAGGCCUAUGGUCGAGAUUUAAUGGAGGCCCAAGAGUGGUGCAGGAAGUACAUGAAAUCAGGGAAUGUCAAGGACCUCCUCCAAGCCUGGGACCUCUAUUAUCAUGUGUUCCGACGAAUCUCAAAGGCUAGCGCCAAGCCUACCACCACCCCUGCCCCUAGACCUCCAACACCCGCCCCAACAAUCGCCAGCCAGCCUCUGUCUCUGAGGCCCGAGGCUUGUAGACCAGCUGCUGGCGGAGCCGUGCACACCAGAGGACUGGAUUUCGCCUGCGACAUCUACAUCUGGGCCCCUCUGGCCGGCACAUGUGGCGUGCUGCUGCUGAGCCUCGUGAUCACCAUGCAUAAACGGGGCAGAAAGAAACUCCUGUAUAUAUUCAAACAACCAUUUAUGAGACCAGUACAAACUACUCAAGAGGAAGAUGGCUGUAGCUGCCGAUUUCCAGAAGAAGAAGAAGGAGGAUGUGAACUGCGGGUGAAGUUCAGCAGAAGCGCCGACGCCCCUGCCUACCAGCAGGGCCAGAAUCAGCUGUACAACGAGCUGAACCUGGGCAGAAGGGAAGAGUACGACGUCCUGGAUAAGCGGAGAGGCCGGGACCCUGAGAUGGGCGGCAAGCCUCGGCGGAAGAACCCCCAGGAAGGCCUGUAUAACGAACUGCAGAAAGACAAGAUGGCCGAGGCCUACAGCGAGAUCGGCAUGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCUGUAUCAGGGCCUGUCCACCGCCACCAAGGAUACCUACGACGCCCUGCACAUGCAGGCCCUGCCCCCAAGGGGC  17 SS-FRB(T2098L)-TM-ATGGCTCTGCCTGTGACAGCTCTGCTGCTGCCTCTGGCCCTGCT 41BB-CD3z DNAGCTCCATGCCGCCAGACCCGGATCCATCCTCTGGCATGAGATGTGGCATGAAGGCCTGGAAGAGGCATCTCGTTTGTACTTTGGGGAAAGGAACGTGAAAGGCATGTTTGAGGTGCTGGAGCCCTTGCATGCTATGATGGAACGGGGCCCCCAGACTCTGAAGGAAACATCCTTTAATCAGGCCTATGGTCGAGATTTAATGGAGGCCCAAGAGTGGTGCAGGAAGTACATGAAATCAGGGAATGTCAAGGACCTCCTCCAAGCCTGGGACCTCTATTATCATGTGTTCCGACGAATCTCAAAGGCTAGCGCCAAGCCTACCACCACCCCTGCCCCTAGACCTCCAACACCCGCCCCAACAATCGCCAGCCAGCCTCTGTCTCTGAGGCCCGAGGCTTGTAGACCAGCTGCTGGCGGAGCCGTGCACACCAGAGGACTGGATTTCGCCTGCGACATCTACATCTGGGCCCCTCTGGCCGGCACATGTGGCGTGCTGCTGCTGAGCCTCGTGATCACCATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCCTGC CCCCAAGGGGC  18SS-FRB(T2098L)- ATGGCTCTGCCTGTGACAGCTCTGCTGCTGCCTCTGGCCCTGCTspacer-TM-41BB-CD3z GCTCCATGCCGCCAGACCCGGATCCATCCTCTGGCATGAGATG DNATGGCATGAAGGCCTGGAAGAGGCATCTCGTTTGTACTTTGGGGAAAGGAACGTGAAAGGCATGTTTGAGGTGCTGGAGCCCTTGCATGCTATGATGGAACGGGGCCCCCAGACTCTGAAGGAAACATCCTTTAATCAGGCCTATGGTCGAGATTTAATGGAGGCCCAAGAGTGGTGCAGGAAGTACATGAAATCAGGGAATGTCAAGGACCTCCTCCAAGCCTGGGACCTCTATTATCATGTGTTCCGACGAATCTCAAAGGCTAGCGAGAGCAAGTACGGACCGCCCTGCCCACCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCACCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGCAAGGCCAAGGGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCACCCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCA CATGCAGGCCCTGCCCCCAAGGGGC 19 FKBP(F36V)-TM- MGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRD41BB-CD3z protein RNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEASAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH DGLYQGLSTATKDTYDALHMQALPPRG 20 SS-FKBP(F36V)-TM- AUGGCUCUGCCUGUGACAGCUCUGCUGCUGCCUCUGGCCCUG41BB-CD3z mRNA CUGCUCCAUGCCGCCAGACCCGGAUCCGGAGUGCAGGUGGAAACCAUCUCCCCAGGAGACGGGCGCACCUUCCCCAAGCGCGGCCAGACCUGCGUGGUGCACUACACCGGGAUGCUUGAAGAUGGAAAGAAAGUUGAUUCCUCCCGGGACAGAAACAAGCCCUUUAAGUUUAUGCUAGGCAAGCAGGAGGUGAUCCGAGGCUGGGAAGAAGGGGUUGCCCAGAUGAGUGUGGGUCAGAGAGCCAAACUGACUAUAUCUCCAGAUUAUGCCUAUGGUGCCACUGGGCACCCAGGCAUCAUCCCACCACAUGCCACUCUCGUCUUCGAUGUGGAGCUUCUAAAACUGGAAGCUAGCGCCAAGCCUACCACCACCCCUGCCCCUAGACCUCCAACACCCGCCCCAACAAUCGCCAGCCAGCCUCUGUCUCUGAGGCCCGAGGCUUGUAGACCAGCUGCUGGCGGAGCCGUGCACACCAGAGGACUGGAUUUCGCCUGCGACAUCUACAUCUGGGCCCCUCUGGCCGGCACAUGUGGCGUGCUGCUGCUGAGCCUCGUGAUCACCAUGCAUAAACGGGGCAGAAAGAAACUCCUGUAUAUAUUCAAACAACCAUUUAUGAGACCAGUACAAACUACUCAAGAGGAAGAUGGCUGUAGCUGCCGAUUUCCAGAAGAAGAAGAAGGAGGAUGUGAACUGCGGGUGAAGUUCAGCAGAAGCGCCGACGCCCCUGCCUACCAGCAGGGCCAGAAUCAGCUGUACAACGAGCUGAACCUGGGCAGAAGGGAAGAGUACGACGUCCUGGAUAAGCGGAGAGGCCGGGACCCUGAGAUGGGCGGCAAGCCUCGGCGGAAGAACCCCCAGGAAGGCCUGUAUAACGAACUGCAGAAAGACAAGAUGGCCGAGGCCUACAGCGAGAUCGGCAUGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCUGUAUCAGGGCCUGUCCACCGCCACCAAGGAUACCUACGACGCCCUGCACAUGCAGGCCCUGCCCCCAAGGGGC  21 SS-FKBP(F36V)-TM-ATGGCTCTGCCTGTGACAGCTCTGCTGCTGCCTCTGGCCCTGCT 41BB-CD3z DNAGCTCCATGCCGCCAGACCCGGATCCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGCTAGCGCCAAGCCTACCACCACCCCTGCCCCTAGACCTCCAACACCCGCCCCAACAATCGCCAGCCAGCCTCTGTCTCTGAGGCCCGAGGCTTGTAGACCAGCTGCTGGCGGAGCCGTGCACACCAGAGGACTGGATTTCGCCTGCGACATCTACATCTGGGCCCCTCTGGCCGGCACATGTGGCGTGCTGCTGCTGAGCCTCGTGATCACCATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCCTGC CCCCAAGGGGC  22SS-FKBP(F36V)- ATGGCTCTGCCTGTGACAGCTCTGCTGCTGCCTCTGGCCCTGCTspacer-TM-41BB-CD3z GCTCCATGCCGCCAGACCCGGATCCGGAGTGCAGGTGGAAAC DNACATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAAGTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGCTAGCGAGAGCAAGTACGGACCGCCCTGCCCACCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCACCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGCAAGGCCAAGGGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCACCCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCA CATGCAGGCCCTGCCCCCAAGGGGC 23 FKBP-TM-41BB-CD3z MGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDprotein RNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEASAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH DGLYQGLSTATKDTYDALHMQALPPRG 24 FKBP-TM-41BB-CD3z AUGGCUCUGCCUGUGACAGCUCUGCUGCUGCCUCUGGCCCUG mRNACUGCUCCAUGCCGCCAGACCCGGAUCCGGAGUGCAGGUGGAAACCAUCUCCCCAGGAGACGGGCGCACCUUCCCCAAGCGCGGCCAGACCUGCGUGGUGCACUACACCGGGAUGCUUGAAGAUGGAAAGAAAUUUGAUUCCUCCCGGGACAGAAACAAGCCCUUUAAGUUUAUGCUAGGCAAGCAGGAGGUGAUCCGAGGCUGGGAAGAAGGGGUUGCCCAGAUGAGUGUGGGUCAGAGAGCCAAACUGACUAUAUCUCCAGAUUAUGCCUAUGGUGCCACUGGGCACCCAGGCAUCAUCCCACCACAUGCCACUCUCGUCUUCGAUGUGGAGCUUCUAAAACUGGAAGCUAGCGCCAAGCCUACCACCACCCCUGCCCCUAGACCUCCAACACCCGCCCCAACAAUCGCCAGCCAGCCUCUGUCUCUGAGGCCCGAGGCUUGUAGACCAGCUGCUGGCGGAGCCGUGCACACCAGAGGACUGGAUUUCGCCUGCGACAUCUACAUCUGGGCCCCUCUGGCCGGCACAUGUGGCGUGCUGCUGCUGAGCCUCGUGAUCACCAUGCAUAAACGGGGCAGAAAGAAACUCCUGUAUAUAUUCAAACAACCAUUUAUGAGACCAGUACAAACUACUCAAGAGGAAGAUGGCUGUAGCUGCCGAUUUCCAGAAGAAGAAGAAGGAGGAUGUGAACUGCGGGUGAAGUUCAGCAGAAGCGCCGACGCCCCUGCCUACCAGCAGGGCCAGAAUCAGCUGUACAACGAGCUGAACCUGGGCAGAAGGGAAGAGUACGACGUCCUGGAUAAGCGGAGAGGCCGGGACCCUGAGAUGGGCGGCAAGCCUCGGCGGAAGAACCCCCAGGAAGGCCUGUAUAACGAACUGCAGAAAGACAAGAUGGCCGAGGCCUACAGCGAGAUCGGCAUGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCUGUAUCAGGGCCUGUCCACCGCCACCAAGGAUACCUACGACGCCCUGCACAUGCAGGCCCUGCCCCCAAGGGGC  25 FKBP-TM-41BB-CD3zATGGCTCTGCCTGTGACAGCTCTGCTGCTGCCTCTGGCCCTGCT DNAGCTCCATGCCGCCAGACCCGGATCCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGCTAGCGCCAAGCCTACCACCACCCCTGCCCCTAGACCTCCAACACCCGCCCCAACAATCGCCAGCCAGCCTCTGTCTCTGAGGCCCGAGGCTTGTAGACCAGCTGCTGGCGGAGCCGTGCACACCAGAGGACTGGATTTCGCCTGCGACATCTACATCTGGGCCCCTCTGGCCGGCACATGTGGCGTGCTGCTGCTGAGCCTCGTGATCACCATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCCTGC CCCCAAGGGGC  26FKBP-spacer-TM- ATGGCTCTGCCTGTGACAGCTCTGCTGCTGCCTCTGGCCCTGCT41BB-CD3z DNA GCTCCATGCCGCCAGACCCGGATCCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGCTAGCGAGAGCAAGTACGGACCGCCCTGCCCACCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCACCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGCAAGGCCAAGGGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCACCCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCA CATGCAGGCCCTGCCCCCAAGGGGC 37 SS-2xDmrB-DmrC- MALPVTALLLPLALLLHAARPGSGGVQVETISPGDGRTFPKRGQTTM-41BB-CD3z CVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVA proteinQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVEFLKLESGTSGTSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSR DRNKPFKFMLGKQEVIRGWEEGV  38SS-2xDmrB-DmrC- AUGGCUCUGCCUGUGACAGCUCUGCUGCUGCCUCUGGCCCUG TM-41BB-CD3zCUGCUCCAUGCCGCCAGACCCGGAUCCGGCGGUGUCCAAGUC mRNAGAAACUAUAUCGCCUGGCGAUGGCAGAACGUUUCCCAAACGUGGCCAGACCUGUGUCGUACACUAUACCGGCAUGCUAGAGGAUGGGAAAAAGGUUGAUUCCAGUCGCGAUCGGAACAAACCGUUUAAAUUCAUGUUGGGGAAGCAAGAGGUUAUCAGGGGAUGGGAAGAGGGUGUCGCGCAAAUGUCGGUUGGGCAACGUGCGAAACUCACAAUUUCCCCGGAUUACGCAUACGGAGCUACCGGACACCCUGGGAUUAUCCCACCGCAUGCGACGCUAGUGUUUGACGUAGAGUUCUUGAAGCUCGAAUCAGGUACAAGCGGCACUUCUGGCGUACAGGUUGAGACAAUUAGUCCCGGAGACGGACGUACAUUCCCAAAGAGAGGGCAAACUUGCGUAGUCCAUUACACUGGAAUGUUGGAAGACGGCAAGAAAGUGGACAGUUCAAGAGACCGCAAUAAGCCUUUCAAGUUUAUGCUCGGAAAACAGGAAGUCAUACGCGGUUGGGAGGAAGGCGUGGCUCAGAUGAGCGUCGGACAGAGGGCAAAGUUGACCAUCAGUCCCGACUAUGCGUAUGGCGCGACAGGCCAUCCCGGAAUCAUACCUCCCCACGCAACCUUGGUAUUCGAUGUCGAACUGCUCAAAUUAGAGGGUAGUAGAUCCAUCCUCUGGCAUGAGAUGUGGCAUGAAGGCCUGGAAGAGGCAUCUCGUUUGUACUUUGGGGAAAGGAACGUGAAAGGCAUGUUUGAGGUGCUGGAGCCCUUGCAUGCUAUGAUGGAACGGGGCCCCCAGACUCUGAAGGAAACAUCCUUUAAUCAGGCCUAUGGUCGAGAUUUAAUGGAGGCCCAAGAGUGGUGCAGGAAGUACAUGAAAUCAGGGAAUGUCAAGGACCUCCUCCAAGCCUGGGACCUCUAUUAUCAUGUGUUCCGACGAAUCUCAAAGGCUAGCGCCAAGCCUACCACCACCCCUGCCCCUAGACCUCCAACACCCGCCCCAACAAUCGCCAGCCAGCCUCUGUCUCUGAGGCCCGAGGCUUGUAGACCAGCUGCUGGCGGAGCCGUACACACCAGAGGACUGGAUUUCGCCUGCGACAUCUACAUCUGGGCCCCUCUGGCCGGCACAUGUGGCGUGCUGCUGCUGAGCCUCGUGAUCACCAUGCAUAAACGGGGCAGAAAGAAACUCCUGUAUAUAUUCAAACAACCAUUUAUGAGACCAGUACAAACUACUCAAGAGGAAGAUGGCUGUAGCUGCCGAUUUCCAGAAGAAGAAGAAGGAGGAUGUGAACUGCGGGUGAAGUUCAGCAGAAGCGCCGACGCCCCUGCCUACCAGCAGGGCCAGAAUCAGCUGUACAACGAGCUGAACCUGGGCAGAAGGGAAGAGUACGACGUCCUGGAUAAGCGGAGAGGCCGGGACCCUGAGAUGGGCGGCAAGCCUCGGCGGAAGAACCCCCAGGAAGGCCUGUAUAACGAACUGCAGAAAGACAAGAUGGCCGAGGCCUACAGCGAGAUCGGCAUGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCUGUAUCAGGGCCUGUCCACCGCCACCAAGGAUACCUACGACGCCCUGCACAUGC AGGCCCUGCCCCCAAGGGGC  39SS-2xDmrB-DmrC- ATGGCTCTGCCTGTGACAGCTCTGCTGCTGCCTCTGGCCCTGCTTM-41BB-CD3z DNA GCTCCATGCCGCCAGACCCGGATCCGGCGGTGTCCAAGTCGAAACTATATCGCCTGGCGATGGCAGAACGTTTCCCAAACGTGGCCAGACCTGTGTCGTACACTATACCGGCATGCTAGAGGATGGGAAAAAGGTTGATTCCAGTCGCGATCGGAACAAACCGTTTAAATTCATGTTGGGGAAGCAAGAGGTTATCAGGGGATGGGAAGAGGGTGTCGCGCAAATGTCGGTTGGGCAACGTGCGAAACTCACAATTTCCCCGGATTACGCATACGGAGCTACCGGACACCCTGGGATTATCCCACCGCATGCGACGCTAGTGTTTGACGTAGAGTTCTTGAAGCTCGAATCAGGTACAAGCGGCACTTCTGGCGTACAGGTTGAGACAATTAGTCCCGGAGACGGACGTACATTCCCAAAGAGAGGGCAAACTTGCGTAGTCCATTACACTGGAATGTTGGAAGACGGCAAGAAAGTGGACAGTTCAAGAGACCGCAATAAGCCTTTCAAGTTTATGCTCGGAAAACAGGAAGTCATACGCGGTTGGGAGGAAGGCGTGGCTCAGATGAGCGTCGGACAGAGGGCAAAGTTGACCATCAGTCCCGACTATGCGTATGGCGCGACAGGCCATCCCGGAATCATACCTCCCCACGCAACCTTGGTATTCGATGTCGAACTGCTCAAATTAGAGGGTAGTAGATCCATCCTCTGGCATGAGATGTGGCATGAAGGCCTGGAAGAGGCATCTCGTTTGTACTTTGGGGAAAGGAACGTGAAAGGCATGTTTGAGGTGCTGGAGCCCTTGCATGCTATGATGGAACGGGGCCCCCAGACTCTGAAGGAAACATCCTTTAATCAGGCCTATGGTCGAGATTTAATGGAGGCCCAAGAGTGGTGCAGGAAGTACATGAAATCAGGGAATGTCAAGGACCTCCTCCAAGCCTGGGACCTCTATTATCATGTGTTCCGACGAATCTCAAAGGCTAGCGCCAAGCCTACCACCACCCCTGCCCCTAGACCTCCAACACCCGCCCCAACAATCGCCAGCCAGCCTCTGTCTCTGAGGCCCGAGGCTTGTAGACCAGCTGCTGGCGGAGCCGTACACACCAGAGGACTGGATTTCGCCTGCGACATCTACATCTGGGCCCCTCTGGCCGGCACATGTGGCGTGCTGCTGCTGAGCCTCGTGATCACCATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCAAG GGGC  41 SS-scFvCD19-DmrA-METDTLLLWVLLLWVPGSTGDYKDEGSDIQMTQTTSSLSASLGD fuP2A-DmrC-TM-RVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFS 41BB-CD3z proteinGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSL PDYGVSWIRQPPRKGLEWLGVIWGSE 42 SS-scFvCD19-DmrA- ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGfuP2A-DmrC-TM- TTCCAGGTTCCACTGGTGACTACAAGGACGAGGGATCCGATAT 41BB-CD3z DNACCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCACCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCTCAGGAGGAGTGCAGGTTGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCGAAGCGCGGACAGACATGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTCGATTCATCGCGGGACAGAAACAAGCCCTTTAAGTTTATGCTGGGCAAGCAGGAGGTCATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTCGGCCAGAGAGCCAAACTGACTATATCACCTGACTACGCCTATGGGGCCACTGGGCACCCTGGCATAATTCCGCCACACGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCGGCCGCGCTCGTTACAAGCGAAGTGTCTCAGGATCTGGCGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCTTCAAGATCCATCCTCTGGCATGAGATGTGGCATGAAGGCCTGGAAGAGGCATCTCGTTTGTACTTTGGGGAAAGGAACGTGAAAGGCATGTTTGAGGTGCTGGAGCCCTTGCATGCTATGATGGAACGGGGCCCCCAGACTCTGAAGGAAACATCCTTTAATCAGGCCTATGGTCGAGATTTAATGGAGGCCCAAGAGTGGTGCAGGAAGTACATGAAATCAGGGAATGTCAAGGACCTCCTCCAAGCCTGGGACCTCTATTATCATGTGTTCCGACGAATCTCAAAGGCTAGCGCCAAGCCTACCACCACCCCTGCCCCTAGACCTCCAACACCCGCCCCAACAATCGCCAGCCAGCCTCTGTCTCTGAGGCCCGAGGCTTGTAGACCAGCTGCTGGCGGAGCCGTACACACCAGAGGACTGGATTTCGCCTGCGACATCTACATCTGGGCCCCTCTGGCCGGCACATGTGGCGTGCTGCTGCTGAGCCTCGTGATCACCATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCC TGCCCCCAAGGGGC  44SS-scFvCD19-DmrA- METDTLLLWVLLLWVPGSTGDYKDEGSDIQMTQTTSSLSASLGDfuP2A-FRB-TM-41BB- RVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSCD3z protein GSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSL PDYGVSWIRQPPRKGLEWLGVIWGSE 45 SS-scFvCD19-DmrA- ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGfuP2A-FRB-TM-41BB- TTCCAGGTTCCACTGGTGACTACAAGGACGAGGGATCCGATAT CD3z DNACCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCACCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCTCAGGAGGAGTGCAGGTTGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCGAAGCGCGGACAGACATGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTCGATTCATCGCGGGACAGAAACAAGCCCTTTAAGTTTATGCTGGGCAAGCAGGAGGTCATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTCGGCCAGAGAGCCAAACTGACTATATCACCTGACTACGCCTATGGGGCCACTGGGCACCCTGGCATAATTCCGCCACACGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCGGCCGCGCTCGTTACAAGCGAAGTGTCTCAGGATCTGGCGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCTTCAAGATCCATCCTCTGGCATGAGATGTGGCATGAAGGCCTGGAAGAGGCATCTCGTTTGTACTTTGGGGAAAGGAACGTGAAAGGCATGTTTGAGGTGCTGGAGCCCTTGCATGCTATGATGGAACGGGGCCCCCAGACTCTGAAGGAAACATCCTTTAATCAGGCCTATGGTCGAGATTTAATGGAGGCCCAAGAGTGGTGCAGGAAGTACATGAAATCAGGGAATGTCAAGGACCTCACCCAAGCCTGGGACCTCTATTATCATGTGTTCCGACGAATCTCAAAGGCTAGCGCCAAGCCTACCACCACCCCTGCCCCTAGACCTCCAACACCCGCCCCAACAATCGCCAGCCAGCCTCTGTCTCTGAGGCCCGAGGCTTGTAGACCAGCTGCTGGCGGAGCCGTACACACCAGAGGACTGGATTTCGCCTGCGACATCTACATCTGGGCCCCTCTGGCCGGCACATGTGGCGTGCTGCTGCTGAGCCTCGTGATCACCATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCC TGCCCCCAAGGGGC  47SS-scFvCD19-DmrA- METDTLLLWVLLLWVPGSTGDYKDEGSDIQMTQTTSSLSASLGDfuP2A-2xDmrB-DmrC- RVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSTM-41BB-CD3z GSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGS proteinTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSL PDYGVSWIRQPPRKGLEWLGVIWGSE 48 SS-scFvCD19-DmrA- ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGfuP2A-2xDmrB-DmrC- TTCCAGGTTCCACTGGTGACTACAAGGACGAGGGATCCGATATTM-41BB-CD3z DNA CCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCACCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCTCAGGAGGAGTGCAGGTTGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCGAAGCGCGGACAGACATGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTCGATTCATCGCGGGACAGAAACAAGCCCTTTAAGTTTATGCTGGGCAAGCAGGAGGTCATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTCGGCCAGAGAGCCAAACTGACTATATCACCTGACTACGCCTATGGGGCCACTGGGCACCCTGGCATAATTCCGCCACACGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCGGCCGCGCTCGTTACAAGCGAAGTGTCTCAGGATCTGGCGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCTTCAAGATCCGGCGGTGTCCAAGTCGAAACTATATCGCCTGGCGATGGCAGAACGTTTCCCAAACGTGGCCAGACCTGTGTCGTACACTATACCGGCATGCTAGAGGATGGGAAAAAGGTTGATTCCAGTCGCGATCGGAACAAACCGTTTAAATTCATGTTGGGGAAGCAAGAGGTTATCAGGGGATGGGAAGAGGGTGTCGCGCAAATGTCGGTTGGGCAACGTGCGAAACTCACAATTTCCCCGGATTACGCATACGGAGCTACCGGACACCCTGGGATTATCCCACCGCATGCGACGCTAGTGTTTGACGTAGAGTTCTTGAAGCTCGAATCAGGTACAAGCGGCACTTCTGGCGTACAGGTTGAGACAATTAGTCCCGGAGACGGACGTACATTCCCAAAGAGAGGGCAAACTTGCGTAGTCCATTACACTGGAATGTTGGAAGACGGCAAGAAAGTGGACAGTTCAAGAGACCGCAATAAGCCTTTCAAGTTTATGCTCGGAAAACAGGAAGTCATACGCGGTTGGGAGGAAGGCGTGGCTCAGATGAGCGTCGGACAGAGGGCAAAGTTGACCATCAGTCCCGACTATGCGTATGGCGCGACAGGCCATCCCGGAATCATACCTCCCCACGCAACCTTGGTATTCGATGTCGAACTGCTCAAATTAGAGGGTAGTAGATCCATCCTCTGGCATGAGATGTGGCATGAAGGCCTGGAAGAGGCATCTCGTTTGTACTTTGGGGAAAGGAACGTGAAAGGCATGTTTGAGGTGCTGGAGCCCTTGCATGCTATGATGGAACGGGGCCCCCAGACTCTGAAGGAAACATCCTTTAATCAGGCCTATGGTCGAGATTTAATGGAGGCCCAAGAGTGGTGCAGGAAGTACATGAAATCAGGGAATGTCAAGGACCTCCTCCAAGCCTGGGACCTCTATTATCATGTGTTCCGACGAATCTCAAAGGCTAGCGCCAAGCCTACCACCACCCCTGCCCCTAGACCTCCAACACCCGCCCCAACAATCGCCAGCCAGCCTCTGTCTCTGAGGCCCGAGGCTTGTAGACCAGCTGCTGGCGGAGCCGTACACACCAGAGGACTGGATTTCGCCTGCGACATCTACATCTGGGCCCCTCTGGCCGGCACATGTGGCGTGCTGCTGCTGAGCCTCGTGATCACCATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCCTGC CCCCAAGGGGC  50SS-CD19scFv-DmrA- MPLGLLWLGLALLGALHAQAGSDIQMTQTTSSLSASLGDRVTISCCD4TM protein RASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGV SWIRQPPRKGLEWLGVIWGSETTYYN 51 SS-CD19scFv-DmrA- ATGCCCCTGGGCCTGCTGTGGCTGGGCCTGGCCCTGCTGGGCGCD4TM DNA CCCTGCACGCCCAGGCCGGATCCGATATCCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCACCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCGGAGGTGGGAGCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCGGCCGCATGGCCCTGATTGTGCTGGGGGGCGTCGCCGGCCTCCTGCTT TTCATTGGGCTAGGCATCTTCTTC  53SS-CD19scFv-DmrA- MPLGLLWLGLALLGALHAQAGSDIQMTQTTSSLSASLGDRVTISCCD8hingeTM protein RASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGV SWIRQPPRKGLEWLGVIWGSETTYYN 54 SS-CD19scFv-DmrA- ATGCCCCTGGGCCTGCTGTGGCTGGGCCTGGCCCTGCTGGGCGCD8hingeTM DNA CCCTGCACGCCCAGGCCGGATCCGATATCCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCACCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCGGAGGTGGGAGCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCGGCCGCGCCAAGCCTACCACCACCCCTGCCCCTAGACCTCCAACACCCGCCCCAACAATCGCCAGCCAGCCTCTGTCTCTGAGGCCCGAGGCTTGTAGACCAGCTGCTGGCGGAGCCGTGCACACCAGAGGACTGGATTTCGCCTGCGACATCTACATCTGGGCCCCTCTGGCCGGCACATGTGGCGTGCTGCTGCTGAGCCTCGTGATCACC  56 SS-CD19scFv-DmrA-MPLGLLWLGLALLGALHAQAGSDIQMTQTTSSLSASLGDRVTISC Spacer-CD4TMRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSG proteinTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGV SWIRQPPRKGLEWLGVIWGSETTYYN 57 SS-CD19scFv-DmrA- ATGCCCCTGGGCCTGCTGTGGCTGGGCCTGGCCCTGCTGGGCGSpacer-CD4TM DNA CCCTGCACGCCCAGGCCGGATCCGATATCCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCACCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCGGAGGTGGGAGCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCGGCCGCGAGAGCAAGTACGGACCGCCCTGCCCACCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCACCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTGAGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGCAAGGCCAAGGGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCACCCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATGGCCCTGATTGTGCTGGGGGGCGTCGCCGGCCTCCTGCTTTTCATTGGGCTAGGCATCTTCTTC  59 SS-CD19scFv-DmrA-MPLGLLWLGLALLGALHAQAGSDIQMTQTTSSLSASLGDRVTISC CD52 GPI anchorRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSG proteinTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGV SWIRQPPRKGLEWLGVIWGSETTYYN 60 SS-CD19scFv-DmrA- ATGCCCCTGGGCCTGCTGTGGCTGGGCCTGGCCCTGCTGGGCGCD52 GPI anchor DNA CCCTGCACGCCCAGGCCGGATCCGATATCCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCACCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCGGAGGTGGGAGCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCGGCCGCACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACC TCTTCTGCTTCAGT  64CD8ss-DmrC-CD8TM- MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGE41BB-CD3z-P2A- RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEIgKss-CD19scFv- WCRKYMKSGNVKDLLQAWDLYYHVFRRISKASAGTGSDIYIWADmrA-CD4TM protein PLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATNFSLLKQAGDVEENPGPSMETDTLLLWVLLLWVPGSTGSDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSASGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGRMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQ  65 CD8ss-DmrC-CD8TM-ATGGCTCTGCCTGTGACAGCTCTGCTGCTGCCTCTGGCCCTGCT 41BB-CD3z-P2A-GCTCCATGCCGCCAGACCCGGATCCATCCTCTGGCATGAGATG IgKss-CD19scFv-TGGCATGAAGGCCTGGAAGAGGCATCTCGTTTGTACTTTGGGG DmrA-CD4TM DNAAAAGGAACGTGAAAGGCATGTTTGAGGTGCTGGAGCCCTTGCATGCTATGATGGAACGGGGCCCCCAGACTCTGAAGGAAACATCCTTTAATCAGGCCTATGGTCGAGATTTAATGGAGGCCCAAGAGTGGTGCAGGAAGTACATGAAATCAGGGAATGTCAAGGACCTCCTCCAAGCCTGGGACCTCTATTATCATGTGTTCCGACGAATCTCAAAGGCTAGCGCCGGCACTGGTTCCGACATCTACATCTGGGCCCCTCTGGCCGGCACATGTGGCGTGCTGCTGCTGAGCCTCGTGATCACCATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCAAGGTCAGGATCTGGCGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCTTCAATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTTCCGATATCCAGATGACCCAGACCACCAGCAGCCTGAGCGCCAGCCTGGGCGATAGAGTGACCATCAGCTGCAGAGCCAGCCAGGACATCAGCAAGTACCTGAACTGGTATCAGCAGAAACCCGACGGCACCGTGAAGCTGCTGATCTACCACACCAGCAGACTGCACAGCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAGGAAGATATCGCTACCTACTTCTGTCAGCAAGGCAACACCCTGCCCTACACCTTCGGCGGAGGCACCAAGCTGGAAATCACCGGCAGCACAAGCGGCAGCGGCAAGCCTGGATCTGGCGAGGGAAGCACCAAGGGCGAAGTGAAACTGCAGGAAAGCGGCCCTGGACTGGTGGCCCCAAGCCAGTCTCTGAGCGTGACCTGTACCGTGTCCGGCGTGTCCCTGCCTGACTATGGCGTGTCCTGGATCAGACAGCCACCCAGAAAGGGCCTGGAATGGCTGGGAGTGATCTGGGGCAGCGAGACAACCTACTACAACAGCGCCCTGAAGTCCCGGCTGACCATCATCAAGGACAACTCCAAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCCATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGACTACTGGGGCCAGGGCACAAGCGTGACCGTGTCCAGCGCTAGCGGCGGAGGTGGGAGCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCGGCCGCATGGCCCTGATTGTGCTGGGGGGCGTCGCCGGCCTCCTGCTTTTCATTGGGCTAGGCATCTTCTTCTGTGTCAGGTGCCGGCACCGAAGG CGCCAATAA  67CD8ss-DmrC-CD8TM- MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGE41BB-CD3z-P2A- RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEIgKss-CD19scFv- WCRKYMKSGNVKDLLQAWDLYYHVFRRISKASAGTGSDIYIWADmrA-CD4TM codon PLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGoptimized protein CSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATNFSLLKQAGDVEENPGPSMETDTLLLWVLLLWVPGSTGDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSPRGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGRMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQ  68 CD8ss-DmrC-CD8TM-ATGGCCCTCCCTGTGACCGCCCTGCTGCTCCCCCTCGCCCTGTT 41BB-CD3z-P2A-GCTCCATGCTGCCCGACCTGGATCCATCCTTTGGCACGAGATG IgKss-CD19scFv-TGGCACGAGGGACTCGAAGAAGCGTCCCGGCTGTACTTCGGA DmrA-CD4TM codonGAGCGGAACGTGAAGGGGATGTTCGAAGTGCTGGAACCCCTG optimized DNACACGCCATGATGGAGCGGGGTCCTCAGACCCTTAAAGAAACAAGCTTCAACCAGGCGTACGGGCGCGACCTGATGGAAGCCCAGGAGTGGTGCCGCAAGTACATGAAGTCCGGAAACGTGAAGGATCTGCTGCAAGCCTGGGATCTGTACTACCACGTGTTCAGAAGGATCTCAAAGGCTAGCGCCGGCACTGGTTCGGATATCTACATTTGGGCACCGCTCGCCGGCACTTGTGGAGTGCTGTTGCTGTCCCTCGTGATCACCATGCATAAGAGGGGACGGAAGAAGCTGCTGTACATTTTCAAGCAGCCATTCATGCGGCCTGTGCAAACCACCCAGGAGGAGGACGGGTGCAGCTGCCGGTTCCCTGAGGAAGAGGAGGGCGGATGCGAACTGCGCGTGAAGTTCAGCCGGAGCGCAGATGCTCCCGCATACCAACAGGGACAGAACCAGCTGTATAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTCGACAAGCGGCGGGGACGCGACCCAGAAATGGGAGGAAAGCCCCGCCGGAAGAACCCGCAGGAAGGCCTGTACAACGAGTTGCAGAAAGACAAGATGGCTGAAGCTTACTCGGAGATTGGCATGAAGGGGGAGAGAAGAAGAGGGAAGGGCCACGACGGCCTTTACCAAGGACTGAGCACTGCCACCAAGGACACCTACGATGCGCTGCACATGCAGGCCCTGCCCCCGCGGTCCGGTTCGGGCGCGACTAACTTCAGCCTGCTGAAGCAGGCCGGAGATGTGGAGGAAAACCCTGGACCGTCCATGGAGACTGATACCCTGCTTCTGTGGGTCCTGCTCCTCTGGGTGCCGGGCTCCACCGGTGACATCCAGATGACCCAGACCACCTCATCCCTGAGCGCCTCTCTGGGTGATCGCGTGACTATCTCCTGCCGGGCGTCGCAGGATATCTCCAAGTACCTGAACTGGTACCAGCAAAAACCGGACGGGACCGTGAAACTGCTGATCTACCATACTTCCCGCCTTCATTCCGGAGTGCCCTCCCGGTTTTCCGGCTCGGGTTCAGGGACTGATTATTCGCTGACCATTTCCAACCTGGAGCAGGAGGACATTGCGACCTACTTCTGCCAACAAGGAAACACCCTGCCCTACACTTTCGGTGGTGGAACCAAGCTCGAGATCACCGGATCAACCTCGGGCAGCGGGAAGCCGGGCAGCGGAGAGGGATCGACGAAAGGAGAAGTCAAGCTGCAGGAATCCGGCCCGGGACTGGTGGCCCCGAGCCAGTCGCTCTCCGTCACTTGCACCGTGTCGGGAGTGTCCTTGCCCGACTACGGAGTGTCATGGATTCGGCAGCCACCTCGCAAGGGCCTGGAATGGCTCGGCGTGATTTGGGGCTCAGAAACCACATACTACAACAGCGCCCTGAAGTCTCGGCTCACCATCATCAAGGACAATTCCAAGTCCCAAGTGTTCCTGAAGATGAATAGCTTGCAGACTGACGACACCGCGATCTACTACTGTGCCAAGCACTACTACTACGGCGGTTCCTACGCCATGGACTACTGGGGACAAGGAACTTCCGTGACTGTCTCCTCCCCTAGGGGGGGTGGTGGTTCGGGGGTCCAGGTGGAAACCATTTCCCCCGGCGACGGGCGCACCTTCCCGAAGCGCGGACAGACCTGTGTGGTGCACTATACCGGAATGCTCGAAGATGGAAAGAAGTTTGACAGCTCCAGGGACCGCAACAAGCCTTTCAAGTTTATGCTTGGAAAGCAGGAAGTCATCCGGGGCTGGGAAGAGGGAGTCGCCCAGATGAGCGTCGGCCAGCGGGCCAAGCTGACGATCTCCCCTGACTATGCCTACGGCGCTACCGGCCATCCCGGAATCATTCCGCCGCACGCAACCCTCGTGTTCGACGTGGAATTGCTCAAGCTGGAAGGCGGCCGCATGGCGCTGATAGTGCTCGGCGGAGTGGCCGGACTGCTGCTGTTCATCGGCCTGGGCATCTTCTTCTGCGTGAGATGCCGCCATAGAAGGCGGCA ATGA  70 SS-DmrC-CD8TM-MRPTWAWWLFLVLLLALWAPARGGSILWHEMWHEGLEEASRL 41BB-CD3z-P2A-SS-YFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLME CD123scFv-DmrA-AQEWCRKYMKSGNVKDLLQAWDLYYHVFRRISKASAGTGSDIY CD4TM proteinIWAPLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRGGRSGSGATNFSLLKQAGDVEENPGPSLWWRLWWLLLLLLLLWPMVWAPRADYKDIVMTQSHKFMSTSVGDRVNITCKASQNVDSAVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGRGSGTDFTLTISSVQAEDLAVYYCQQYYSTPWTFGGGTKLEIKRGGGGSGGGGSGGGGSGGGGSEVKLVESGGGLVQPGGSLSLSCAASGFTFTDYYMSWVRQPPGKALEWLALIRSKADGYTTEYSASVKGRFTLSRDDSQSILYLQMNALRPEDSATYYCARDAAYYSYYSPEGAMDYWGQGTSVTVSSSASGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGRMALIVLGGVAG LLLFIGLGIFFCVRCRHRRRQ  71SS-DmrC-CD8TM- ATGCGCCCCACCTGGGCCTGGTGGCTGTTCCTGGTGCTGCTGC41BB-CD3z-P2A-SS- TGGCCCTGTGGGCACCCGCTCGCGGCGGATCCATCCTCTGGCACD123scFv-DmrA- TGAGATGTGGCATGAAGGCCTGGAAGAGGCATCTCGTTTGTAC CD4TM DNATTTGGGGAAAGGAACGTGAAAGGCATGTTTGAGGTGCTGGAGCCCTTGCATGCTATGATGGAACGGGGCCCCCAGACTCTGAAGGAAACATCCTTTAATCAGGCCTATGGTCGAGATTTAATGGAGGCCCAAGAGTGGTGCAGGAAGTACATGAAATCAGGGAATGTCAAGGACCTCCTCCAAGCCTGGGACCTCTATTATCATGTGTTCCGACGAATCTCAAAGGCTAGCGCCGGCACTGGTTCCGACATCTACATCTGGGCCCCTCTGGCCGGCACATGTGGCGTGCTGCTGCTGAGCCTCGTGATCACCATGCATAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCCTGCCCCCAAGGGGCGGCCGCTCAGGATCTGGCGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGATGTTGAAGAAAACCCCGGGCCTTCACTGTGGTGGCGCCTGTGGTGGCTGCTCCTGCTTCTGTTGCTCCTGTGGCCCATGGTGTGGGCCCCTAGGGCGGACTACAAAGATATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAACATCACCTGCAAGGCCAGTCAGAATGTGGATAGTGCTGTAGCCTGGTATCAACAGAAACCAGGGCAATCTCCTAAAGCACTGATTTACTCGGCATCCTACCGGTACAGTGGAGTCCCTGATCGCTTCACAGGCAGGGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGCAATATTATAGCACTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAACGTGGTGGTGGTGGTTCTGGTGGTGGTGGTTCTGGCGGCGGCGGCTCCGGTGGTGGTGGATCCGAGGTGAAGCTGGTGGAGTCTGGAGGAGGCTTGGTACAGCCTGGGGGTTCTCTGAGTCTCTCCTGTGCAGCTTCTGGATTCACCTTCACTGATTACTACATGAGCTGGGTCCGCCAGCCTCCAGGGAAGGCACTTGAGTGGTTGGCTTTGATTAGAAGCAAAGCTGATGGTTACACAACAGAATACAGTGCATCTGTGAAGGGTCGGTTCACCCTCTCCAGAGATGATTCCCAAAGCATCCTCTATCTTCAAATGAATGCCCTGAGACCTGAAGACAGTGCCACTTATTACTGTGCAAGAGATGCGGCCTACTATAGTTACTATAGTCCCGAGGGGGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCGAGCGCTAGCGGCGGAGGTGGGAGCGGAGTGCAGGTGGAAACCATCTCCCCAGGAGACGGGCGCACCTTCCCCAAGCGCGGCCAGACCTGCGTGGTGCACTACACCGGGATGCTTGAAGATGGAAAGAAATTTGATTCCTCCCGGGACAGAAACAAGCCCTTTAAGTTTATGCTAGGCAAGCAGGAGGTGATCCGAGGCTGGGAAGAAGGGGTTGCCCAGATGAGTGTGGGTCAGAGAGCCAAACTGACTATATCTCCAGATTATGCCTATGGTGCCACTGGGCACCCAGGCATCATCCCACCACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACTGGAAGGCGGCCGCATGGCCCTGATTGTGCTGGGGGGCGTCGCCGGCCTCCTGCTTTTCATTGGGCTAGGCATCTTCTTCTGTGTCA GGTGCCGGCACCGAAGGCGCCAATAA 78 CD8ss.DmrC.CD8TM. MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGE41BB.Zeta.P2A.IgKss. RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQECD19scFv.DmrA.CD1 WCRKYMKSGNVKDLLQAWDLYYHVFRRISKASAGTGSDIYIWA54TM codon optimized PLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGprotein CSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATNFSLLKQAGDVEENPGPSMETDTLLLWVLLLWVPGSTGDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSPRGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGRMKIFMYLLTVFLITQMIGSALFAVYLHRR  80 CD8ss.DmrC.CD8hinge-MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGE TM.41BB.ZetaRNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQE proteinWCRKYMKSGNVKDLLQAWDLYYHVFRRISKASAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR  82 hScnSS.CD19scFv.MPLGLLWLGLALLGALHAQAGSDIQMTQTTSSLSASLGDRVTISC DmrA proteinRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSASGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAY GATGHPGIIPPHATLVFDVELLKLEG 84 hScnSS.CD20scFv. MPLGLLWLGLALLGALHAQAGSEVQLQQSGAELVKPGASVKMSDmrA protein CKASGYTFTSYNMHWVKQTPGQGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSADYYCARSNYYGSSYWFFDVWGAGTTVTVSSGSTSGGGSGGGSGGGGSSDIVLTQSPAILSASPGEKVTMTCRASSSVNYMDWYQKKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGGGTKLEIKASGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEG  86 CD8ss.FRB.CD8TM.MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGE 41BB.Zeta.P2A.IgKss.RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQE CD19scFv.DmrA.CD4TMWCRKYMKSGNVKDLTQAWDLYYHVFRRISKASAGTGSDIYIWA codon optimizedPLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDG proteinCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATNFSLLKQAGDVEENPGPSMETDTLLLWVLLLWVPGSTGDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSPRGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGRMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQ 88 CD8ss.FRB.CD8TM.MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGE 41BB.Zeta.P2A.IgKss.RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQE CD19scFv.DmrA.CD154TMWCRKYMKSGNVKDLTQAWDLYYHVFRRISKASAGTGSDIYIWA codon optimizedPLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDG proteinCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATNFSLLKQAGDVEENPGPSMETDTLLLWVLLLWVPGSTGDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSPRGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGRMKIFMYLLTVFLITQMIGSALFAVYLHRR   90 CD8ss.FRB.CD8hinge-MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGE TM.41BB.Zeta.P2A.RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQE IgKss.CD19scFv.DmrA.WCRKYMKSGNVKDLTQAWDLYYHVFRRISKASAKPTTTPAPRPP CD154TM codonTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT optimized proteinCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATNFSLLKQAGDVEENPGPSMETDTLLLWVLLLWVPGSTGDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSPRGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGRMKIF MYLLTVFLITQMIGSALFAVYLHRR 92 CD8ss.FRB.AMN. MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGE41BB.Zeta.P2A.IgKss. RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQECD19scFv.DmrA.CD154TM WCRKYMKSGNVKDLTQAWDLYYHVFRRISKASVWGSSAAGLAcodon optimized GGVAAAVLLALLVLLVAPPLLMHKRGRKKLLYIFKQPFMRPVQT proteinTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATNFSLLKQAGDVEENPGPSMETDTLLLWVLLLWVPGSTGDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSPRGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGRMKIFMYLLTVFLITQMIGSALFAVYLHRR  96 CD8ss.DmrC.CD8TM.MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGE 41BB.Zeta.P2A.IgKss.RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQE CD19scFv.DmrA.CD71TMWCRKYMKSGNVKDLLQAWDLYYHVFRRISKASAGTGSDIYIWA codon optimizedPLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDG proteinCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATNFSLLKQAGDVEENPGPSMETDTLLLWVLLLWVPGSTGDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSPRGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGRRCSGSICYGTIAVIVFFLIGFMIGYLGY  98 CD8ss.DmrC.CD8TM.MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGE 41BB.Zeta.P2A.CD71TM.RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQE DmrA.CD19scFvWCRKYMKSGNVKDLLQAWDLYYHVFRRISKASAGTGSDIYIWA codon optimizedPLAGTCGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDG proteinCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATNFSLLKQAGDVEENPGPSRCSGSICYGTIAVIVFFLIGFMIGYLGYTGGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSPRDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQG TSVTVSS 100CD8ss.FRB.CD8Hinge. MALPVTALLLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGECD8TM.41BB.Zeta. RNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEP2A.IgKss.CD19scFv. WCRKYMKSGNVKDLTQAWDLYYHVFRRISKASAKPTTTPAPRPPDmrA codon optimized TPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTprotein CGVLLLSLVITMHKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRSGSGATNFSLLKQAGDVEENPGPSMETDTLLLWVLLLWVPGSTGDIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSPRGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE

EXAMPLES Example 1 Construction of DARIC Building and SignalingComponents

The DARIC binding and signaling components were each separately clonedinto a plasmid vector containing a T7 promoter, a hScn or hCD8 secretionsignal, respectively, and a downstream linearization site. Linearizedplasmids were then used as templates for in vitro transcriptionreactions, followed by 3′-polyadenylation and 5′-capping steps to createmature in vitro transcribed mRNA (IVT-mRNA) to be electroporated intoprimary human T cells. Human T cells were isolated from PBMCs bynegative selection using paramagnetic beads and expanded withanti-CD³/anti-CD28 beads for 48 hours prior to electroporation. Controlelectroporations using IVT-mRNA encoding fluorescent proteins wereperformed in parallel to confirm transfection efficiency, or 2Aprotein-linked fluorescent proteins were incorporated directly into theDARIC component mRNA species.

Exemplary IVT-mRNA encoding binding components (scFv specific for CD19and multimerization domain FKBP12 (“DmrA”), FKBP12 F36V (“DmrB”), FRB(2021-2113) T2098L (“DmrC”)) are provided in SEQ ID NOs.:2, 5, and 8(scFv specific for CD19 and multimerization domain FKBP12, FKBP12 F36V,or FRB (2021-2113) T2098L, respectively). Exemplary IVT-mRNA encodingsignaling components are provided in SEQ ID NOs.:16, 20, and 24(multimerization domain FRB (2021-2113) T2098L, FKBP12 F36V, or FKBP12,respectively, transmembrane domain, 4-1BB, and CD3ζ).

Multimerization is promoted with a bridging factor, such as rapamycin orrapalogs thereof, or gibberellin or derivatives thereof. Rapamycin andits derivatives (e.g., AP21967, also known asC-16-(S)-7-methylindolerapamycin, ICd₅₀=10nM, a chemically modifiednon-immunosuppressive rapamycin analogue) can induce heterodimerizationof FKBP12 and FRB-containing fusion proteins. AP1903 or AP20187 arehomo-bivalent drugs based on the FKBP12-interacting component ofrapamycin, which can be used in homodimerization scenarios describedherein.

Example 2 Cytotoxicity of T Cells Encoding DARIC Components

Recombinant T cells expressing the two DARIC components were incubatedwith K562 target cells (a human myeloid leukemia cell line), which weremodified to express either CD19 or CD20 antigen, to examine target celllysis. Briefly, T cells were co-incubated with a 50:50 mixture ofK562-CD19 and K562-CD20 target cell lines, at 3:1 or 10:1 T cell totarget cell ratios. In experimental samples, 500 nM final concentrationof the hetero-bivalent rapalog AP21967 was added. The relativepercentage of each of the target cell lines was monitored by flowcytometry staining for the CD19 and CD20 antigens to evaluate cell lysis(see FIG. 3).

Four samples of primary human T cells were prepared by electroporationwith IVT-mRNA encoding (i) an extensively validated single-chainchimeric antigen receptor (CAR) (CD19-CAR, SEQ ID NO.:14, positivecontrol); (ii) the DARIC signaling component only (DSC, SEQ ID NO.:16,negative control); iii) the DARIC binding component only (DBC-CD19, SEQID NO.:2, negative control); and (iv) both DARIC binding and signalingcomponents (DSC, SEQ ID NO.:16 plus DBC-CD19, SEQ ID NO.:2). Therelative percentages of each of the target cell lines were monitored byflow cytometry staining for the CD19 and CD20 antigens (FIG. 3A).

The percent specific cytotoxicity was calculated for each condition asthe percentage change relative the input K562-CD19:K562-CD20 ratio. Tcells expressing the validated CD19-CAR (SEQ ID NO.:14) showedsubstantial cytotoxicity and skewing of the ratio of CD19 versus CD20cells in the live cell gate, particularly at a 10:1 T cell to targetcell ratio. The T cells expressing the DARIC binding component alone,DARIC signaling component alone, or both DARIC components but withoutthe addition of the hetero-bivalent rapalog AP21967, showed nosignificant cytotoxicity. In the presence of AP21967, a substantialspecific cytotoxicity and loss of the K562-CD19 target cells wasobserved upon co-incubation with T cells expressing both DARICcomponents (FIG. 3B).

These results indicate that the DARIC mechanism can reconstituteantigen-specific target cell lysis. Furthermore, the DARIC designenables pharmacological control of antigen-specific T cell cytotoxicity.

Example 3 Cytokine Secretion Profile of T Cells Encoding DARICComponents

Recombinant T cells expressing the two DARIC components were incubatedwith K562 target cells (a human myeloid leukemia cell line), which weremodified to express either CD19 or CD20 antigen, to examine cytokineexpression. Briefly, IVT-mRNA transfected T cells were co-incubated witheither the K562-CD19 or K562-CD20 cell lines using T cell to targetratios of 1:1, with or without the addition of 500nM AP21967.Supernatants were isolated for analysis of cytokine production (see FIG.4).

Two samples of primary human T cells were isolated, expanded, and thenprepared by electroporation with IVT-mRNA encoding either (i) thevalidated single-chain CAR (CD19-CAR, SEQ ID NO.:13, positive control);or (ii) both DARIC binding and signaling components (DSC, SEQ ID NO.:16plus DBC-CD19, SEQ ID NO.:2). After extensively washing the expanded andelectroporated T cells to remove residual cytokines from the growthmedia, the T cells were co-incubated with K562 cell lines expressingeither the human CD19 antigen (left panels) or the CD20 antigen (rightpanels) at 1:1 T cell to target cell ratios and in the presence orabsence of the AP21967 rapalog. The supernatants were then collected andassayed for analyte concentrations using cytokine captureantibody-labeled beads (Becton Dickenson Cytokine Bead Array, humanTh1/Th2 kit). Comparison with recombinant protein standards enabledcalculation of absolute concentrations of each of the six cytokinesencompassed by the bead array.

Consistent with previous cytotoxicity findings, T cells expressing thepositive control CD19-CAR produced substantial amounts ofinterferon-gamma (IFNγ) and interleukin-2 (IL-2) when co-incubated withCD19 expressing K562 target cells. T cells expressing the DARICcomponents in the absence of bridging factor AP21967 showed nosignificant cytokine production, but in the presence of AP21967 producedIFNy and IL-2 at levels equivalent, or superior, to the single chainCD19-CAR positive control.

Example 4 Lentiviral Delivery of DARIC Components

Primary human T cells were isolated, activated, and then transduced withlentiviral vectors encoding DARIC binding and signaling components (SEQID NOS.:44 and 47). The transduced T cells were then co-incubated withabout a 50:50 mixture of the K562 target cells expressing either CD19(K562-CD19) or CD20 (K562-CD20) to evaluate antigen-specificcytotoxicity. The overall ratio of T cells to K562 cells was 5:1 in allsamples. In control samples, no bridging factor was added, whereas inexperimental samples either rapamycin (10 nM) or AP21967 (100 nM) wereapplied as the bridging factor for the secreted antigen bindingcomponent and the signaling component (see, e.g., FIG. 1B). The DARICantigen binding component includes a CD19 antigen binding scFv domainand a FKBP12 multimerization domain, which was linked to a mCherryfluorescent protein. Two independent multimerization domains havingdifferent specificities for bridging components were tested on the DARICsignaling component: FRB, which is responsive to rapamycin, and the FRB(2021-2113) T2098L variant, which is responsive to both rapamycin andAP21967, each linked to the blue fluorescent protein (BFP).

Flow cytometric analysis of the lentivirus-transduced T cellsdemonstrated expression of both mCherry and BFP proteins simultaneously,indicating both DARIC components were being expressed within the samecells (see FIG. 5, first column for each treatment). Flow cytometricanalysis of the K562 cells demonstrated rapamycin and AP21967-dependentelimination of the CD19 expressing K562 cells in the sample expressingvariant FRB (2021-2113) T2098L multimerization domain, whereas noaddition of a bridging factor had no effect on cell survival (see FIG.5, top row of second column for each treatment). But, only rapamycin wasable to activate the elimination of the K562-CD19 cells by T cellsexpressing the FRB dimerization domain, while AP21967 or no addition ofa bridging factor had no effect on cell survival (see FIG. 5, second rowof second column for each treatment). These data show the specificity ofcytotoxic activity that can be achieved with the DARIC multipartitecomponent system.

In addition, two distinct T cell populations were mixed, wherein onepopulation was expressing a DARIC antigen binding component and theother population was expressing a DARIC signaling component. This mixedcell population, when co-cultured with the CD19 and CD20 expressing K562cells, showed a rapamycin-dependent cytotoxicity response againstK562-CD19 cells, while the absence of a bridging factor had no effect ontarget cell survival (see FIG. 5, bottom row). These data indicate thata DARIC antigen binding component expressed by one T cell population canact in trans with a different population of T cells that express a DARICsignaling component and attack the target cells.

The flexibility of the DARIC system was validated by swapping themultimerization domains such that the DARIC binding component targetingCD19 comprised the FRB based DmrC domain and the DARIC signalingcomponent comprised the FKBP12 based DmrA domain (SEQ ID NOs.:12, 31).Primary human T cells were made to express the ‘swapped’ DARICcomponents and then co-incubated with 50:50 mixtures of the K562-CD19and C562-CD20 target cells either in the absence or presence of theindicated concentrations of rapamycin (FIG. 10). Antigen specificcytotoxicity was observed in the experimental samples containing thebridging factor, but absent from the control sample lacking rapamycin.These data demonstrate that the architecture of the DARIC system isflexible and amenable to a variety of multimerization domainorientations.

Example 5 Titration of Bridging Factors to Sub-Therapeutic Levels

A broad range of bridging factor (rapamycin and everolimus)concentrations were tested to determine whether a DARIC system canfunction at clinically relevant concentrations. As in the Example 4,primary human T cells were isolated, activated, and then transduced withlentiviral vectors expressing a DARIC binding component (SEQ ID NOS.:1,4, 7) and a DARIC signaling component (SEQ ID NOS.:15, 19, 23). TheDARIC expressing T cells were then co-incubated with 50:50 mixtures ofthe K562-CD19 and K562-CD20 target cells to evaluate antigen-specificcytotoxicity. The overall ratio of T cells to K562 cells was 5:1 in allsamples.

The indicated concentrations of rapamycin and everolimus were added tothe co-culture samples and then the cytotoxicity responses wereevaluated by flow cytometry (FIG. 6). Cytotoxicity responses weremaintained to sub-nanomolar drug concentrations, well below the steadystate concentrations of rapamycin and everolimus that are presentlyachieved when these drugs are administered to patients in the clinic.

Example 6 Use of a Tethered DARIC Binding Component

A series of additional DARIC molecules, in which the antigen bindingcomponent was maintained on the T cell surface rather than released intothe extracellular space, were tested (see, e.g., FIG. 1I). Severalprotein regions and transmembrane domains were used to anchor thebinding domain to the T cell surface (SEQ ID NOS.:50, 53, 56, 59), eachaltering the spacing or steric parameters governing multimerization ofthe DARIC binding and signaling components. As in the previous examples,antigen-specific cytotoxicity responses using lentivirus-transduced Tcells and 50:50 mixtures of the K562-CD19 and K562-CD20 target cellswere used to evaluate the tethered DARIC binding component. The overallratio of T cells to K562 cells was 5:1 in all samples, with theindicated concentrations of a bridging factor used in experimentalsamples.

Each design had the property of bridging factor-responsive,antigen-specific cytotoxicity against the K562-CD19 cells. The tetheredDARIC binding component containing the CD8 hinge/CD8 transmembranedomain (SEQ ID NO.:53) showed a measurable level of activity in theabsence of a bridging factor. The tethered DARIC binding componentcomprising the IgG4 CH2CH3 spacer with CD4 transmembrane domain (SEQ IDNO.:56) provided the strongest cytotoxic response upon addition of therapamycin (bridging factor), while the tethered DARIC binding componentcomprising only the CD4 transmembrane domain (SEQ ID NO.:50) weremoderately active (FIG. 7). A DARIC binding components comprising a GPIsignal sequence from the CD52 protein (see schematic in FIG. 1K) werealso tested. The GPI anchored DARIC produced an antigen specificcytotoxicity response only in the presence of an appropriate bridgingfactor (FIG. 8). These data demonstrate that a DARIC binding componentcan be either released or tethered to the cell surface and stillfunction with a DARIC signaling component.

Additional lentiviral constructs comprising tethered DARIC bindingcomponents were generated and similarly tested in human T cells,including a modified CD4 transmembrane domain with improved activityover other transmembrane tethered DARIC binding components (SEQ IDNOs.:64-69). Additionally, the DARIC signaling and binding componentswere integrated into a single open reading frame comprising a 2A peptidesituated between the two components (such as that used in FIG. 11), thusvalidating a simplified DARIC delivery scheme using a single lentiviralvector (SEQ ID NOs.:66, 69, 72).

For any of the DARIC componentry designs, similar results are expectedusing a variety of lentiviral vector designs, such as those comprisingbi-directional promoters (SEQ ID NO.:73) for example, or usingalternative transgene delivery vectors (e.g., adenovirus or AAV) andschemes such as including the targeted integration of transgenes viahomologous recombination, a process that can be stimulated to highefficiency using gene-specific nucleases.

Example 7 DARIC Targeting of Additional Model Antigens

The DARIC system was extended to an additional model antigen to show thebroad applicability of artificial cells expressing drug regulatedmultipartite receptors contemplated herein. K562 target cell lines weregenerated to express the CD123 antigen by sub-cloning this antigen intoa lentiviral vector comprising a puromycin selection cassette (SEQ IDNO.:74), lentiviral particles were produced, and K562 cells wereinfected and selected with puromycin. Primary human T cells wereisolated, activated, and then transduced with lentiviral vectorsencoding a CD123 targeting DARIC binding component along with the DARICsignaling component (SEQ ID NOs.:70-72). Antigen-specific cytotoxicityresponses were evaluated using lentivirus-transduced T cells co-culturedwith 50:50 mixtures of the K562-CD19 and K562-CD123 target cells, usinga traditional CD123 targeting chimeric antigen receptor (CAR) as apositive control. The overall ratio of T cells to K562 cells was 5:1 inall samples, with the indicated concentrations of a bridging factor usedin experimental samples. Cytotoxicity was observed in the positivecontrol sample and in the CD123 DARIC sample containing rapamycin,. Theresults demonstrated that bridging factor dependent cytotoxic activitycould be achieved with the DARIC system targeting diverse antigens (FIG.9).

Example 8 Deactivation of DARIC Using an Anti-Bridging Factor

Deactivation of the DARIC system by the addition of a pharmacologicalagent that competes for binding to one of the multimerization domainswas tested. Primary human T cells expressing either a traditional CD19targeting CAR or primary human T cells expressing the CD19 targetingDARIC components (SEQ ID NO.:66) were co-incubated with 50:50 mixturesof K562-CD19 and K562-CD20 cells. For the T cells expressing the CD19targeting CAR (SEQ ID NO.:14), cytotoxicity was observed both in thepresence or absence of rapamycin. In contrast, CD19 targeting DARIC Tcells, showed efficient antigen-specific cytotoxicity in the presence ofsub-nanomolar levels of rapamycin, but showed no cytotoxicity in theabsence of the bridging factor (FIG. 11). However, when FK506 was added,a marked reduction in antigen specific cytotoxicity was observed for theDARIC T cells while a minimal reduction was observed for the CAR Tcells, indicating that FK506 disrupted the coupling of the DARICcomponentry and deactivated the antigen-driven cytotoxicity response.

This example shows that a competitive inhibitor of a bridging factorsubstantially inhibited DARIC antigen receptors and therefore issuitable for clinical use to limit pathology that can arise as a resultof excessive proliferation or activation of administered cells. Withoutwishing to be bound to any particular theory, this strategy may beparticularly effective if the inhibitor has additional immunosuppressivemechanisms of action involving native proteins that contribute incellular responses, as is true of FK506 inhibiting intracellularcyclophilins that promote T cell proliferative responses.

Example 9 DARIC System Leveraging an Endogenous Signaling Receptor

A DARIC system was designed to provide two secreted DARIC components(SEQ ID NO.:75). The DARIC binding component comprises a binding domainthat binds CD19 and the DARIC signaling component comprises a bindingdomain that binds CD3 and a multimerization domain. This system will betested using a modified co-culture cytotoxicity experiment. Supernatantsfrom T cells transduced with lentiviral particles encoding the twosecreted DARIC components will be transferred to a 50:50 mix ofK562-CD19 and K562-CD20 target cells also containing non-transduced Tcells. Cytotoxicity will be measured in the presence and absence ofbridging factor. Control samples comprising the supernatant that is keptin a decoupled state by not providing the bridging factor are notexpected to show any antigen specific cytotoxicity. However, samples inwhich the supernatant and bridging factor are added are expected toinitiate the antigen specific cytotoxicity response. This result willdemonstrate that artificial cells can be made to express a soluble DARICsystem that can systemically initiate cytotoxicity responses in a drugregulated fashion.

Example 10 Bicistronic DARIC Vectors

Primary human T cells were isolated, activated, and then transduced withlentiviral vectors encoding bicistronic DARIC vectors (SEQ ID NOS.: 73and 76) or polycistronic vectors that encode both anti-CD19 DARICbinding and DARIC signaling components. The transduced T cells were thenco-incubated with about a 50:50 mixture of the K562 target cellsexpressing CD19 (K562-CD19) or a human leukemic B cell line expressingCD19 (Nalm6-DSMZ no.: ACC 128).

Antigen specific cytotoxicity was observed in the presence of thebridging factor rapamycin (10 nM) in both bicistronic and polycistronicDARIC vectors as shown in FIG. 12.

Example 11 Secreted DARIC Signaling Components Show Antigen SpecificCytotoxicity

Primary human T cells were isolated, activated, and then transduced withlentiviral vectors encoding DARIC signaling components (SEQ ID NOS.: 79and 80) and HEK293T cells were transduced with vectors encoding DARICbinding components (SEQ ID NOS.: 82 and 84). The transduced HEK293Tcells secreted the DARIC binding component into the culture medium (see,e.g., FIG. 13A).

The transduced T cells were then co-incubated with K562 target cellsexpressing either CD19 (K562-CD19) or CD20 (K562-CD20) in the presenceof a secreted DARIC binding component that targets either CD19 or CD20to evaluate antigen-specific cytotoxicity. In control samples,untransduced T cells were used.

In the presence of the bridging factor rapamycin (1 nM), culturescontaining a secreted anti-CD19 DARIC binding component and a DARICsignaling component show cytotoxicity at all T cell:K562-CD19 cellratios tested (8:1, 4:1, and 2:1) (see, e.g., FIG. 13B). In the presenceof the bridging factor rapamycin (1 nM), cultures containing a secretedanti-CD20 DARIC binding component and a DARIC signaling component showcytotoxicity at the only T cell:K562-CD20 cell ratio tested (10:1) (see,e.g., FIG. 13C). Little or no cytotoxicity was observed in theuntransduced T cell controls, which do not express DARIC signalingcomponents.

Example 12 Use of Tethered DARIC Binding Components with Improved BasalCytotoxicity Characteristics

Primary human T cells were isolated, activated, and then transduced withlentiviral vectors encoding (i) an anti-CD19 single-chain chimericantigen receptor (CAR) (CD19-CAR, SEQ ID NO.:14; (ii) a transmembraneDARIC that targets CD19 expressing cells and that has residual cytotoxicactivity independent of bridging factor (SEQ ID NO: 64); (iii) a solubleDARIC that targets CD19 expressing cells (SEQ ID NOs: 99-100); and (iv)a transmembrane DARIC that targets CD19 expressing cells and that lacksresidual cytotoxic activity in the absence of bridging factor (SEQ IDNO: 77).

Transduced T cells were co-incubated with K562-CD19 target cells or ahuman B cell line expressing CD19 at ratios of 8:1, 4:1, and 2:1.Antigen specific cytotoxicity was measured in the presence and absenceof the bridging factor rapamycin (1 nM). T cells that expressed thesoluble DARIC and T cells that expressed the CD154 transmembrane DARICshowed low to absent cytotoxicity in the absence of the bridging factorrapamycin compared to the CD19 CAR or a CD4 transmembrane DARIC, and Tcells that expressed any of the CAR or DARIC constructs delivered potentcytotoxic effects in the presence of rapamycin. FIGS. 14A and B.

Example 13 Second Generation DARIC Constructs Show Improved AntigenSpecific Cytotoxicity Profiles

Primary human T cells were isolated, activated, and then transduced withlentiviral vectors encoding second generation DARIC constructscomprising (A) CD19 DARIC binding components that contain a CD154transmembrane domain or (B) CD19 DARIC binding components comprisingthat contain a CD71 transmembrane domain.

Four groups of T cells were transduced with one or more vectors encodinga CD19 DARIC binding component that contains a CD154 transmembranedomain and: (i) a DARIC signaling component comprising a DmrCmultimerization domain and a CD8 transmembrane domain (SEQ ID NO: 77);(ii) a DARIC signaling component comprising an FRB multimerizationdomain and a CD8 transmembrane domain (SEQ ID NO: 87); a DARIC signalingcomponent comprising an FRB multimerization domain, a CD8 hinge domain,and a CD8 transmembrane domain (SEQ ID NO: 89); or a DARIC signalingcomponent comprising a FRB multimerization domain and an AMNtransmembrane domain (SEQ ID NO: 91). Transduced T cells wereco-incubated with CD19 expressing Daudi cells at ratios of 8:1, 4:1,2:1, 1:1, and 0.5:1. T cells that expressed CD154 transmembrane DARICsexhibited low to absent cytotoxicity in the absence of the bridgingfactor rapamycin compared to untransduced T cells and delivered potentcytotoxic effects in the presence of rapamycin. FIG. 15A.

Two groups of T cells transduced with one or more vectors encoding (i) afirst generation transmembrane DARIC that targets CD19 expressing cellsand that has residual cytotoxic activity independent of bridging factor(SEQ ID NO: 64); (ii) a CD19 DARIC binding component that contains aCD71 type I transmembrane domain and a DARIC signaling componentcomprising a DmrC multimerization domain and a CD8 transmembrane domain(SEQ ID NO: 95); or (iii) a CD19 DARIC binding component that contains aCD71 type II transmembrane domain and a DARIC signaling componentcomprising a DmrC multimerization domain and a CD8 transmembrane domain(SEQ ID NO: 97). Transduced T cells were co-incubated with CD19expressing Nalm6 cells at ratios of 8:1, 4:1, 2:1, 1:1, and 0.5:1. Tcells that expressed the CD71 transmembrane DARICs exhibited low toabsent cytotoxicity in the absence of the bridging factor rapamycincompared to untransduced T cells and delivered potent cytotoxic effectsin the presence of rapamycin. FIG. 15B.

The various embodiments described above can be combined to providefurther embodiments. All of the U.S. patents, U.S. patent applicationpublications, U.S. patent applications, foreign patents, foreign patentapplications and non-patent publications referred to in thisspecification and/or listed in the Application Data Sheet areincorporated herein by reference, in their entirety. Aspects of theembodiments can be modified, if necessary to employ concepts of thevarious patents, applications and publications to provide yet furtherembodiments.

These and other changes can be made to the embodiments in light of theabove-detailed description. In general, in the following claims, theterms used should not be construed to limit the claims to the specificembodiments disclosed in the specification and the claims, but should beconstrued to include all possible embodiments along with the full scopeof equivalents to which such claims are entitled. Accordingly, theclaims are not limited by the disclosure.

What is claimed is:
 1. A non-natural cell, comprising: (a) a firstnucleic acid molecule encoding a first fusion protein comprising a firstmultimerization domain, a hydrophobic domain, and an actuator domain,wherein the first multimerization domain localizes extracellularly whenthe first fusion protein is expressed; and (b) a second nucleic acidmolecule encoding a second fusion protein comprising a binding domainand a second multimerization domain, wherein the second fusion proteinlocalizes extracellularly when expressed; wherein a first bridgingfactor promotes the formation of a polypeptide complex on thenon-natural cell surface with the bridging factor associated with anddisposed between the multimerization domains of the first and secondfusion proteins.
 2. The non-natural cell according to claim 1, whereinthe first and second multimerization domains are the same or different.3. The non-natural cell according to claim 1 or claim 2, wherein themultimerization domains of the first and second fusion proteinsassociate with a bridging factor selected from rapamycin or a rapalogthereof, coumermycin or a derivative thereof, gibberellin or aderivative thereof, abscisic acid (ABA) or a derivative thereof,methotrexate or a derivative thereof, cyclosporin A or a derivativethereof, FKCsA or a derivative thereof, trimethoprim (Tmp)-syntheticligand for FKBP (SLF) or a derivative thereof, or any combinationthereof.
 4. The non-natural cell according to any one of the precedingclaims, wherein the first and second multimerization domains are a pairselected from FKBP and FRB, FKBP and calcineurin, FKBP and cyclophilin,FKBP and bacterial DHFR, calcineurin and cyclophilin, PYL1 and ABI1, orGIB1 and GAI, or variants thereof.
 5. The non-natural cell according toany one of the preceding claims, wherein the first multimerizationdomain comprises a first FKBP polypeptide or variant thereof, and thesecond multimerization domain comprises a first FRB polypeptide orvariant thereof
 6. The non-natural cell according to any one of thepreceding claims, wherein the first multimerization domain comprises afirst FRB polypeptide or variant thereof, and the second multimerizationdomain comprises a first FKBP polypeptide or variant thereof
 7. Thenon-natural cell according to claim 5 or 6, wherein the bridging factoris sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus,tacrolimus, temsirolimus, umirolimus, or zotarolimus.
 8. The non-naturalcell according to any one of the preceding claims, wherein the firstnucleic acid molecule encodes a first fusion protein further comprisinga third multimerization domain.
 9. The non-natural cell according toclaim 8, wherein the third multimerization domain of the first fusionprotein is a binding domain for a bridging factor selected fromrapamycin or a rapalog thereof, coumermycin or a derivative thereof,gibberellin or a derivative thereof, ABA or a derivative thereof,methotrexate or a derivative thereof, cyclosporin A or a derivativethereof, FKCsA or a derivative thereof, Tmp-SLF or a derivative thereof,or any combination thereof.
 10. The non-natural cell according to anyone of the preceding claims, wherein a second bridging factor promotesthe association of at least two first fusion proteins with the bridgingfactor associated with and disposed between the third multimerizationdomains of the first fusion proteins.
 11. The non-natural cell accordingto any one of the preceding claims, wherein the protein complex is ahomocomplex comprising at least two first fusion proteins.
 12. Thenon-natural cell according to any one of the preceding claims, whereinthe first fusion protein has at least one multimerization domain ofFKBP, DHFR or GyrB.
 13. The non-natural cell according to any one ofclaims 1-12, wherein the binding domain of the polypeptide complexspecifically binds to a target located on a target cell surface.
 14. Thenon-natural cell according to claim 13, wherein the protein complex is aheterocomplex comprising one or more first fusion proteins and one ormore second fusion proteins.
 15. The non-natural cell according to claim14, wherein the binding domain of the protein heterocomplex specificallybinds to a target located on a target cell surface.
 16. The non-naturalcell according to any one of the preceding claims, wherein thehydrophobic domain is a transmembrane domain.
 17. The non-natural cellaccording to any one of the preceding claims, wherein the transmembranedomain is a CD4, CD8 or CD28 transmembrane domain.
 18. The non-naturalcell according to any one of the preceding claims, wherein the actuatordomain comprises a lymphocyte receptor signaling domain.
 19. Thenon-natural cell according to any one of the preceding claims, whereinthe actuator domain comprises one or a plurality of immunoreceptortyrosine-based activation motifs (ITAMs).
 20. The non-natural cellaccording to any one of the preceding claims, wherein the actuatordomain comprises CD3ε, CD3δ, CD3ζ, pTα, TCRα, TCRβ, FcRα, FcRβ, FcRγ,NKG2D, CD22, CD79A, or CD79B, or any combination thereof.
 21. Thenon-natural cell according to any one of the preceding claims, whereinthe first nucleic acid molecule encodes the first fusion protein furthercomprising a different actuator domain, a costimulatory domain, anadhesion factor, or any combination thereof.
 22. The non-natural cellaccording to claim 18, wherein the costimulatory domain is selected fromCD27, CD28, CD30, CD40, LAT, Zap70, ICOS, DAP10, 4-1BB, CARD11, HVEM,LAG3, SLAMF1, Lck, Fyn, Slp76, TRIM, OX40, or any combination thereof.23. The non-natural cell according to any one of the preceding claims,wherein the actuator domain comprises a cytoplasmic portion thatassociates with a cytoplasmic signaling protein.
 24. The non-naturalcell according to claim 23, wherein the cytoplasmic signaling protein isa lymphocyte receptor or signaling domain thereof, a protein comprisinga plurality of immunoreceptor tyrosine-based activation motifs (ITAMs),a costimulatory domain, an adhesion factor, or any combination thereof.25. The non-natural cell according to claim 24, wherein the lymphocytereceptor or signaling domain thereof is CD3ε, CD3δ, CD3ζ, pTα, TCRα,TCRβ, FcRα, FcRβ, FcRγ, NKG2D, CD22, CD79A, or CD79B, or any combinationthereof.
 26. The non-natural cell according to claim 24, wherein thecostimulatory domain is selected from CD27, CD28, CD30, CD40, LAT,Zap70, ICOS, DAP10, 4-1BB, CARD11, HVEM, LAG3, SLAMF1, Lck, Fyn, Slp76,TRIM, OX40, or any combination thereof.
 27. The non-natural cellaccording to any one of the preceding claims, further overexpressing acostimulatory factor, an immunomodulatoy factor, an agonist for acostimulatory factor, an agonist for an immunomodulatoy factor, or anycombination thereof.
 28. The non-natural cell according to any one ofthe preceding claims, wherein the second nucleic acid molecule furtherencodes a secretion signal such that the second fusion protein issecreted from the non-natural cell when expressed, and optionallyfurther encodes an anchor domain.
 29. The non-natural cell according toany one of the preceding claims, wherein the binding domain of thesecond fusion protein is a single chain antibody variable region, areceptor ectodomain, or a ligand.
 30. The non-natural cell according toclaim 29, wherein the single chain antibody variable region is a domainantibody, sFv, scFv, F(ab′)₂, or Fab.
 31. The non-natural cell accordingto any one of the preceding claims, wherein the binding domain of thesecond fusion protein is amino terminal to the multimerization domain.32. The non-natural cell according to any one of the preceding claims,wherein the binding domain of the second fusion protein is carboxyterminal to the multimerization domain.
 33. The non-natural cellaccording to any one of the preceding claims, wherein the second nucleicacid molecule encoding the second fusion protein further comprises asequence encoding a linker disposed between the binding domain and thesecond multimerization domain.
 34. The non-natural cell according to anyone of the preceding claims, wherein the cell further comprises a thirdnucleic acid molecule encoding a third fusion protein comprising abinding domain and a second multimerization domain, wherein the thirdfusion protein localizes extracellularly when expressed.
 35. Thenon-natural cell according to any one of the preceding claims, whereinthe fusion proteins comprising a binding domain have one, two, three, orfour binding domains.
 36. The non-natural cell according to any one ofthe preceding claims, wherein the one, two, three, or four bindingdomains are specific for one target or up to four different targets. 37.The non-natural cell according to any one of the preceding claims,wherein the binding domain is specific for a target that is an antigenassociated with a cancer, an inflammatory disease, an autoimmunedisease, or a graft versus host disease.
 38. The non-natural cellaccording to claim 37, wherein the cancer is a solid malignancy or ahematologic malignancy.
 39. The non-natural cell according to claim 38,wherein the hematologic malignancy associated antigen target is CD19,CD20, CD22, CD33, or CD37.
 40. The non-natural cell according to any oneof the preceding claims, wherein the binding domain specifically bindsto a target selected from a-folate receptor, α_(v)β₆ integrin, BCMA,B7-H3, B7-H6, CAIX, CD19, CD20, CD22, CD30, CD33, CD37, CD44, CD44v6,CD44v7/8, CD70, CD123, CD138, CD171, CEA, DLL4, EGP-2, EGP-40, CSPG4,EGFR, EGFR family including ErbB2 (HER2), EGFRvIII, EPCAM, EphA2, EpCAM,FAP, FBP, fetal acetylcholine receptor, Fzd7, GD2, GD3, Glypican-3(GPC3), h5T4, IL-11Rα, IL13R-α2, KDR, κ light chain, λ light chain, LeY,L1CAM, MAGE-A1, mesothelin, MHC presented peptides, MUC1, MUC16, NCAM,NKG2D ligands, Notch1, Notch2/3, NY-ESO-1, PRAME, PSCA, PSMA, Survivin,TAG-72, TEMs, TERT, VEGFR2, and ROR1.
 41. The non-natural cell accordingto any one of the preceding claims, wherein the first bridging factor israpamycin or a rapalog thereof, coumermycin or a derivative thereof,gibberellin or a derivative thereof, ABA or a derivative thereof,methotrexate or a derivative thereof, cyclosporin A or a derivativethereof, FKCsA or a derivative thereof, or Tmp-SLF or a derivativethereof.
 42. The non-natural cell according to claim 10, wherein thesecond bridging factor is rapamycin or a rapalog thereof, coumermycin ora derivative thereof, gibberellin or a derivative thereof, ABA or aderivative thereof, methotrexate or a derivative thereof, cyclosporin Aor a derivative thereof, FKCsA or a derivative thereof, or Tmp-SLF or aderivative thereof.
 43. The non-natural cell according to any one of thepreceding claims, wherein the encoded first fusion protein comprises afirst multimerization domain of FRB T2098L, a transmembrane domain, acostimulatory domain of 4-1BB, and actuator domain of CD3ζ; wherein thesecond encoded fusion protein comprises a binding domain of an scFvspecific for CD19 and a second multimerization domain of FKBP12; andwherein the first bridging factor that promotes the formation of apolypeptide complex on the non-natural cell surface is rapalog AP21967.44. The non-natural cell according to claim 43, wherein the first fusionprotein has an amino acid sequence as set forth in SEQ ID NO.:15 and thesecond fusion protein has an amino acid sequence as set forth in SEQ IDNO.:1.
 45. A method for treating a hyperproliferative, inflammatory,autoimmune, or graft-versus-host disease, comprising: (a) administeringa recombinant cell comprising a first and a second nucleic acidmolecule, wherein the first nucleic acid molecule encodes a first fusionprotein comprising a first multimerization domain, a hydrophobic domain,and an actuator domain, wherein the first multimerization domainlocalizes extracellularly when the first fusion protein is expressed,and the second nucleic acid molecule encodes a second fusion proteincomprising a binding domain and a second multimerization domain, whereinthe second fusion protein localizes extracellularly when expressed; and(b) administering a bridging factor, wherein the bridging factorpromotes the formation of a polypeptide complex on the recombinant cellsurface with the bridging factor associated with and disposed betweenthe multimerization domains of the first and second fusion proteins;wherein the binding domain of the polypeptide complex specifically bindsa cell surface target on a hyperproliferative, inflammatory, autoimmune,or graft-versus-host disease cell to promote an immunomodulatoryresponse and thereby treats the hyperproliferative, inflammatory,autoimmune, or graft-versus-host disease.
 46. A method for treating ahyperproliferative, inflammatory, autoimmune, or graft-versus-hostdisease, comprising: (a) administering a non-natural cell comprising afirst nucleic acid molecule encoding a first fusion protein comprising afirst multimerization domain, a hydrophobic domain, and an actuatordomain, wherein the first multimerization domain localizesextracellularly when the first fusion protein is expressed; (b)administering a second fusion protein comprising a binding domain and asecond multimerization domain; and (c) administering a bridging factor,wherein the bridging factor promotes the formation of a polypeptidecomplex on the recombinant cell surface with the bridging factorassociated with and disposed between the multimerization domains of thefirst and second fusion proteins; wherein the binding domain of thepolypeptide complex specifically binds a cell surface target on ahyperproliferative, inflammatory, autoimmune, or graft-versus-hostdisease cell to promote an immunomodulatory response and thereby treatsthe hyperproliferative, inflammatory, autoimmune, or graft-versus-hostdisease.
 47. The method according to claim 45 or 46, wherein the firstand second multimerization domains are the same or different.
 48. Themethod according to any one of claims 45-47, wherein the multimerizationdomains of the first and second fusion proteins associate with abridging factor selected from rapamycin or a rapalog thereof,coumermycin or a derivative thereof, gibberellin or a derivativethereof, abscisic acid (ABA) or a derivative thereof, methotrexate or aderivative thereof, cyclosporin A or a derivative thereof, FKCsA or aderivative thereof, trimethoprim (Tmp)-synthetic ligand for FKBP (SLF)or a derivative thereof, or any combination thereof.
 49. The methodaccording to any one of claims 45-48, wherein the first and secondmultimerization domains are a pair selected from FKBP and FRB, FKBP andcalcineurin, FKBP and cyclophilin, FKBP and bacterial DHFR, calcineurinand cyclophilin, PYL1 and ABI1, or GIB1 and GAI, or variants thereof.50. The method according to any one of claims 45-49, wherein the firstmultimerization domain comprises a first FKBP polypeptide or variantthereof, and the second multimerization domain comprises a first FRBpolypeptide or variant thereof.
 51. The method according to any one ofclaims 45-50, wherein the first multimerization domain comprises a firstFRB polypeptide or variant thereof, and the second multimerizationdomain comprises a first FKBP polypeptide or variant thereof.
 52. Themethod according to claim 50 or 51, wherein the bridging factor issirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus,tacrolimus, temsirolimus, umirolimus, or zotarolimus.
 53. The methodaccording to any one of claims 45-52, wherein the first nucleic acidmolecule encodes a first fusion protein further comprising a thirdmultimerization domain.
 54. The method according to claim 53, whereinthe third multimerization domain of the first fusion protein is abinding domain for a bridging factor selected from rapamycin or arapalog thereof, coumermycin or a derivative thereof, gibberellin or aderivative thereof, ABA or a derivative thereof, methotrexate or aderivative thereof, cyclosporin A or a derivative thereof, FKCsA or aderivative thereof, Tmp-SLF or a derivative thereof, or any combinationthereof.
 55. The method according to any one of claims 45-54, wherein asecond bridging factor promotes the association of at least two firstfusion proteins with the bridging factor associated with and disposedbetween the third multimerization domains of the first fusion proteins.56. The method according to any one of claims 45-55, wherein the proteincomplex is a homocomplex comprising at least two first fusion proteins.57. The method according to any one of claims 45-56, wherein the firstfusion protein has at least one multimerization domain of FKBP, DHFR orGyrB.
 58. The method according to any one of claims 45-57, wherein thebinding domain of the polypeptide complex specifically binds to a targetlocated on a target hyperproliferative disease cell surface.
 59. Themethod according to claim 58, wherein the protein complex is aheterocomplex comprising one or more first fusion proteins and one ormore second fusion proteins.
 60. The method according to claim 59,wherein the binding domain of the protein heterocomplex specificallybinds to a target located on a target hyperproliferative disease cellsurface.
 61. The method according to any one of claims 45-60, whereinthe hydrophobic domain is a transmembrane domain.
 62. The methodaccording to any one of claims 45-61, wherein the transmembrane domainis a CD4, CD8 or CD28 transmembrane domain.
 63. The method according toany one of claims 45-62, wherein the actuator domain comprises alymphocyte receptor signaling domain.
 64. The method according to anyone of claims 45-63, wherein the actuator domain comprises a pluralityof immunoreceptor tyrosine-based activation motifs (ITAMs).
 65. Themethod according to any one of claims 45-64, wherein the actuator domaincomprises CD3ε, CD3δ, CD3ζ, pTα, TCRα, TCRβ, FcRα, FcRβ, FcRγ, NKG2D,CD22, CD79A, or CD79B, or any combination thereof.
 66. The methodaccording to any one of claims 45-65, wherein the first nucleic acidmolecule encodes the first fusion protein further comprising a differentactuator domain, a costimulatory domain, an adhesion factor, or anycombination thereof.
 67. The method according to claim 66, wherein thecostimulatory domain is selected from CD27, CD28, CD30, CD40, LAT,Zap70, ICOS, DAP10, 4-1BB, CARD11, HVEM, LAG3, SLAMF1, Lck, Fyn, Slp76,TRIM, OX40, or any combination thereof.
 68. The method according to anyone of claims 45-67, wherein the actuator domain comprises a cytoplasmicportion that associates with a cytoplasmic signaling protein.
 69. Themethod according to claim 68, wherein the cytoplasmic signaling proteinis a lymphocyte receptor or signaling domain thereof, a proteincomprising one or a plurality of immunoreceptor tyrosine-basedactivation motifs (ITAMs), a costimulatory domain, an adhesion factor,or any combination thereof.
 70. The method according to claim 69,wherein the lymphocyte receptor or signaling domain thereof is CD3ε,CD3,δ, CD3ζ, pTα, TCRα, TCRβ, FcRα, FcRβ, FcRγNKG2D, CD22, CD79A, orCD79B, or any combination thereof.
 71. The method according to claim 69,wherein the costimulatory domain is selected from CD27, CD28, CD30,CD40, LAT, Zap70, ICOS, DAP10, 4-1BB, CARD11, HVEM, LAG3, SLAMF1, Lck,Fyn, Slp76, TRIM, OX40, or any combination thereof.
 72. The methodaccording to claim 69, wherein the cytoplasmic signaling protein iscombination of CD3ζ and 4-1BB or a combination of CD3t and OX40.
 73. Themethod according to any one of claims 45-72, wherein the non-naturalcell is further overexpressing a costimulatory factor, animmunomodulatoy factor, an agonist for a costimulatory factor, anagonist for an immunomodulatoy factor, or any combination thereof. 74.The method according to any one of claims 45-73, wherein the bindingdomain of the second fusion protein is a single chain antibody variableregion, a receptor ectodomain, or a ligand.
 75. The method according toclaim 74, wherein the single chain antibody variable region is a domainantibody, sFv, scFv, F(ab′)2, or Fab.
 76. The method according to anyone of claims 45-75, wherein the binding domain of the second fusionprotein is amino terminal to the multimerization domain.
 77. The methodaccording to any one of claims 45-76, wherein the binding domain of thesecond fusion protein is carboxy terminal to the multimerization domain.78. The method according to any one of claims 45-77, wherein the secondfusion protein further comprises a linker disposed between the bindingdomain and the second multimerization domain.
 79. The method accordingto any one of claims 45-78, wherein the cell further comprises a thirdnucleic acid molecule encoding a third fusion protein comprising abinding domain and a second multimerization domain, wherein the thirdfusion protein localizes extracellularly when expressed.
 80. The methodaccording to any one of claims 45-76, wherein the fusion proteinscomprising a binding domain have one, two, three, or four bindingdomains.
 81. The method according to any one of claims 45-80, whereinthe one, two, three, or four binding domains are specific for one targetor up to four different targets.
 82. The method according to any one ofclaims 45-81, wherein the binding domain is specific for a target thatis an antigen associated with a cancer.
 83. The method according toclaim 82, wherein the cancer is a solid malignancy or a hematologicmalignancy.
 84. The method according to claim 83, wherein thehematologic malignancy associated antigen target is CD19, CD20, CD22,CD33, or CD37.
 85. The method according to any one of claims 45-84,wherein the binding domain specifically binds to a target selected fromα-folate receptor, α_(v)β₆ integrin, BCMA, B7-H3, B7-H6, CAIX, CD19,CD20, CD22, CD30, CD33, CD37, CD44, CD44v6, CD44v7/8, CD70, CD123,CD138, CD171, CEA, DLL4, EGP-2, EGP-40, CSPG4, EGFR, EGFR familyincluding ErbB2 (HER2), EGFRvIII, EPCAM, EphA2, EpCAM, FAP, FBP, fetalacetylcholine receptor, Fzd7, GD2, GD3, Glypican-3 (GPC3), h5T4,IL-11Rα, IL13R-α2, KDR, κ light chain, λ light chain, LeY, L1CAM,MAGE-A1, mesothelin, MHC presented peptides, MUC1, MUC16, NCAM, NKG2Dligands, Notchl, Notch2/3, NY-ESO-1, PRAME, PSCA, PSMA, Survivin,TAG-72, TEMs, TERT, VEGFR2, and ROR1.
 86. The method according to anyone of claims 45-85, wherein the first bridging factor is rapamycin or arapalog thereof, coumermycin or a derivative thereof, gibberellin or aderivative thereof, ABA or a derivative thereof, methotrexate or aderivative thereof, cyclosporin A or a derivative thereof, FKCsA or aderivative thereof, or Tmp-SLF or a derivative thereof.
 87. The methodaccording to claim 55, wherein the second bridging factor is rapamycinor a rapalog thereof, coumermycin or a derivative thereof, gibberellinor a derivative thereof, ABA or a derivative thereof, methotrexate or aderivative thereof, cyclosporin A or a derivative thereof, FKCsA or aderivative thereof, or Tmp-SLF or a derivative thereof.
 88. The methodaccording to any one of claims 45-87, wherein the first fusion proteincomprises a first multimerization domain of FRB T2098L, a transmembranedomain, a costimulatory domain of 4-1BB, and actuator domain ofCD3ζ;wherein the second fusion protein comprises a binding domain of anscFv specific for CD19 and a second multimerization domain of FKBP12;and wherein the first bridging factor that promotes the formation of apolypeptide complex on the non-natural cell surface is rapalog AP21967.89. The method according to claim 88, wherein the first fusion proteinhas an amino acid sequence as set forth in SEQ ID NO.:15 and the secondfusion protein has an amino acid sequence as set forth in SEQ ID NO.:1.90. The method according to any one of claims 45-89, wherein the methodfurther comprises administering an agent that antagonizes or blocks aninhibitor of T-cell activation.
 91. The method according to claim 90,wherein the agent antagonizes or blocks a T-cell ligand.
 92. The methodaccording to claim 90, wherein the agent antagonizes or blocks a T-cellreceptor.
 93. The method according to any one of claims 90-92, whereinthe agent that antagonizes or blocks an inhibitor of T-cell activationis an anti-PD1 antibody or antigen binding fragment thereof, anti-PD-L1antibody or antigen binding fragment thereof, or an anti-CTLA4 antibodyor antigen binding fragment thereof or an engineered homing endonucleasethat targets PD-1.
 94. The method according to any one of claims 45-93,wherein the method further comprises administering a cytokine agonist.95. A fusion polypeptide heterocomplex, comprising: (a) a first fusionprotein comprising a first multimerization domain, a hydrophobic domain,and an actuator domain; (b) a second fusion protein comprising anextracellular binding domain and second multimerization domain; and (c)a bridging factor; wherein the first fusion protein, second fusionprotein, and bridging factor associate to form a polypeptideheterocomplex with the bridging factor associated with and disposedbetween the multimerization domains of the first and second fusionproteins.
 96. The polypeptide heterocomplex according to claim 95,wherein the binding domain is a single chain antibody variable region, areceptor ectodomain, or a ligand.
 97. The polypeptide heterocomplexaccording to claim 96, wherein the single chain antibody variable regionis a domain antibody, sFv, scFv, F(ab′)₂, or Fab.
 98. The polypeptideheterocomplex according to any one of claims 95-97, wherein the bindingdomain is amino terminal to the multimerization domain.
 99. Thepolypeptide heterocomplex according to any one of claims 95-97, whereinthe binding domain is carboxy terminal to the multimerization domain.100. The polypeptide heterocomplex according to any one of claims 95-99,wherein the first multimerization domain comprises a first FKBPpolypeptide or variant thereof, and the second multimerization domaincomprises a first FRB polypeptide or variant thereof.
 101. Thepolypeptide heterocomplex according to any one of claims 95-99, whereinthe first multimerization domain comprises a first FRB polypeptide orvariant thereof, and the second multimerization domain comprises a firstFKBP polypeptide or variant thereof.
 102. The polypeptide heterocomplexaccording to any one of claims 95-101, wherein the hydrophobic domain isa transmembrane domain.
 103. The polypeptide heterocomplex according toany one of claims 95-102, wherein the actuator domain comprises alymphocyte receptor chain.
 104. The polypeptide heterocomplex accordingto any one of claims 95-103, wherein the bridging factor is rapamycin ora rapalog thereof, coumermycin or a derivative thereof, gibberellin or aderivative thereof, ABA or a derivative thereof, methotrexate or aderivative thereof, cyclosporin A or a derivative thereof, FKCsA or aderivative thereof, or Tmp-SLF or a derivative thereof.
 105. Thepolypeptide heterocomplex according to any one of claims 95-104, whereinthe second fusion protein further comprises an anchor domain.
 106. Thepolypeptide heterocomplex according to claim 105, wherein the anchordomain is a transmembrane domain.
 107. The polypeptide heterocomplexaccording to claim 105 or 106, wherein the second fusion protein furthercomprises a sub-threshold signaling domain.
 108. The polypeptideheterocomplex according to claim 105, wherein the anchor domain is a GPIsignal sequence.
 109. The polypeptide heterocomplex according to claim105, wherein the GPI signal sequence has been altered and the secondfusion protein further comprises a GPI molecule.
 110. The polypeptideheterocomplex according to any one of claims 95-109, wherein the bindingdomain is specific for a target that is an antigen associated with acancer, an inflammatory disease, an autoimmune disease, or a graftversus host disease.
 111. The polypeptide heterocomplex according toclaim 110, wherein the cancer is a hematologic malignancy having anantigen target of CD19, CD20, CD22, CD33, or CD37.
 112. A nucleic acidmolecule encoding any one or more of the fusion proteins according toany one of claim 1-44 or 95-109.
 113. The nucleic acid molecule of claim112, wherein the nucleic acid molecule is disposed between 5′ and 3′polynucleotide sequences homologous to a genomic locus.
 114. Anexpression vector containing a nucleic acid according to claim 112 orclaim
 113. 115. The expression vector according to claim 114, whereinthe first and second fusion proteins are encoded as a polycistronicmessage or as a single protein separated by a 2A peptide.
 116. Theexpression vector according to claim 115, wherein the polycistronicmessage comprises an internal ribosome entry site (IRES) between thenucleotide sequences that encode the fusion proteins.
 117. A non-naturalcell, comprising: (a) a first nucleic acid molecule encoding a firstfusion protein comprising a binding domain that binds a receptor on a Tcell and a first multimerization domain, wherein the first fusionprotein is secreted from the cell; and (b) a second nucleic acidmolecule encoding a second fusion protein comprising a binding domainthat binds a target located on a target cell surface and a secondmultimerization domain, wherein the second fusion protein is secretedfrom the cell; wherein a bridging factor promotes the formation of apolypeptide complex with the bridging factor associated with anddisposed between the multimerization domains of the first and secondfusion proteins.
 118. The non-natural cell according to claim 117,wherein the first and second multimerization domains are the same ordifferent.
 119. The non-natural cell according to claim 117 or claim118, wherein the multimerization domains of the first and second fusionproteins associate with a bridging factor selected from rapamycin or arapalog thereof, coumermycin or a derivative thereof, gibberellin or aderivative thereof, abscisic acid (ABA) or a derivative thereof,methotrexate or a derivative thereof, cyclosporin A or a derivativethereof, FKCsA or a derivative thereof, trimethoprim (Tmp)-syntheticligand for FKBP (SLF) or a derivative thereof, or any combinationthereof.
 120. The non-natural cell according to any one of claims117-119, wherein the first and second multimerization domains are a pairselected from FKBP and FRB, FKBP and calcineurin, FKBP and cyclophilin,FKBP and bacterial DHFR, calcineurin and cyclophilin, PYL1 and ABI1, orGIB1 and GAI, or variants thereof.
 121. The non-natural cell accordingto any one of claims 117-120, wherein the first multimerization domaincomprises a first FKBP polypeptide or variant thereof, and the secondmultimerization domain comprises a first FRB polypeptide or variantthereof.
 122. The non-natural cell according to any one of claims117-120, wherein the first multimerization domain comprises a first FRBpolypeptide or variant thereof, and the second multimerization domaincomprises a first FKBP polypeptide or variant thereof.
 123. Thenon-natural cell according to claim 121 or claim 122, wherein thebridging factor is sirolimus, everolimus, novolimus, pimecrolimus,ridaforolimus, tacrolimus, temsirolimus, umirolimus, or zotarolimus.124. The non-natural cell according to any one of claims 117-123,further overexpressing a costimulatory factor, an immunomodulatoyfactor, an agonist for a costimulatory factor, an agonist for animmunomodulatoy factor, or any combination thereof.
 125. The non-naturalcell according to any one of claims 117-124, wherein the binding domainof the first fusion protein and the binding domain of the second fusionprotein are each independently selected from the group consisting of: asingle chain antibody variable region, a receptor ectodomain, or aligand.
 126. The non-natural cell according to claim 125, wherein thesingle chain antibody variable region is a domain antibody, sFv, scFv,F(ab′)₂, or Fab.
 127. The non-natural cell according to any one ofclaims 117-126, wherein the binding domain of the first fusion proteinis amino terminal to the first multimerization domain.
 128. Thenon-natural cell according to any one of claims 117-126, wherein thebinding domain of the first fusion protein is carboxy terminal to thefirst multimerization domain.
 129. The non-natural cell according to anyone of claims 117-126, wherein the binding domain of the second fusionprotein is amino terminal to the second multimerization domain.
 130. Thenon-natural cell according to any one of claims 117-126, wherein thebinding domain of the second fusion protein is carboxy terminal to thesecond multimerization domain.
 131. The non-natural cell according toany one of claims 117-130, wherein the first nucleic acid moleculeencoding the first fusion protein further comprises a sequence encodinga linker disposed between the binding domain and the firstmultimerization domain.
 132. The non-natural cell according to any oneof claims 117-130, wherein the second nucleic acid molecule encoding thesecond fusion protein further comprises a sequence encoding a linkerdisposed between the binding domain and the second multimerizationdomain.
 133. The non-natural cell according to any one of claims117-132, wherein the binding domain of the second nucleic acid moleculeis specific for a target that is an antigen associated with a cancer, aninflammatory disease, an autoimmune disease, or a graft versus hostdisease.
 134. The non-natural cell according to claim 133, wherein thecancer is a solid malignancy or a hematologic malignancy.
 135. Thenon-natural cell according to claim 134, wherein the hematologicmalignancy associated antigen target is CD19, CD20, CD22, CD33, or CD37.136. The non-natural cell according to any one of claims 117-132,wherein the binding domain of the second nucleic acid moleculespecifically binds to a target selected from a-folate receptor, α_(v)β₆integrin, BCMA, B7-H3, B7-H6, CAIX, CD19, CD20, CD22, CD30, CD33, CD37,CD44, CD44v6, CD44v7/8, CD70, CD123, CD138, CD171, CEA, DLL4, EGP-2,EGP-40, CSPG4, EGFR, EGFR family including ErbB2 (HER2), EGFRvIII,EPCAM, EphA2, EpCAM, FAP, FBP, fetal acetylcholine receptor, Fzd7, GD2,GD3, Glypican-3 (GPC3), h5T4, IL-11Rα, IL13R-α2, KDR, κ light chain, λlight chain, LeY, L1CAM, MAGE-A1, mesothelin, MHC presented peptides,MUC1, MUC16, NCAM, NKG2D ligands, Notchl, Notch2/3, NY-ESO-1, PRAME,PSCA, PSMA, Survivin, TAG-72, TEMs, TERT, VEGFR2, and ROR1.
 137. Thenon-natural cell according to any one of claims 117-136, wherein thebridging factor is rapamycin or a rapalog thereof, coumermycin or aderivative thereof, gibberellin or a derivative thereof, ABA or aderivative thereof, methotrexate or a derivative thereof, cyclosporin Aor a derivative thereof, FKCsA or a derivative thereof, or Tmp-SLF or aderivative thereof.
 138. The non-natural cell according to any one ofclaims 117-137, wherein the first nucleic acid encodes a first fusionprotein comprising a binding domain of an scFv specific for CD3 and afirst multimerization domain of FRB T2098L; wherein the second nucleicacid encodes a second fusion protein comprising a binding domain of anscFv specific for CD19 and a second multimerization domain of FKBP12;and wherein the bridging factor that promotes the formation of apolypeptide complex is rapalog AP21967.
 139. The non-natural cellaccording to any one of claims 117-137, wherein the first nucleic acidencodes a first fusion protein comprising a binding domain of an scFvspecific for CD3 and a first multimerization domain of FRB T2098L;wherein the second nucleic acid encodes a second fusion proteincomprising a binding domain of an scFv specific for BCMA and a secondmultimerization domain of FKBP12; and wherein the bridging factor thatpromotes the formation of a polypeptide complex is rapalog AP21967. 140.A method for treating a hyperproliferative, inflammatory, autoimmune, orgraft-versus-host disease, comprising administering a non-natural cellaccording to any one of claims 117-139 and administering a bridgingfactor, wherein the bridging factor promotes the formation of apolypeptide complex with the bridging factor associated with anddisposed between the multimerization domains of the first and secondfusion proteins; wherein the binding domain of the second fusionpolypeptide specifically binds a cell surface target on ahyperproliferative disease cell to promote an immunomodulatory responseand thereby treats the hyperproliferative disease.
 141. A method fortreating a hyperproliferative, inflammatory, autoimmune, orgraft-versus-host disease, comprising: (a) administering a first fusionprotein comprising a binding domain that binds a receptor on a T celland a first multimerization domain; and a second fusion proteincomprising a binding domain that binds a cell surface target on ahyperproliferative, inflammatory, autoimmune, or graft-versus-hostdisease cell and a second multimerization domain; and (b) administeringa bridging factor that promotes the formation of a polypeptide complexwith the bridging factor associated with and disposed between themultimerization domains of the first and second fusion proteins; therebytreating the hyperproliferative, inflammatory, autoimmune, orgraft-versus-host disease.
 142. A fusion polypeptide heterocomplex,comprising: (a) a first fusion protein comprising a binding domain thatbinds a receptor on a T cell and a first multimerization domain; (b) asecond fusion protein comprising a binding domain that binds a cellsurface target on a target cell; and (c) a bridging factor; wherein thefirst fusion protein, second fusion protein, and bridging factorassociate to form a polypeptide heterocomplex with the bridging factorassociated with and disposed between the multimerization domains of thefirst and second fusion proteins.
 143. The fusion polypeptideheterocomplex according to claim 142, wherein the first and secondmultimerization domains are the same or different.
 144. The fusionpolypeptide heterocomplex according to claim 142 or claim 143, whereinthe multimerization domains of the first and second fusion proteinsassociate with a bridging factor selected from rapamycin or a rapalogthereof, coumermycin or a derivative thereof, gibberellin or aderivative thereof, abscisic acid (ABA) or a derivative thereof,methotrexate or a derivative thereof, cyclosporin A or a derivativethereof, FKCsA or a derivative thereof, trimethoprim (Tmp)-syntheticligand for FKBP (SLF) or a derivative thereof, or any combinationthereof.
 145. The fusion polypeptide heterocomplex according to any oneof claims 142-144, wherein the first and second multimerization domainsare a pair selected from FKBP and FRB, FKBP and calcineurin, FKBP andcyclophilin, FKBP and bacterial DHFR, calcineurin and cyclophilin, PYL1and ABI1, or GIB1 and GAI, or variants thereof.
 146. The fusionpolypeptide heterocomplex according to any one of claims 142-145,wherein the first multimerization domain comprises a first FKBPpolypeptide or variant thereof, and the second multimerization domaincomprises a first FRB polypeptide or variant thereof.
 147. The fusionpolypeptide heterocomplex according to any one of claims 142-145,wherein the first multimerization domain comprises a first FRBpolypeptide or variant thereof, and the second multimerization domaincomprises a first FKBP polypeptide or variant thereof.
 148. The fusionpolypeptide heterocomplex according to any one of claims 146 or claim147, wherein the bridging factor is sirolimus, everolimus, novolimus,pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, orzotarolimus.
 149. The fusion polypeptide heterocomplex according to anyone of claims 142-148, wherein the binding domain of the first fusionprotein and the binding domain of the second fusion protein are eachindependently selected from the group consisting of: a single chainantibody variable region, a receptor ectodomain, or a ligand.
 150. Thefusion polypeptide heterocomplex according to claim 149, wherein thesingle chain antibody variable region is a domain antibody, sFv, scFv,F(ab′)₂, or Fab.
 151. The fusion polypeptide heterocomplex according toany one of claims 142-150, wherein the binding domain of the secondfusion polypeptide specifically binds to a target selected from a-folatereceptor, 46 integrin, BCMA, B7-H3, B7-H6, CAIX, CD19, CD20, CD22, CD30,CD33, CD37, CD44, CD44v6, CD44v7/8, CD70, CD123, CD138, CD171, CEA,DLL4, EGP-2, EGP-40, CSPG4, EGFR, EGFR family including ErbB2 (HER2),EGFRvIII, EPCAM, EphA2, EpCAM, FAP, FBP, fetal acetylcholine receptor,Fzd7, GD2, GD3, Glypican-3 (GPC3), h5T4, IL-11Rα, IL13R-α2, KDR, κ lightchain, λ light chain, LeY, L1CAM, MAGE-A1, mesothelin, MHC presentedpeptides, MUC1, MUC16, NCAM, NKG2D ligands, Notchl, Notch2/3, NY-ESO-1,PRAME, PSCA, PSMA, Survivin, TAG-72, TEMs, TERT, VEGFR2, and ROR1. 152.The fusion polypeptide heterocomplex according to any one of claims141-150, wherein the first fusion protein comprises a binding domain ofan scFv specific for CD3 and a first multimerization domain of FRBT2098L; wherein the second fusion protein comprises a binding domain ofan scFv specific for CD19 and a second multimerization domain of FKBP12;and wherein the bridging factor is rapalog AP21967.
 153. The fusionpolypeptide heterocomplex according to any one of claims 141-150,wherein the first fusion protein comprises a binding domain of an scFvspecific for CD3 and a first multimerization domain of FRB T2098L;wherein the second fusion protein comprises a binding domain of an scFvspecific for BCMA and a second multimerization domain of FKBP12; andwherein the bridging factor is rapalog AP21967.
 154. A nucleic acidmolecule encoding any one or more of the fusion proteins according toany one of claims 117-153.
 155. The nucleic acid molecule of claim 154,wherein the nucleic acid molecule is disposed between 5′ and 3′polynucleotide sequences homologous to a genomic locus.
 156. Anexpression vector containing a nucleic acid according to claim 154 orclaim
 155. 157. The expression vector according to claim 156, whereinthe first and second fusion proteins are encoded as a polycistronicmessage or as a single protein separated by a 2A peptide.
 158. Theexpression vector according to claim 157, wherein the polycistronicmessage comprises an internal ribosome entry site (IRES) between thenucleotide sequences that encode the fusion proteins.